Régulations divergentes du récepteur c-Kit par la TPO et la tétraspanine CD9 : implication dans le contrôle de la balance prolifération / maturation mégacaryocytaire by Chaabouni, Azza
Divergent regulations of c-Kit receptor by TPO and CD9
in megakaryocytic cells : implication in the dynamic
control of the balance proliferation/differentiation
Azza Chaabouni
To cite this version:
Azza Chaabouni. Divergent regulations of c-Kit receptor by TPO and CD9 in megakaryocytic
cells : implication in the dynamic control of the balance proliferation/differentiation. Cellular
Biology. Universite´ Claude Bernard - Lyon I, 2015. English. <NNT : 2015LYO10144>. <tel-
01328160>
HAL Id: tel-01328160
https://tel.archives-ouvertes.fr/tel-01328160
Submitted on 7 Jun 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
 
 
1 
Année 2015                                                          
Thèse présentée à l’Université Claude Bernard Lyon1 
ECOLE DOCTORALE BIOLOGIE MOLECULAIRE INETGRATIVE ET CELLULAIRE 
 
Pour l’obtention du titre de 
DOCTEUR DE L’UNIVERSITE LYON1 
SPECIALITE : Biologie cellulaire et Hématologie 
Date de soutenance : 6 Octobre 2015 
N° d’ordre : 144-2015 
Azza CHAABOUNI 
 
Régulations divergentes du récepteur c-Kit par la TPO 
et la tétraspanine CD9 : 
Implication dans le contrôle de la balance 
prolifération/maturation mégacaryocytaire 
 
Directeur de thèse : Dr François MORLE 
Jury de thèse :  
Mme Michèle SOUYRI   Rapporteur 
Mme Evelyne LAURET   Rapporteur 
Mme Kathrin GIESELER   Examinateur 
Mr. Boris GUYOT    Examinateur 
Mr. François MORLE   Examinateur 
 
 
 
2 
UNIVERSITE CLAUDE BERNARD - LYON 1 
 
 
Président de l’Université 
Vice-président du Conseil d’Administration 
Vice-président  du Conseil des Etudes et de la Vie 
Universitaire  
Vice-président du Conseil Scientifique 
Directeur Général des Services 
M. François-Noël GILLY 
M. le Professeur Hamda BEN HADID 
M. le Professeur Philippe LALLE 
M. le Professeur Germain GILLET 
M. Alain HELLEU 
 
 
COMPOSANTES SANTE 
 
Faculté de Médecine Lyon Est – Claude Bernard 
Faculté de Médecine et de Maïeutique Lyon Sud – 
Charles Mérieux 
Faculté d’Odontologie  
Institut des Sciences Pharmaceutiques et 
Biologiques 
Institut des Sciences et Techniques de la 
Réadaptation 
Département de formation et Centre de Recherche 
en Biologie Humaine 
Directeur : M. le Professeur J. ETIENNE 
Directeur : Mme la Professeure C. BURILLON 
Directeur : M. le Professeur D. BOURGEOIS 
Directeur : Mme la Professeure C. 
VINCIGUERRA 
Directeur : M. le Professeur Y. MATILLON 
Directeur : Mme. la Professeure A-M. SCHOTT 
 
 
 
 
 
 
 
 
3 
COMPOSANTES ET DEPARTEMENTS DE SCIENCES ET TECHNOLOGIE 
Faculté des Sciences et Technologies 
Département Biologie 
Département Chimie Biochimie 
Département GEP 
Département Informatique 
Département Mathématiques 
 
Département Mécanique 
Département Physique 
UFR Sciences et Techniques des Activités Physiques et 
Sportives 
Observatoire des Sciences de l’Univers de Lyon 
Polytech Lyon 
Ecole Supérieure de Chimie Physique Electronique 
Institut Universitaire de Technologie de Lyon 1 
Ecole Supérieure du Professorat et de l’Education 
 
Institut de Science Financière et d'Assurances 
Directeur : M. F. DE MARCHI 
Directeur : M. le Professeur F. FLEURY 
Directeur : Mme Caroline FELIX 
Directeur : M. Hassan HAMMOURI 
Directeur : M. le Professeur S. AKKOUCHE 
Directeur : M. le Professeur Georges 
TOMANOV 
Directeur : M. le Professeur H. BEN HADID 
Directeur : M. Jean-Claude PLENET  
Directeur : M. Y.VANPOULLE   
Directeur : M. B. GUIDERDONI  
Directeur : M. P. FOURNIER 
Directeur : M. G. PIGNAULT 
Directeur : M. le Professeur C. VITON 
Directeur : M. le Professeur A. MOUGNIOTTE 
 
Directeur : M. N. LEBOISNE 
 
  
 
 
4 
Remerciements 
 
J’aimerai remercier Dr Michèle SOUYRI et Dr Evelyne LAURET pour avoir accepté 
d’évaluer mon travail de thèse et la qualité de ce manuscrit. J’aimerai aussi remercier Pr  
Kathrin GIESELER d’avoir bien voulu évaluer mon travail en participant au jury de thèse.  
Je remercie les Dr. Véronique MAGUER-SATTA et Thomas MERCHER pour leurs conseils 
précieux transmis lors des comités de thèse.  
Je ne saurai exprimer l’ampleur de ma gratitude à mon directeur de thèse le Dr. François 
MORLE tout d’abord pour m’avoir accepté dans son équipe, mais aussi d’avoir toujours été 
disponible, de s’être montré patient, d’avoir bien voulu m’apprendre le métier et me 
transmettre ses connaissances. Merci pour les discussions toujours enrichissantes, mais 
aussi de vous être accroché pour faire face aux temps difficiles. Merci d’être passionné par 
ce que vous faites. 
Je remercie énormément le Dr. Boris GUYOT pour s’être montré très patient, d’avoir pris 
le temps de m’expliquer les choses et pour les nombreux échanges m’ayant permis de 
progresser à de nombreux moments au cours de ma thèse. Merci pour ta franchise.  
Je suis reconnaissante envers Guy Mouchiroud et Michèle pour leur aide à différents 
moments de ma thèse. 
Un grand merci à tous les anciens et nouveaux membres de l’équipe, de même que les 
membres du laboratoire CGPhiMC pour la chaleureuse ambiance créée rendant ainsi le 
quotidien plus agréable. 
Je remercie sincérement pour leur encouragement et leur soutien mes amis qui sont aussi 
entrain de traverser cette épreuve. 
Je remercie aussi ma tante de m’avoir assez intrigué pour que je me lance dans cette 
aventure et pour ses nombreux conseils. 
Un grand merci à Raphael pour m’avoir toujours encouragé, m’avoir épaulé et rassuré et 
sans qui je n’aurai pu m’accrocher pour continuer à avancer durant cette épreuve.  
Je remercie par-dessus tous mes parents pour m’avoir toujours épaulé, toujours poussé à 
aller de l’avant, pour leur soutien infaillible et leurs conseils.  
  
 
 
5 
Régulations divergentes du récepteur c-Kit par la TPO et la tétraspanine CD9 : 
Implication dans le contrôle de la balance prolifération/maturation mégacaryocytaire 
 
La thrombopoïétine (TPO) favorise successivement la prolifération et la maturation des 
progéniteurs mégacaryocytaires, soulevant la question du mécanisme expliquant cette dualité 
d’action. La signalisation SCF/ c-Kit est essentielle pour la prolifération de tous les progéniteurs 
hématopoïétiques, alors que l’extinction de l’expression du récepteur c-Kit est requise pour 
l’engagement en différenciation terminale. Réciproquement, l’équipe a montré que la stimulation de 
la voie Notch affecte une sous-population  de progéniteurs bipotents érythro-mégacaryocytaires 
exprimant fortement CD9 (tétraspanine induite durant la maturation mégacaryocytaire) et favorise la 
reprise de leurs divisions au détriment de leur différenciation mégacaryocytaire terminale. Cet effet 
de la voie Notch s’accompagne d’une augmentation de l’expression de c-Kit. Ces observations m’ont 
conduite à m’intéresser aux mécanismes de régulation de c-Kit par la TPO en m’appuyant sur un 
modèle de progéniteurs bipotents immortalisés et dont la prolifération est strictement dépendante 
de la TPO (cellules G1ME). Les travaux réalisés durant ma thèse m’ont permis d’établir que (i) La 
stimulation des cellules G1ME par le ligand de Notch DLL1 favorise l’expression de c-Kit et réprime 
celle de CD9 (ii) L’activation inattendue de c-Kit par la TPO contribue à la prolifération (iii) c-Kit 
contribue activement à restreindre la polyploïdisation des cellules G1ME en présence de TPO (iv) La 
tétraspanine CD9 elle-même réprime l’expression de c-Kit à la membrane. Sur la base de ces 
résultats, nous proposons le modèle selon lequel, la TPO participerait à la fois à la prolifération  des 
progéniteurs du fait de sa capacité à activer c-Kit, mais contribue aussi à l’augmentation de 
l’expression de CD9 qui en atteignant un seuil  suffisant conduit à l’extinction de l’expression de c-Kit 
à la surface, entrainant alors l’arrêt des divisions et la différenciation mégacaryocytaire terminale. 
 
Mots-clés : TPO, Notch, c-Kit, tétraspanine, CD9,  différenciation érythro-mégacaryocytaire 
Divergent regulations of c-Kit receptor by TPO and CD9 in megakaryocytic cells: 
Implication in the dynamic control of the balance proliferation/differentiation 
 
The Thrombopoietin (TPO) favors both the proliferation and the maturation of megakaryocytic 
progenitors, raising the question of the molecular mechanism explaining its dual function. SCF/ c-Kit 
signaling is essential for all hematopoietic progenitors amplification, whereas terminal differentiation 
requires the extinction of c-Kit receptor expression. Reciprocally, we evidenced in our team that 
Notch stimulation enables the induction of c-Kit expression and act on a particular subpopulation of 
bipotent erythro-megakaryocytic progenitors highly expressing the tetraspanin CD9 (induced during 
megakaryocytic maturation) and favors their re-entry in a cycling state by blocking their 
megakaryocytic maturation. These observations lead to the investigation of the molecular 
mechanism of c-Kit regulation by TPO in a cellular model of bipotent progenitors immortalized and 
dependent on TPO, the G1ME cells. During my thesis, I evidenced that: i) Notch stimulation induces 
the expression of c-Kit while repressing CD9 expression; ii) Surprisingly TPO is able to activate c-Kit 
allowing its contribution to cell proliferation; iii) c-Kit also represses megakaryocytic polyploidization 
(endomitosis characterizing megakaryocytic maturation) of G1ME cells; iv) The tetraspanin CD9 
represses the expression of c-Kit. The ensemble of these data allows us to propose the following 
model wherein TPO activates c-Kit allowing the proliferation of megakaryocytic progenitors, while 
concomitantly induces the expression of the tetraspanin CD9 that will reach a sufficient level to 
provoke the extinction of c-Kit expression at the cell surface, thus enabling the arrest of cell cycling 
progress and the engagement into terminal megakaryocytic maturation.  
 
Keywords:TPO, Notch, c-Kit, tetraspanin, CD9, erythro-megakaryocytic differentiation 
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Résumé 
Même dans un environnement stable, tout progéniteur se divise un nombre limité de fois 
avant de s‘engager irrémédiablement en différenciation, suggérant ainsi l’existence d’une 
horloge cellulaire contrôlant son maintien à l’état indifférencié.  
Dans notre équipe, nous nous sommes interrogés sur les mécanismes moléculaires 
permettant le maintien à l’état indifférencié avant le basculement définitif en différenciation 
terminale et avons choisi comme modèle d’étude les progéniteurs hématopoïétiques 
bipotents érythro-mégacaryocytaires (MEP). Dans ce contexte, la voie de signalisation Notch 
étant connue comme un intervenant crucial du choix de destinée cellulaire, nous avons 
choisi de l’utiliser comme outil pour disséquer les mécanismes moléculaires contrôlant la 
balance prolifération/ différenciation des MEP. 
Ainsi, précédemment à mon intégration, des travaux de l’équipe ont mis en évidence un 
rôle positif de la voie Notch sur l’amplification de la descendance bipotente E/MK des 
progéniteurs MEP murins. Cette observation nous a amené à rechercher le mécanisme 
d’action de la voie Notch permettant l’amplification des MEP. Dans ce contexte, des travaux 
de l’équipe avaient permis de montrer que la destinée cellulaire des progéniteurs MEP 
reposait essentiellement sur l’antagonisme fonctionnel entre les deux facteurs de 
transcription Fli-1 et EKLF, tous deux requérant leur interaction avec un partenaire commun 
GATA1, afin d’induire respectivement la différenciation soit mégacaryocytaire soit 
érythrocytaire. De plus, l’action de la voie Notch sur l’amplification des MEP s’est avéré 
strictement dépendant de la présence de SCF, le ligand du récepteur c-Kit dont l’expression a 
été augmentée, suggérant l’intervention d’un axe Notch/c-Kit dans l’amplification des 
progéniteurs MEP. Par ailleurs, des travaux plus récents ont montré un effet plus prononcé 
de la voie Notch sur une sous-population de MEP exprimant fortement la tétraspanine CD9, 
initialement biaisée vers la différenciation mégacaryocytaire, suggérant ainsi une interaction 
fonctionnelle entre CD9 et la voie Notch impliquée dans le contrôle de la balance 
prolifération/ différenciation mégacaryocytaire. 
Ces observations ont amené plusieurs questions et les objectifs de ma thèse ont été  
premièrement d’explorer l’implication de GATA1 en aval de la voie Notch au cours de 
l’amplification des MEP, deuxièmement d’étudier la régulation de c-Kit par Notch et son 
 
 
7 
implication dans le contrôle de la balance prolifération/différenciation et enfin d’explorer 
l’interaction fonctionnelle entre Notch, CD9 et TPOR, ce dernier étant connu pour avoir un 
rôle double à la fois sur la prolifération et la différenciation des progéniteurs 
mégacaryocytaires.  
Ainsi, au cours de ma thèse j’ai étudié dans un premier temps la capacité de la voie Notch 
à réguler l’expression de GATA1 en formulant comme hypothèse que l’augmentation de son 
niveau d’’expression ou de phosphorylation permettrait de diminuer la stringence entre les 
facteurs Fli-1 et EKLF expliquant ainsi le maintien de l’état bipotent. Parallèlement, nous 
avons testé l’implication de la phosphorylation de GATA1 dans l’effet pro-amplificateur de 
Notch sur les MEP en utilisant un modèle murin exprimant une forme non-phosphorylable. 
J’ai pu observer que la stimulation des cellules L8057 par la voie Notch n’induit 
l’augmentation ni des niveaux d’expression ni de phosphorylation de GATA1. De plus, 
l’expression d’une forme non-phosphorylable de GATA1 n’a pas affecté la capacité de la voie 
Notch à induire l’amplification des progéniteurs bipotents MEP, permettant ainsi d’exclure 
l’implication de la phosphorylation de GATA1 dans l’effet pro-amplificateur de Notch sur les 
MEP. Au contraire de notre hypothèse de départ, j’ai pu démontrer un effet répresseur de la 
voie Notch sur l’expression de GATA1 dans les cellules L8057, qui a pu être confirmé dans les 
MEP natifs. Ces résultats suggérent ainsi l’intervention potentielle de taux diminués de 
GATA1 dans l’amplification des MEP.    
Dans un deuxième temps, j’ai exploré la régulation de c-Kit par la voie Notch et la TPO 
dans la lignée bipotente E/MK G1ME immortalisée en absence de GATA1 et en présence de 
TPO. Ainsi, j’ai pu démontrer que la voie Notch régule positivement l’expression de c-Kit 
directement au niveau transcriptionnel et cet effet s’est avéré indépendant des régulateurs 
les plus connus de c-Kit GATA2 et SCL. De plus, cet effet s’est accompagné par une 
répression de l’expression de marqueurs de différenciation mégacaryocytaire terminale 
comme CD9 et PF4. De manière plus importante, en couplant une stratégie d’ARN 
interférence et d’inhibiteurs pharmacologique, j’ai pu mettre en évidence l’implication 
critique de c-Kit dans la prolifération TPO-dépendante des cellules G1ME. De plus, j’ai pu 
mettre en évidence  une activation de c-Kit non par son ligand canonique le SCF mais par la 
TPO. Conjointement à son effet pro-prolifératif, c-Kit contribuerait à la répression de la 
différenciation mégacaryocytaire des cellules G1ME comme suggéré par l’augmentation de 
la population polyploïde en présence d’un inhibiteur de c-Kit, le Masitinib. De manière 
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originale, j’ai pu mettre en évidence un nouveau rôle de la tétraspanine CD9 dans la 
répression de l’expression de surface de c-Kit, comme attesté par la forte corrélation inverse  
de leurs niveaux d’expression observée suite à la transfection des cellules G1ME avec des 
siARN ciblant les transcrits de CD9.  
L’ensemble de ces résultats nous a permis de proposer un modèle expliquant le rôle 
double de la TPO sur le contrôle à la fois de la prolifération et de la différenciation 
mégacaryocytaire. Ainsi, nous proposons qu’au cours de la progression vers la 
différenciation mégacaryocytaire, la TPO par le biais de l’activation de c-Kit permet 
l’amplification des progéniteurs mégacaryocytaires tout en restreignant leur différenciation 
terminale. Concomitamment, l’augmentation progressive de l’expression de CD9 cause la 
diminution progressive de l’expression de c-Kit jusqu’à atteindre un niveau seuil causant la 
perte totale de son expression et signant ainsi l’engagement définitif en différenciation 
terminale.  
En somme, mes travaux de thèse ont permis de mettre en évidence l’intégration de 
signaux Notch et TPO sur la régulation de GATA1, c-Kit, et CD9. Ces acteurs feraient partie 
d’un même réseau qui contribuerait à la régulation de la balance prolifération/ 
différenciation des progéniteurs bipotents MEP. Nous proposons que la voie Notch permette 
le maintien des MEP en restreignant leur différenciation à la fois érythrocytaire et 
mégacaryocytaire par la répression de l’interaction de GATA1 avec les facteurs de 
transcription Fli-1 et EKLF. D’un autre côté, nous proposons que Notch induise l’expression 
de c-Kit en réprimant l’expression de ses régulateurs négatifs GATA1 ou CD9, définissant 
ainsi un axe Notch/c-Kit favorable à l’amplification des progéniteurs à l’état bipotent.  
En nous basant sur des études récentes mettant en évidence l’implication de CD9 dans le 
contrôle de certaines voies de signalisation à travers le contrôle de leur sécrétion sous forme 
d’exosomes, ainsi que l’intense activité sécrétoire précédemment décrite des 
mégacaryocytes, mon travail de thèse ouvre sur une nouvelle perspective impliquant le 
contrôle de l’engagement en différenciation mégacaryocytaire signée par le contrôle par 
CD9 de la sécrétion de c-Kit sous forme d’exosomes.  
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Figure 1: The different fates of hematopoietic stem cells 
Stem cells transit between active (cell cycling) and dormant (quiescence) states. By exiting 
the cell cycle and entering in a quiescent state, stem cells are protected from external 
damaging agents. By symmetrical divisions, stem cells can generate two identical stem cells 
and amplify their pool without losing their multipotency. By asymmetrical divisions, stem 
cells generate a stem cell with conserved multipotency (self-renewal) and a second cell 
which can either differentiate inducing the progressive loss of oligopotency and self-renewal 
abilities or becomes senescent.  
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1 Hematopoiesis 
 
The hematopoietic system is responsible for the production of all mature blood cells, which 
have to be renewed continuously in steady state condition because of their limited lifespan 
or in stress condition when facing infections or hemorrhage. Mature blood cells derive from 
hematopoietic stem cells (HSC) which irrevocably lose their multipotency or die by 
senescence after multiple cell cycles. As presented in Figure 1, HSCs can be maintained 
through either cell cycle exit and entering a quiescent state, or through self-renewing 
(asymmetrical division) and amplification (symmetrical division). Consequently, HSCs can 
replenish blood cells compartment throughout all individual lifespan. Thus, the balance 
between quiescence, amplification/self-renewal and differentiation has to be tightly 
regulated in order to avoid stem cell pool exhaustion.  
Mature blood cells (including lymphocytes, macrophages, granulocytes, platelets and red 
blood cells) are produced in a hierarchical manner through the successive differentiation of 
the multipotent hematopoietic stem cell into pluripotent then bipotent and monopotent 
progenitors. This hierarchical model implies that HSC has to be activated in order to 
generate all mature blood cells. Nevertheless, recent studies pointed out unexpected 
overlap between stem and progenitor cells properties, HSC pool heterogeneity and special 
properties of megakaryocytic biased HSC. In the first part of this chapter I will present our 
current understanding of megakaryocytic cells production according to the classical 
hierarchical model of hematopoiesis, while in the second part I will summarize recent 
observations highlighting the proximity between HSC and megakaryocytic lineage.  
1.1 Hierarchical processing of hematopoiesis 
The hierarchical model was built from progeny analyses of hematopoietic stem/progenitor 
cells either in vivo by transplantation or in vitroby colony assays. These techniques were 
allowed and complemented by HSC and progenitors purification upon their fractionation 
based on different sets of cell surface markers. Using serial or competitive transplantation 
assay, different subtypes of HSC were discovered depending on their self-
renewal/maintenance ability: Long-term HSCs (LT-HSCs) are the most primitive and 
differentiate into  
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Figure 2: The standard hierarchical model of hematopoiesis 
Multipotent hematopoietic stem cells with long-term self-renewal ability (LT-HSC) 
differentiate and lose progressively their self-renewal capacity giving rise to short-term (ST-) 
HSCs and multipotent progenitors (MPP). MPP give rise to either common lymphoid (CLP) or 
common myeloid pluripotent progenitors (CMP). CLP further differentiate into monopotent 
progenitors responsible for the generation of B or T lymphocytes or Natural Killer cells (NK). 
CMP further differentiate into bipotent progenitors either common to granulocytes and 
monocytes (GMP), or common to erythrocytes and megakaryocytes (MEP). Monopotent 
erythrocytic progenitors terminally differentiate into red blood cells, while megakaryocytic 
progenitors differentiate into platelets.  
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less self-renewing short-term HSCs (ST-HSCs), then into multipotent progenitors (MPP). Both 
in vivo and in vitro studies showed specific lineage-combinations, thus suggesting the 
existence of common pluri- or bi-potent progenitors. Indeed, MPP differentiate into either 
common lymphoid progenitor from which B and T lymphocytes and Natural Killer cells are 
derived, or into common myeloid progenitor (CMP) from which bipotent megakaryocyte 
erythrocyte progenitor (MEP) and granulocyte monocyte progenitor (GMP) are derived. The 
bipotent MEP further differentiates into monopotent erythrocytic (producing red blood cells 
(RBC) or monopotent megakaryocytic progenitor (producing platelets) and the bipotent 
GMP further differentiate into monopotent granulocytic progenitor (producing all types of 
granulocytes) or into monopotent monocytic progenitor (producing monocytes/ 
macrophages when infiltrated into tissues) (Figure 2)(Akashi et al., 2000). 
 
1.2 Main regulators of HSC cell fate 
Whether remaining in a quiescent state, proliferating or differentiating into one or another 
lineage, HSCs and progenitors choice is governed by a complex and permanent crosstalk 
between external signals (represented by the microenvironment including cytokines) and 
internal signals (represented by signaling pathways and their influence on transcription 
factors and micro-RNAs networks). Given the huge number of studies on HSCs cell fate 
maintenance and differentiation, here I will only exemplify some general regulation 
mechanisms and cite some main important actors controlling HSCs cell fates.  
1.2.1 Cytokines and receptors 
Hematopoietic stem and progenitor cells are under the influence either of common 
cytokines necessary for their proliferation and survival such as the Stem Cell Factor (SCF), or 
of lineage-specific cytokines acting also on progenitors’ maturation such as Interleukin-7 for 
lymphocytes B and T, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) for 
granulocytes and monocytes, erythropoietin (EPO) for red blood cells and thrombopoietin 
(TPO) for platelets (Figure 3). The integration of external signals is ensured at the cell 
membrane by receptors which haveselective affinity for their specific ligands.For example, 
SCF binds to c-Kit receptor, EPO to EPO-R and thrombopoietin (TPO) to c-MPL. This level of  
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Figure 3: Main cytokines, cytokine receptors and transcription factors controlling 
hematopoiesis  
A: Hematopoietic tree on which are indicated the main cytokines (green), cytokine-
receptors (blue) and transcription factors (red) contributing to each lineage commitment 
and identity.  
B: Focus on the main transcription factors and miRNA controlling bipotent (blue), 
erythrocytic (red) or megakaryocytic (green) lineages identity. Functional cross-antagonism 
between FLI-1 and EKLF is one of the main transcriptional mechanisms involved in the 
commitment between erythrocytic and megakaryocytic lineages. Few specific differentiation 
markers expressed in mature red blood cells or platelets are indicated at the bottom.  
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specificity is complemented by selectiveexpression of eachcytokine/receptor couple for 
each lineagewhich can mediate different cellular responses depending on the cell context or 
history. As a matter of fact, the same signaling pathway can induce opposed effects when 
comparing two different cellular contexts. For instance, TPO can both induce proliferation or  
quiescence of HSC (Yoshihara et al., 2007)and SCF/c-Kit stimulates proliferation and 
survival in stem and all hematopoietic progenitors, whereas it is essential for mast cells 
differentiation (Serve et al., 1995)(Papadimitriou et al., 1995) 
1.2.2 Transcription factors 
Transcription factors, which levels can be modulated in response to cytokines, act in 
combination by forming activating or repressing complexes and inter-regulate their 
expression in order to define lineage specific transcriptional programs (reviewed in (Sarrazin 
and Sieweke, 2011). For instance, HSCs and myeloid progenitors identity is defined notably 
by common transcription factors members of GATA and ETS families such as GATA-2 and FLI-
1. Otherwise, PU.1 transcription factor is essential for B-Lymphopoiesis and monopoiesis and 
is repressed by GATA-1 at the level of the pluripotent CMP or by GATA-1 and GATA-2 at the 
level of megakaryocytic progenitors in order to maintain cell identity. Among other 
important lineage-specific transcription factors we can cite GATA-3 for T-lymphopoiesis, 
CEBP-α for granulopoiesis, EKLF for erythropoiesis and FLI-1 for megakaryopoiesis (Figure 3). 
 
1.2.3 The hematopoietic niche 
The activity of HSCs is regulated by external signals provided by their microenvironment 
which is located into the bone marrow and called hematopoietic niche(reviewed in (Boulais 
and Frenette, 2015)(Figure 4). The hematopoietic niche is innerved by the sympathetic 
nervous system and vascularised by specialized venules called sinusoids and by arterioles. 
Principal cell types composing the hematopoietic niche are notably osteoblasts, endothelial 
cells, mesenchymal progenitors but also hematopoietic cells such as megakaryocytes and 
macrophages.  
The hypothesis of low oxygenic niche (hypoxia) being essential for the maintenance of 
HSCs by quiescence and self-renewal is mainly based on the correlation between gradual cell 
cycle staining and distance from blood flow. Indeed, on the contrary to short-term cycling 
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Figure 4: The hematopoietic niche : Cellular and molecular components affecting HSCs 
function 
HSCs (black) evolve in a specialized microenvironment called niche which is located into the 
bone marrow.  The niche is vascularized by arterioles (blue) and specialized veinules called 
sinusoids (red), as well as innerved by the sympathetic system represented here by Schwann 
cells. The cellular components of the niche influencing HSCs function are osteoblasts (brown) 
and several other hematopoietic or non hematopoietic cells (grey) including endothelial cells 
(EC), Mesenchymal stem and progenitor cell (MSPC), as well as megakaryocytes (MK) and 
macrophages. Niche cells affect HSCs function by secreting different factors, or through the 
expression of different ligands (in green) which bind to their specific receptor (in blue) on 
HSCs. 
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HSCs, quiescent long-term HSCs were located far from blood flow(Winkler et al., 2010). 
Furthermore, they were characterized by a hypoxic profile based on low mitochondrial 
activity (Simsek et al., 2010), location into a sub-fraction of the bone marrow positively 
stained with pimonidazole (Parmar et al., 2007)(chemical agent forming complexes only into 
reduced environment) and a high level of hypoxia induced factors (HIF-1 α) (Takubo et al., 
2010).  
This hypothesis was recently reassessed based on the refinement of HSCs location in 
relation to the vasculature and the reinterpretation of the hypoxic profile.As a matter of 
fact, HSCs are located into the endosteum (bone surface) with no preferential association 
with sinusoids or arterioles (Nombela-Arrieta and Silberstein, 2014). A complementary study 
showed that HSCs location depends on their cycling state as quiescent LT-HSCs are enriched 
into the endosteum and preferentially associated with arterioles, whereas their activation 
induces their migration next to sinusoids (Kunisaki et al., 2013).Besides, direct measurement 
of O2 concentration confirmed the global hypoxic state of the niche but highlighted its 
heterogeneity. Surprisingly, O2 concentration was lower next to sinusoids and higher next to 
arterioles (Spencer et al., 2014). Additionally, global hypoxia into the niche and the hypoxic 
profile of HSC can be explained by a combination of intrinsic and extrinsic factors. 
Intrinsically, HIF-1 expression is stabilized by MEIS-1 (Simsek et al., 2010), a co-factor for HOX 
transcription factors (Shen et al., 1999). Extrinsically, SCF (Pedersen et al., 2008) and TPO 
(Kirito and Kaushansky, 2005)induce HIF-1α expression.  
SCF is mostly produced by endothelial and perivascular cells and is essential for the 
maintenance of HSCs(Ding et al., 2012). Endothelial cells also express Notch ligands which 
regulate HSCs maintenance(Bowers et al., 2015; Butler et al., 2010; Chiang et al., 2013). TPO 
is produced by osteoblasts (Yoshihara et al., 2007)and megakaryocytes(Nakamura-Ishizu et 
al., 2014b) and induces HSCs quiescence (Qian et al., 2007). The regulation of HSC activity by 
megakaryocytes will be detailed in the following chapters. 
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Population name Molecular marker Reference 
MEP Lin- Sca1- cKit+ IL7R- CD34-CD16/32 
low 
(Akashi et al., 2000) 
PEM Lin- Sca1- cKit+ CD34-CD16/32 low (Sanchez et al., 2006) 
PreMegE Lin- Sca1-cKit+ Flk2- IL7Rα- CD34- 
CD41- CD150+ CD105 low 
(Pronk et al., 2007) 
BEMP Lin- Sca1- cKit+ Flt3- IL7Rα- 
CD150+ CD105 low CD9 low 
(Ng et al., 2012) 
MERP HSC Lin- cKit+ CD34- Sca1+ CD150+  CD41 
+/-  
(Yamamoto et al., 
2013) 
 
 
Table 1: Prospective purification of bipotent erythro-megakaryocytic progenitors identified 
in mice 
Membrane markers used for mouse bipotent erythro-megakaryocytic progenitors 
prospective purification by FACS and the corresponding references describing their 
phenotype are indicated. Functional data indicate that PreMegE and BEMP largely overlap, 
whereas MEP subset is included in the PreMegE/BEMP. PEM are bipotent cells derived from 
MEP identified in stress conditions and are unable to proliferate in vitro.  MERP HSCs have 
been identified by single cell transplantation showing long term repopulation activity with 
only erythroid and megakaryocytic potential. MERP differ from other bipotent progenitors 
by the expression of stem cell marker Sca1.  
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1.3 The main regulators of the bipotent MEP cell fate 
1.3.1 The bipotent megakaryocyte erythrocyte progenitor (MEP) 
The existence of a bipotent erythrocytic megakaryocytic progenitor was first evidenced by 
in vitro observation of mixed colonies containing both erythrocytic and megakaryocytic cells, 
following flow-cytometry sorting of human bone marrow cells according to CD34 and CD38 
markers (Debili et al., 1996). Next, the purification of murine MEPs was reported from 
different sources like spleen, bone marrow from normal or anemia-stressed mice(Akashi et 
al., 2000)(Vannucchi et al., 2000) or fetal liver (Traver et al., 2001).As recapitulated in Table 
1, combinations of cell surface markers were used for MEPs purification including CD34, 
CD16/32 (Akashi et al., 2000), CD9 and CD150 (Ng et al., 2012). Interestingly, when seeded in 
vitro, MEP progenitors generate not only mixed colonies but also uni-lineage erythrocytic 
and megakaryocytic colonies, suggesting low stability of the bipotent state leading to rapid 
commitment toward either lineage.  
 
1.3.2 Erythropoiesis 
Erythropoiesis is the process allowing the production of red blood cells (RBC) which are 
responsible for tissue oxygenation. RBCs highly express hemoglobin, an iron-containing 
molecule which is able to bind oxygen.  
1.3.2.1 The cooperation between SCF and EPO signaling  
As schematized in Figure 5, the most immature erythrocytic progenitors are BFU-E (Burst-
Forming-Unit-Erythroid) from which are derived CFU-E (Colony-Forming-Unit-Erythroid). 
Both of BFU-E and CFU-E progenitors depend on the cooperation between SCF/c-Kit and 
EPO/EPO-R signaling for their survival and expansion in normal and stress 
erythropoiesis(Broudy et al., 1996; Huddleston et al., 2003). In hypoxic conditions, EPO 
production by the kidney is increased favoring the survival of CFU-E progenitors and 
subsequent increase of BFU-E production (Mide et al., 2001). While renewing divisions of 
erythrocytic progenitors requires both SCF and EPO, differentiation into mature erythrocytes 
requires the presence of EPO alone and concomitant loss of c-Kit expression (Muta et al., 
1995).  
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Figure 5: The erythrocytic differentiation steps and cytokine dependency  
A.The cooperation between Erythropoietin (EPO) and Stem cell factor (SCF) allows the 
proliferation of erythrocytic progenitors BFU-E (Burst-Forming-Unit-Erythrocyte), CFU-E 
(Cell-Forming-Unit-Erythrocyte) and pro-erythroblasts which express both c-Kit and EPO-R 
receptors. The transition to erythroid precursors is characterized by the loss of c-Kit 
expression (blue triangle) and the increase of EPO-R expression (red triangle). The extinction 
of c-Kit expression marks the dependency upon EPO alone (red rectangle) and the 
engagement into terminal erythroid divisions. During terminal maturation, the nucleus is 
condensed until its enucleation from the reticulocytes which then enter into circulation to 
generate mature red blood cells. The size of erythroid progenitors’ pool is regulated by 
apoptosis of early Fas expressing progenitors induced by late progenitors expressing FasL.  
 
B. Schematic representation of the erythroid island 
wherein a central macrophage is surrounded by 
erythroid cells at different stages of maturation 
(adapted from (Chasis and Mohandas, 2008)).   
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In vitro studies establish the role of SCF/c-Kit signaling during the expansion of pro-
erythroblasts by stimulating cell cycle progression mediated by c-Myc (Munugalavadla and 
Kapur, 2005). The cooperation between EPO and c-Kit can be illustrated by the stabilization 
of EPO-R by SCF/c-Kit signaling, which allows the induction of Bcl-xL and the survival of 
erythroid progenitors (Kapur and Zhang, 2001). Furthermore, c-Kit and EPO-R associate 
physically and SCF induces the phosphorylation of EPO-R in 32D myeloid cell line (Wu et al., 
1995). Additionally, co-stimulation by EPO and SCF shows synergistic effect on downstream 
signaling molecules such as JAK-2 (Arcasoy and Jiang, 2005), STAT-5 (Boer et al., 2003)and 
MAPK ERK-1/2 (Sui et al., 1998). During erythroid differentiation, c-Kit expression is down-
regulated by the combination of transcriptional repression by GATA-1 ((Munugalavadla et 
al., 2005) and depletion from thecell surfaceand subsequent degradation induced by EPO 
through Lyn kinase (Kosmider et al., 2009) and c-CBL(Masson et al., 2006; Odai et al., 1995; 
Zeng et al., 2005).Consequently, the absence of SCF/c-Kit signaling and the stimulation by 
EPO/ EPO-R signaling induces cell cycle arrest, partly mediated by p27 (Tamir et al., 2000), 
and engagement into maturation.  
1.3.2.2 From erythroblasts to RBC 
Erythroblasts undergo terminal divisions which are accompanied by cell size reduction and 
hemoglobin accumulation rendering the cytoplasm more and more acidophilic. The 
acidophilic erythroblast extrudes its nucleus becoming a reticulocyte which will lose its 
organelles (mitochondria and endoplasmic reticulum) and enter blood flow as a red blood 
cell.  
1.3.2.3 The erythroblastic niche 
The erythroblastic island is constituted of a central macrophage surrounded by erythroid 
cells at all stages of maturation(Chasis and Mohandas, 2008)(Bessis, 1958)(Mohandas and 
Prenant, 1978)(Figure 5). The regulation of RBC production rate is allowed by cell to cell 
interactions. Indeed, while undergoing terminal divisions, erythroblasts (Fas-Ligand positive 
cells) negatively regulate the number of erythrocytic progenitors (Fas receptor positive cells) 
by inducing their apoptosis through Fas/Fas-L interaction(De Maria et al., 1999). 
Besides, macrophages regulate many aspects all along erythropoiesis such as proliferation 
(Rhodes et al., 2008)adhesion-dependent survival (Fabriek et al., 2007; Hanspal et al., 1998) 
of erythroid progenitors, iron-uptake (Leimberg et al., 2008), as well as their maturation 
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(Chow et al., 2013), nucleus extrusion (Soni et al., 2006);(Yoshida et al., 2005) and finally 
senescent RBC phagocytosis in the liver and spleen. 
 
 
 
 
Figure 6: The megakaryocytic differentiation steps and cytokine dependency  
Megakaryocytic progenitors amplify under TPO and SCF signals and generate 
megakaryocytes which maturation depends onthe cooperation between TPO and other 
cytokines. Megakaryocytes’ maturation is characterized by endomitosis, the increase of 
cytoplasm/ nucleus ratio and the formation of membrane extensions, called pro-platelets 
which expand between endothelial cells and are shredded into platelets notably under the 
effect of blood stream.  
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1.3.2.4 Transcription factors essential for erythropoiesis 
At the MEP level, EKLF transcription factor antagonizes FLI-1 activity allowing the 
specification of erythrocytic versus megakaryocytic cell fate (Bouilloux et al., 2008; Frontelo 
et al., 2007)(Figure 3). During the amplification of erythrocytic progenitors, GATA-2 allows 
the expression of c-Kit and the progress into cell-cycle(Munugalavadla et al., 2005). The 
engagement into final maturation is characterized by the replacement of GATA-2 by GATA-1 
notably on GATA-2 (Grass et al., 2003)and c-Kit (Jing et al., 2008)transcription regulatory 
sequences, inducing their transcriptional repression. Along with its co-factors (FOG-1, LMO2, 
LDB1) and other transcription factors such as LRF, TAL-1, RUNX-1 and SCL, GATA-1 and EKLF 
induce the expression of erythrocytic genes responsible for heme synthesis, cytoskeletal 
modifications and energy production (Hodge et al., 2006)(Tallack et al., 2012)(Dore et al., 
2012).  
 
1.3.3 Megakaryopoiesis 
Megakaryopoiesis is the process allowing the production of platelets, important for blood 
vessel repair due to their expression of adhesion proteins, their aggregation and pro-
inflammatory functions. Megakaryopoiesis is an active process allowing the production of 
approximately 1011 platelets per day in humans, a number that can be induced 10 timesupon 
emergency(Kaushansky, 2005). 
1.3.3.1 From megakaryocytic progenitors to platelets 
As schematized in Figure 6, the most immature megakaryocytic progenitors are BFU-MK 
(Burst-Forming-Unit-Megakaryocyte) from which are derived CFU-MK (Colony-Forming-Unit-
Megakaryocyte). Both CFU-MK and BFU-MK progenitors amplify under TPO/c-MPL(Ng et al., 
2014)and SCF/c-Kit (Zeuner et al., 2007) signals. Differentiation of CFU-MK allows the 
generation of megakaryoblasts which undergo variable number of cytokinesis-abortive 
mitosis,also called endomitosis, inducing the increase of cell ploidy up to 16N in average in 
mammals. Following important accumulation of granules and membrane into the cytoplasm 
accompanied by nucleus size reduction, mature megakaryoblasts migrate next to blood 
vessels and extrude membrane extensions called pro-platelets which expand between the 
endothelial cells. By the help of blood stream, pro-platelets are shredded and platelets 
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released into the circulation where they will circulate during 7 to 10 days in humans before 
their degradation in the spleen (reviewed in (Chang et al., 2007)).  
1.3.3.2 Main Cytokines involved in megakaryopoiesis 
The TPO/c-MPL couple drives early steps of megakaryopoiesis as it allows the specification 
and amplification of megakaryocytic progenitors, their maturation (de Sauvage et al., 1996); 
(Gurney et al., 1994) and the control of platelets number (Ng et al., 2014). However, TPO 
and c-MPL knock-out mice stillhave 10% of the normal platelets count and do not suffer 
from hemorrhage(Bunting et al., 1997), suggesting the contribution of other cytokines to 
platelet production. For instance, the administration of Interleukin IL-6 (Neben et al., 1993) 
and IL-11 (Ishibashi et al., 1989) to mice enhanced megakaryocytes maturation. Additionally, 
numerous ex-vivo studies aiming to derive great number of platelets from human cord or 
peripheral blood for transplantation-recovery purposes pointed out different combinations 
of cytokines (Panuganti et al., 2013) that help the expansion and maturation of 
megakaryocytes, including CXCL-12, IL-9, EPO (Cortin et al., 2005; Fujiki et al., 2002), IL-3 
(Panuganti et al., 2010), Flt-3L (Proulx et al., 2003), GM-CSF (Lennartsson et al., 2004), and 
SCF (Minamiguchi et al., 2001). 
SCF contribution to megakaryopoiesis is based on several arguments. For instance, mutant 
mice with conditional deletion of SCF show slight thrombocytopenia (cited in (Kaushansky, 
2009)). Furthermore, enforced expression of constitutively active c-Kit mutant (D816V) in 
murine bone marrow cells enhances megakaryocytic differentiation (Ferrao et al., 2003). 
Additionally, SCF protects megakaryocytes from chemotherapy-induced apoptosis (Zeuner et 
al., 2007)(Bartucci et al., 2011). The most striking evidence for a role of c-Kit in 
megakaryopoiesis comes from HSCs progeny analysis in transplantation assay, where HSCs 
expressing high levels of c-Kit produce high amounts of platelets (Shin et al., 2014b). Except 
few in vitro studies showing the synergy between TPO and SCF to activate STAT-5 and JAK-2 
(Drayer et al., 2005) or MAPK (Minamiguchi et al., 2001), the molecular mechanism of TPO 
and SCF cooperation is poorly characterized, contrarily to EPO-SCF synergy. 
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1.3.3.3 Main transcription factors involved in megakaryopoiesis 
 
The identity of megakaryocytic progenitors is ensured by GATA-1 and GATA-2 transcription 
factors which antagonize the expression of lymphocytic-monocytic transcription factor SPI-
1/PU.1 (Chou et al., 2009; Iwasaki et al., 2003). All steps of megakaryopoiesis require the 
cooperation between GATA (1 and 2), ETS (Fli-1) and RUNX-1 transcription factors (Figure 3). 
GATA-1 interaction with its co-factor FOG-1 regulates megakaryocytic amplification, 
cytoplasmic maturation and platelet formation. While early steps are characterized by a high 
GABPα/Fli-1 ratio, this ratio is inverted during later steps. The endomitosis step is regulated 
notably by RUNX-1 and its target MYH-10 as well as by Tal-1 and its targets p21 and STAT-1. 
The formation of proplatelets is regulated by Tal-1, SRF, NF-E2 and Fli-1 and the activation of 
platelets is regulated by Runx-1 (reviewed in (Tijssen and Ghevaert, 2013). The expression of 
megakaryocytic markers such as CD41, CD42, GPIX, c-MPL and PF-4 is principally regulated 
by GATA-1, GATA-2, Tal-1, Runx-1 and Fli-1 (reviewed in (Szalai et al., 2006) 
 
1.4 HSC and megakaryocytic lineage proximity 
1.4.1 HSC heterogeneity 
The hematopoietic stem cell was initially identified with the observation of CFU-S, clones of 
lymphoid and myeloid potential forming nodules into the spleen of lethally irradiated mice, 
offering them radioprotection. The clones composing these nodules were maintained over 
serial transplantation into multiple recipients and showed low cycling activity, defining HSCs 
as unique cells with self-renewal ability and multipotency maintained by quiescence 
(reviewed in (Eaves, 2015)).  
1.4.1.1  Heterogeneity in repopulation kinetic 
Transplantation assays of bone marrow cells into irradiated recipient mice allowed the 
identification of different sub-populations of HSCs with some displaying only rapid 
replenishment of blood cells with transient splenic activity, while others displayed more long 
term reconstitution (Osawa et al., 1996). Moreover, quantification of long-term repopulating 
ability at the single cell level showed that stem cells progeny possess lower activity than 
parental cells, indicating limited self-renewal potential of HSC (Ema et al., 2014). The  
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Figure 7: Continuous loss of HSCs self-renewal ability correlates with progressive G0 exit 
delay until irreversible quiescence exit 
Quiescent HSCs are stimulated by external stimulus (lightning) inducing their cycling, but 
once activated some HSCs can return into quiescence instead of proliferate and 
differentiate. A recent study (Laurenti et al, 2015) has shown that LT-HSCs differ from ST-
HSCs by shorter delay in G0 exit which is at least partially determined by lower levels of 
CDK6. Based on this study and other data, we propose the following model wherein HSCs 
would progressively lose their self-renewal potential by accumulating CDK6, until their 
irreversible exit from quiescence following several iterative cycles of activation.  
c-Kit levels have also been shown to be higher in ST-HSC than in LT-HSC thus further 
suggesting that c-Kit levels might also increase during the successive rounds of stimulation of 
HSCs. Given the strong megakaryocytic bias of c-Kit High HSCs (Shin et al, 2014b), this model 
raises the intriguing possibility that megakaryocytic biased HSCs could correspond to “old” 
HSCs that have undergone a high number of reactivation rounds. Alternatively, different 
lineage bias of HSCs could reflect a sort of memory of all previous stimuli that led to their 
generation allowing the maintenance ofa specific subset that can be more rapidly activated 
upon emergency. For example, “old” HSC resulting from preferential EPO or TPO stimulation 
history could contribute to maintain specific erythroid or megakaryocytic stem cells, 
respectively. 
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transplantation of phenotypically enriched HSC population showed different duration of 
clone’s persistence defining retrospectively the parental cells as long-term HSC when 
sustained for over than ten months, intermediate-term HSC when sustained for six to eight 
months (Benveniste et al., 2010) and short-term HSC that extinguishes after only four to six 
weeks (Osawa et al., 1996) 
1.4.1.2 Heterogeneity in self-renewal ability and quiescence 
Quiescence is defined as the inability of cells to pass the restriction check point into G1 cell 
cycle phase and their exit into the so called G0 quiescent state which is accompanied by a 
low metabolic activity. Quiescent cells can be detected using different methods such as 
fluorescent labeling of mitochondrial activity (Rhodamine-123: (Nibley and Spangrude, 
1998), dual labeling of DNA (Hoechst 33342) with nucleolar marker Ki-67 or with RNA marker 
(Pyronin-Y: (Gothot et al., 1997), DNA synthesis monitoring (Thymidine 3H, BrdU 
incorporation(Passegue et al., 2005)), or nucleosome labeling (inducible H2B-GFP (Foudi et 
al., 2009). The use of labeling strategies either in vivo or ex-vivo before transplantation into 
myelo-ablated mice showed not only the heterogeneity of HSCs considering their cycling 
state, but also established that in contrast to short-term HSCs, long-term multilineage HSCs 
are mostly found in a quiescent state. The differences in methods and the duration or 
periodicity of labeling resulted in different estimations of HSC cycling frequency ranging 
from one cell division per 1 or 12 months (reviewed in (Nakamura-Ishizu et al., 2014a). The 
association of BrdU labeling and pulse-chase chromatin labeling using inducible H2B-GFP 
expression evidenced the existence of a deeply quiescent/dormant HSCs population that 
cycle upon stress and return to quiescence in steady state conditions (Wilson et al., 2008). 
Interestingly, the identification of non cell-cycle-related SLAM (Signaling Lymphocyte 
Activation Molecule) family members allowed prospective isolation of deeply quiescent HSCs 
standing in the CD229low CD244low  (Oguro et al., 2013) sub-fraction of CD150+ CD48- CD41- 
LSK cells (Kiel et al., 2005) with maintained long-term repopulation potential over serial 
transplantation assay and lymphoid-myeloid reconstitution ability. However, a recent study 
using Pyronin-Y/Hoechst fractionation over serial transplantation assay argues that highly 
purified HSCs with the latter markers do not encompass all long-term reconstituting HSCs 
but causes a substantial loss of cycling HSCs able of long-term reconstitution (Goldberg et al., 
2014). Contrarily to non-cell-cycle SLAM markers that allowed a modest refinement of  
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Figure 8: Progenitors’ stemness and hierarchical proximity between HSCs and MK lineage 
HSC is no longer considered as a unique cell, but is represented by a pool of heterogeneous 
transcriptionally primed cells that can give rise to self-renewable multipotent progenitors. 
The position of GMP was revised as it can derive either from a common lympho-myeloid 
progenitor (LMPP), or a common myeloid progenitor (CMP). Likewise, recent studies indicate 
that megakaryocytic cells can be generated either through the classical bipotent progenitor 
MEP derived from CMP or directly from megakaryocytic biased HSCs. Moreover, the 
existence of bipotent erythro-megakaryocytic and even monopotent megakaryocytic 
progenitors displaying long term repopulation activity has also been reported. These data 
highlight the striking proximity between HSCs and the megakaryocytic lineage (blue 
rectangle), as well as the less stringent frontier between the specific properties of stem cells 
and progenitors.  
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quiescent HSC population purity, the identification of cell-cycle marker CDK6 allowed 
resolving the heterogeneity of the latter population considering their delay of response to 
mitogenic signal which depended on their delay of exit from G0 quiescent state. Indeed, 
CDK6/CyclinD were found to be hierarchically expressed along the differentiation of HSC 
from LT-HSC (CDK6- CyclinD-) through ST-HSC (CDK6+ CyclinD-) to bipotent GMP (CDK6+ 
CyclinD+) (Laurenti et al., 2015). This study evidenced that the loss of self-renewal ability 
correlates with the decreased delay of exit from G0 quiescent state in a continuous manner 
along with the progressive expression of cell-cycle components (Figure 7). 
1.4.1.3 Preferential lineage output and transcriptional priming 
Previously, the observation of preferential association between some lineages led to the 
definition of myeloid versus lymphoid dichotomy as a first step of differentiation and 
multipotency loss of HSCs, whereas increasing numbers of more recent studies show that all 
HSCs do not contribute equally to all hematopoietic lineages because of their 
heterogeneity(Figure 8).  
Depending on the lineage output of different HSCs clones over serial transplantation, a 
subset of HSCs appeared to be less efficient for lymphoid reconstitution and was called 
Myeloid-biased HSC (My-HSC), as opposed to Lymphoid-Biased HSCs and Balanced-
HSCs(Muller-Sieburg et al., 2002). Another method consisted in in vivotracking of HSCs 
progeny over serial transplantation of either single cell HSC or in vitro cultured HSCs clones 
confirming the existence of different subsets of HSCs skewed either towards myeloid or 
lymphoid differentiation and were named α, β, δ and ϒ (Dykstra and de Haan, 2008). 
Moreover, the myeloid/lymphoid ratio was preserved over serial transplantation suggesting 
its dependency upon intrinsic cues. Of note, aging is associated with increased self-renewal 
and myeloid over lymphoid bias of HSCs (Rossi et al., 2005), suggesting the proximity 
between myeloid lineage and stemness.   
Contrarily to the previously spread idea of myeloid versus lymphoid dichotomy as the first 
differentiation choice faced by HSCs, the observation of preferential association between B 
lymphoid cells with mono-myeloid cells in CFU-S colonies (Jordan et al., 1990), the 
persistence of lymphoid potential in GMP and the lack of lymphoid and E/MK combination in 
prospectively isolated CD34 FLT3 (Adolfsson et al., 2005; Mansson et al., 2007) or CD150 
HSCs (Morita et al., 2010), initiated the idea of E/MK potential exclusion as the first choice 
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faced by HSC, followed by lymphoid exclusion and ending by GM differentiation. These 
hypotheses were lately confirmed by single cell transplantation (Oguro et al., 2013)assay and 
transcriptome analysis.  
First, both these analyses performed at the single cell level confirmed the heterogeneity of 
prospectively isolated HSC or pluripotent progenitors, independently of the phenotypic 
markers used (Guo et al., 2013; Mansson et al., 2007). Secondly, the comparison of the 
transcriptional profile of HSC sorted upon CD34 and FLT3 markers at the population and 
single cell levels showed a strong association between HSC and erythro-megakaryocytic 
programs, and virtually absent association between erythro-megakaryocytic and lymphoid 
programs. Granulo-monocytic program was equivalently associated with lymphocytic or E/ 
MK program (Mansson et al., 2007). Transcriptional profiling of single cell sorted CD48- 150+ 
HSC showed that the most striking variation when facing E/MK versus lympho-myelocytic 
choice resides in the transcription factor GATA-2 which negatively correlates with lympho-
myelocytic module (Flt3, Cebpa and Notch1) and positively correlates with both E/MK 
module (with GATA-1, Fli-1, c-MPL, CD41, CD150), and stem cells module (Runx-1 ,Meis-1, 
SCL) (Guo et al., 2013). Conversely, HSC priming toward lympho-myelocytic lineages is 
favored by transcription factor Ikaros (Ng et al., 2009), PU.1 and E2A (Dias et al., 2008), 
whereas HSC priming toward granulo-monocytic program is restricted notably by CEBPα 
(Hasemann et al., 2014). Thirdly, whereas E/MK transcriptional signature is associated with 
stemness, the restriction to lymphoid differentiation of HSC limits their self-renewal ability 
(van Galen et al., 2014).  
1.4.1.4 Transcriptional priming and quiescence 
Interestingly, transcriptome analysis on HSC sorted upon megakaryocytic markers shows a 
correlation with the quiescent state. For instance, CD34 Flt3 sorted long-term HSC sub-
fractioned upon CD9 marker shows a correlation between high expression of CD9 and low 
expression of Ki-67 (a marker of nucleolar activity) and cyclins, suggesting a quiescent state 
(Karlsson et al., 2013). Moreover, transcriptional analysis of HSC sorted upon FLT3 and sub-
fractioned depending on CD41 expression level complemented by transplantation studies 
from wild-type or CD41 knock-out mice evidenced that CD41+ HSCs are less proliferative, 
participate to long-term reconstitution, are myeloid biased and able to generate CD41- HSCs 
which are more proliferative and lymphoid-biased (Gekas and Graf, 2013). Similarly, 
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multiplex-qPCR on single cell CD150+ CD48- HSCs revealed that vWF HighHSCs present 
megakaryocytic transcriptional signature compared to vWF Low HSCs which express mainly 
lymphoid genes. Functional assay invivo revealed that vWF High HSCs are quiescent, depend 
on TPO for their reactivation and are highly biased toward platelet reconstitution on the 
short-term, but able to generate vWFLow and all hematopoietic lineages on the long-term 
(Sanjuan-Pla et al., 2013). In summary, the fraction of HSCs expressing high levels of 
megakaryocytic markers tends to be quiescent, long-term reconstituting, platelet/myeloid 
biased and more primitive as it generates more proliferative and lymphoid biased HSCs. 
Thus, HSCs are not unique cells, but a heterogeneous population of transcriptionally 
primed stem cells conditioning their cell-cycling and blood-cell type generation. Additionally, 
the hierarchical proximity between HSCs and bipotent E/MK or the transcriptional 
megakaryocytic priming of quiescent long-term HSCs suggests the ability of progenitors to 
act as stem cells.  
1.4.2 Progenitors’ stemness 
1.4.2.1 Progenitors are able to self-renew 
Contrarily to previous idea standing that HSCs are the only cells capable of multipotency 
and self-renewal, recent studies grant the self-renewal ability to progenitors themselves. 
Indeed, in anemia-induced stressed mice, a population of erythrocytic progenitors emerges 
into the spleen and is able of self-maintenance over long-term and serial transplantation 
proving its self-renewal ability (Harandi et al., 2010). Additionally, single cell transplantation 
of murine LSK HSCs sub-fractioned upon CD150 and CD41 markers into irradiated primary 
recipient followed by whole bone marrow transplantation into secondary irradiated 
recipient showed the existence of pluripotent (CMRP), megakaryo-erythrocytic bipotent 
(MERP) and megakaryocytic monopotent (MKP) progenitors displaying long term 
repopulation activity. These progenitors emerged from CD150+ CD41+ and CD41- 
subpopulation and sustainedover at least 8 weeks the production of myeloid, erythrocytes 
and megakaryocytes or only megakaryocytes, respectively (Yamamoto et al., 2013). Thus, 
even differentiation-restrained progenitors are able of self-renewal(Figure 8).  
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1.4.2.2 Progenitors are the main contributors to steady-state 
hematopoiesis 
Surprisingly, in steady state condition, HSCs are not activated every time that mature blood 
cells must be produced. A recent study set up a new murine model allowing the labeling of 
each individual cell at a given time with a unique inducible transposition event. By following 
HSCs progeny, this method allowed to determine the contribution of different clones to the 
renewal of different blood cell types at steady state. Using this approach, this study revealed 
that steady-state blood cells production is maintained by the successive recruitment of 
thousands of clones, with each clone contributing only transiently to mature progeny. 
Moreover this study revealed that in contrast to what occurs during transplantation, 95% of 
mature blood cells are generated directly from MPP and progenitors without activating HSCs 
division (Sun et al., 2014). 
Given the existence of HSCs displaying strong lineage priming and of multipotent/bipotent 
progenitors displaying long-term self-renewalcapability, the distinction between stem cells 
and progenitors becomes much less contrasted than thought before.     
1.4.3 Megakaryocytes are critical actors of HSC maintenance by acting directly 
into their niche 
Megakaryocytes are located in close proximity to HSCs in the hematopoietic niche being 
either in direct contact (Zhao et al., 2014), or at less than 2.5 cell-diameters (Nakamura-
Ishizu et al., 2014b)} or 25 microns (Bruns et al., 2014). Additionally,the treatment by 
diphteria-toxin of mice expressing the diphteria-toxin receptor under the control of Cre 
recombinase driven by the megakaryocytic PF4 promoter allowed the depletion of 
megakaryocytes which resulted in the reduction of quiescent HSCs number, the increase of 
their proliferation and the reduction of their long-term initiating potential. The HSCs of 
megakaryocyte-depleted mice displayed perturbed cell cycle due to the increase of Cyclin E/ 
CDK2 expression (Bruns et al., 2014)which is responsible for the entry in S phase. RNA-seq 
and ELISA assays revealed that the depletion of megakaryocytes actually induced a decrease 
of TPO levels in serum  (Nakamura-Ishizu et al., 2014b), as well as TGF-β (Zhao et al., 2014) 
and CXCL4/PF4(Bruns et al., 2014) levels into the bone marrow. Furthermore, among all the 
cell types present into the niche, megakaryocytes were responsible for most of these 
cytokines production. The injection of these cytokines in megakaryocyte-depleted mice  
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Figure 9: Progenitors with megakaryocytic potential  
Numerous studies indicate that the main pathway (black arrows) contributing to the 
production of megakaryocytes (Meg) at steady state involves a bipotent erythro-
megakaryocytic progenitor intermediate (named MEP, BiEMP or PreMegE depending onthe 
surface markers used for their prospective isolation) produced by multipotent stem cells 
through the CMP intermediate. However, recent studies indicate the existence of a specific 
subset of stem cells that while being multipotent are highly biased towards megakaryocytic 
lineage and directly generates unipotent megakaryocytic progenitor upon emergency. This 
alternative pathway (red arrows) thus contributes to the rapid and efficient restoration of 
platelets number during stress megakaryopoiesis (adapted from Nishikii et al, 2015).  
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restored the quiescence of LT-HSC and the implication of these molecules into HSCs 
quiescence was further confirmed in the corresponding knock-out mice models. (Bruns et 
al., 2014)(Kunisaki et al.,2013). Overall, these studies established thatseveral factors 
released by megakaryocytes are involved in the maintenance of HSCs quiescence in steady 
state conditions.  
Yet, megakaryocytes also secrete pro-proliferative factors inducing the expansion of HSCs. 
Indeed, mature megakaryocytes secrete IGF-1 (Insulin-like Growth Factor) and IGFBP-3 (IGF 
Binding Protein) which induce the expansion of HSCs in steady state condition (Heazlewood 
et al., 2013). Furthermore, in myelo-ablated mice, megakaryocytes rapidly and transiently 
liberate FGF-1 which allows their own expansion and subsequent HSCs expansion(Zhao et 
al., 2014). Following total body irradiation, megakaryocytes migrate to the endosteal niche 
and secrete PDGF-BB which induces the expansion of osteoblasts. The blockade of c-MPL 
mediated megakaryocytes migration reduces HSCs engraftment, contrarily to the injection of 
TPO which improves it (Olson et al., 2013)(Figure 4). 
In summary, megakaryocytes evolve in close proximity to HSCs and secrete various factors 
that induce either their quiescence, or their expansion in response to injury. 
1.4.4 Common features between HSC and megakaryocytic lineage 
Overall, the hematopoietic stem cells and the megakaryocytic lineage share numerous 
features. Megakaryocytes secrete different factors that influence their own migration, cell 
fate and modulate the expansion of the osteoblastic niche. Megakaryocytes contribute to 
the niche of HSCs either through direct contact or in a paracrine fashion, participating to 
HSCs engraftment and regulating the balance between quiescence and proliferation in 
normal or stress conditions. As HSCs and megakaryocytes share the same niche, they are 
subject to common signals such as TPO, SCF, Notch ligands to which they are able to respond 
through the expression of c-MPL, c-Kit and Notch receptors. Both HSCs maintenance and 
megakaryocytes’ differentiation depend on common transcription factors such as GATA-2, 
FLI-1, RUNX-1 and SCL. HSCs and megakaryocytes also share the expression ofseveral surface 
markers such as CD9, CD41, CD150 and vWF which make part of the transcriptional priming 
of HSCs that are characterized by quiescence, long-term maintenance and 
myeloid/megakaryocytic biased differentiation. The megakaryocytic marker CD9 is a known 
partner of CD81 tetraspanin, which is required for the re-entry into quiescence of HSCs after 
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injury (Lin et al., 2011). More strikingly, HSCs and megakaryocytes are hierarchically 
proximate as self-renewable megakaryocytic progenitors can derive directly from HSCs, a 
result demonstrated by paired daughter-cell transplantation (Yamamoto et al., 2013). 
Moreover, a recent study evidenced the existence of a subset of HSCs which express CD41, 
are able of multipotency and are skewed toward megakaryocytic differentiation in steady 
state conditions. In stress condition, CD41+ HSCs generate a second subset of HSCs 
expressing CD42b which is strongly skewed toward megakaryocytic differentiation and 
allows rapid and efficient platelets recovery (Nishikii et al., 2015)(Figure 9). 
All these data highlight the intriguing proximity between megakaryocytes and HSCs at 
different levels: physical, functional and hierarchical, although its relevance remains 
presently unclear. Among severalpossibilities, this proximity can indicate that common 
actors regulate both megakaryopoiesis and HSCs function, potentially through common 
mechanisms. In the next chapter of the introduction, I will present the different signaling 
pathways and the tetraspanin family and their role in the regulation of both HSCs and 
megakaryocytes cell fate.   
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Figure 10: Notch ligands and receptors structure  
Jag ligands differ from DLL ligands by the presence of a Cystein-rich (green flag) domain 
close to the transmembrane region (TM). Jag-1 harbors a PDZL domain in the C-terminal tail 
contrarily to Jag-2. DLL-3 differs from other DLL ligands by a degenerate DSL domain (Clear 
blue box). The domains common to both Jag and DLL ligands are indicated on the left: N1 
(Cystein-containing) and N2 (non Cystein-containing), DSL (Delta-Serrate-Lag2) domain 
containing DOS (Delta_OSM-11 like proteins) motif, EGF-like repeats (Epidermal Growth 
Factor), transmembrane region and intracellular PDZL (PSD-95/ Dlg/ ZO-1) motif. N1, N2, DSL 
and the two first EFG-like repeats correspond to the domain of interaction with Notch 
receptor. The different domains of Notch receptors are indicated on the right: EGF-like 
repeats containing multiple glycosylation sites, LNR (LIN-12 Notch repeats) and HD (Hetero-
dimerization domain).  HD-N and –C are separated by S1 cleavage site and HD-C (C-terminal) 
harbors S2 cleavage site. S3 cleavage site follows the transmembrane region. Intracellular 
Notch comprises from top to bottom: RAM (Rbp associated molecule), ANK (ANKyrin 
repeats) surrounded by two NLS (Nuclear Localization Signal), TAD (Transactivation domain) 
and PEST sequence. 
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2 Notch signaling pathway 
2.1 Notch signaling pathway 
Notch signaling pathway plays a crucial role in binary cell fate decisions in all three 
developmental cell layers and their derived tissues both during development and adulthood. 
Notch is activated following cell to cell contact and different mechanisms allow the 
distinction between signal receiving and signal emitting cell which have two opposite and 
mutually exclusive cell fates. This process called lateral inhibition, controls the balance 
between proliferation and differentiation in numerous tissues. 
2.1.1 Ligands and receptors 
Notch signaling is activated following the interaction between one of the 4 Notch receptors 
(Notch 1/2/3/4) with one member of the Notch ligand families Jagged (Jag-1/2) or Delta-like 
(Dll- 1/2/3).  
2.1.1.1 Ligands structure and maturation  
Both families of canonical ligands include the DSL (Delta, Serrate, Lag-1) domain, with the 
exception of Delta-like 3 which is the most structurally divergent ligand(Figure 10). In the N-
terminus, both families of ligands have cysteine conserved residues and EGF-like repeats 
involved in the interaction with the receptor. Following the transmembranar region, the C-
ter cytoplasmic tail includes the PDZL motif (PSD-95/ Dlg/ ZO-1 ligand)which allows the 
interaction with the cytoskeleton and plays a role independent of Notch. The presence of a 
Cysteine-rich domain in the juxta-membranar region characterizes Jagged (Jag) family 
members from their Delta-like counterparts.  
Notch ligands glycosylation and ubiquitinylation are essential for their maturation, the 
definition of their affinity to receptor and for signal transduction, all steps being mediated by 
endocytosis(Figure 11). Jagged and Delta-like ligands can also be proteolically cleaved by 
ADAM (A Disintegrin And Metalloproteinase) metalloprotease family members (9/10/12/17), 
generating soluble fragments which generally act as signaling inhibitors by competing for 
membrane-attached ligand binding (Reviewed (D'Souza et al., 2010)). 
2.1.1.2 Non canonical ligands 
Non canonical Notch ligands differ from their canonical counterparts by the absence of the 
DSL domain. Both canonical and non-canonical ligands share the capacity to interact with  
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Figure 11: Biosynthesis of Notch ligands and receptors  
Notch (purple rectangle) is O-fucosylated by POFUT-1 in the endoplasmic reticulum which 
is necessary for its N-glycosylation (Glucosamine N Acetyl GlcNAc) by Fringe in Golgi 
apparatus. Notch is cleaved at S1 site by Furin-like convertase enzyme generating a hetero-
dimer non-covalently attached at the level of HD domain before its expression at the cell 
surface as a mature receptor.   
Jag or DLL ligand (blue rectangle) is ubiquitinylated (black star) by the E3-Uquitin Ligase 
MYB, inducing its internalization into sorting endosome (SE) from which the ligand can be 
either targeted for lysosomal degradation or recycled to the cell surface into recycling 
endosome (RE). Ligand ubiquitinylation and recycling into the endosomal compartment are 
required for the activation of Notch receptor.  
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Notch receptors and to transduce Notch signals. Non-canonical ligands are structurally 
heterogeneous as they can be membrane-tethered or attached by GPI-anchor or secreted. 
Interestingly, some of the non-canonical ligands (such as DLK-1) were described as 
competitors for canonical ligands, whereas others (such as TSP-2) co-activate them 
(Reviewed in (D'Souza et al., 2010)).   
2.1.1.3 Notch receptor structure and maturation 
Notch receptors are synthesized as single-pass membrane-protein with a molecular mass 
ranging from 300 to 350 KDa. The receptor has to be glycosylated by POFUT-1 or Fringe to 
ensure its affinity and interaction ability to its ligand(Figure 11). For example, Fringe 
induced-glycosylation favors the interaction of Notch receptor with Delta-like ligands instead 
of Jagged ligands. The receptor is then matured by proteolytic cleavage at the S1 site with 
furin-like convertase, inducing the formation of a heterodimer which will translocate to the 
cell-surface. The extracellular part of Notch receptor(Figure 10) is composed of EGF-like 
repeats which interact with the ligand, LNR domain (Lin12 Notch repeats) which is essential 
for the repression of the receptor in the absence of the ligand and hetero-dimerization 
domain (HD) which contains the S2 cleavage site. Following the transmembrane region 
which contains S3 cleavage site, intracellular domain of Notch is composed of RAMdomain 
(RBPJ associated molecule) essential for the binding to RBPJ-k, ankyrin repeats (ANK), 
surrounded by two Nuclear Localization Signal (NLS), transactivation domain (TAD) which 
allows transcriptional activation and PEST C-terminal domain which is ubiquitinylated 
allowing the degradation of the receptor (Reviewed in (Kovall and Blacklow, 2010).  
2.1.2 Signal transduction 
In absence ofthe ligand, Notch receptor adopts an inactive self-inhibited compacted 
conformation due to the LNR domain that forms a ring-shaped structure around the HD 
domain thus hiding the proteolytic site S2(Figure 10).  
Following receptor-ligand binding(Figure 12), ligand ubiquitinylation by Neur or Mindbomb 
is essential for its clathrin and dynamin-dependent endocytosis in order to create the 
sufficient mechanical force and membrane constriction that triggers out the extracellular 
domain of the receptor and uncovers S2 cleavage site. For this reason, ligands have to be 
attached either to a membrane or coated on plastic support in order to allow Notch 
receptors activation. At the S2 site, Notch receptors are cleaved by a metalloprotease  
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Figure 12: Notch signaling pathway: activation and signal transduction  
Initially, Notch target gene (ie hes) transcription is repressed due to the binding of RBPJ-k 
(red oval) and transcriptional co-repressors (white squares) on its promoter. The interaction 
between Jag or DLL ligand and Notch receptor, through the interaction between signal 
sending cell (blue) and signal receiving cell (purple), induces the internalization of the ligand 
and the extracellular fragment of Notch into the signal sending cell, thus uncovering S2 
cleavage site (red star) on Notch receptor. Following the cleavage by ADAM10 
metalloprotease at the S2 site, Notch is further cleaved by the ϒ-secretase complex at the S3 
site, allowing the release of Notch Intracellular Domain (NICD). NICD translocates into the 
nucleus where it binds to Mastermind-Like (MAML) and RBPJ-k. The ternary complex recruits 
transcriptional activators (green squares) and the transcription of Notch target genes is 
activated. 
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member of the ADAM family, principally ADAM-10, generating a transmembranar fragment 
which will be further cleaved by the gamma-secretase complex. This complex is composed of 
Presenilin 1 and 2 catalytic subunit, Nicastrin which recognizes the substrate, APH2 that 
allows membrane localization and PEN2 which stabilizes the complex.  
The liberated intracellular domain of Notch receptor (NICD or ICN) then translocates to the 
nucleus. NICD lacks DNA-binding domain but interacts with RBPJ-k through its RAM domain. 
Initially, RBPJ-k binds to DNA in specific but low affinity manner on its site (GTGGGAA) and 
represses the expression of Notch target genes, due to its cooperation with histone 
deacetylase (HDAC) machinery and transcriptional co-repressors such as N-Cor, ETO and 
SMRT which are gathered by MINT. The binding of NICD to RBPJ-k allows the recruitment of 
Mastermind-like (MAML) and the formation of a ternary complex that possess low 
transcriptional activation potential. Due to existence of head-to-head RBPJ-k binding 
sequences on the promoter of target genes (described for hes-1 promoter) and the 
interaction between the ANK domains of multiple NICD molecules, the complex is stabilized 
and the signal can be amplified (Liu et al., 2010a). The ternary complex (NICD/RBPJ/MAML) 
recruits transcriptional activators such as the histone acetylase p300 and cooperates with 
tissue-specific transcriptional activators to induce the expression of Notch target genes 
(Reviewed in (Kovall and Blacklow, 2010)).  
2.1.3 Notch target genes 
Notch signaling directly activates the expression of Hes and Hey family members which 
correspond to the C class of transcriptional repressors from basic helix-loop helix (bHLH) 
protein family. This family also comprises transcriptional activators such as Myo-D and 
Mash-1 and Leucine zipper transcription factors such as c-Myc. There are 7 identified 
members of Hes family and 3 members of Hey family, but their direct activation by RBPJ-k/ 
NICD couple was assessed mostly for Hes-1, Hes-5, Hey-1 and Hey-2 (Reviewed in (Iso et al., 
2003)).  
Hes and Hey share common structure but can differ by their expression pattern and their 
mechanism of transcriptional repression. Both Hes and Hey are composed of bHLH and 
orange domains in their N-terminal region and a conserved tetrapeptide in the C-terminal 
region. They differ by a conserved residue in the basic region as Hes family members express 
a Proline residue, while Hey family members possess a Glycine residue(Figure 13).  
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Figure 13: HES and HEY structure and mode of function  
A. Schematic presentation of HES and HEY structures: HES and HEY are DNA binding 
proteins acting as transcriptional repressors that harbor a bHLH (basic Helix Loop Helix) 
domain, an Orange domain and a conserved tetrapeptide at the C-terminal extremity. HES 
and HEY proteins differ by the presence of a conserved Proline or Glycine residue at the 
same position in their N-terminal part. B. Schematic presentation of HES and HEY modes of 
action: 1- HES (black circle) are able to repress transcription by the sequestration of others 
b-HLH factor (blue circle). 2- HES homodimers can bind to N or C boxes and repress 
transcription through the recruitment of TLE co-repressor. 3- HEY homo-dimers can binds to 
B or C boxes and represses transcription through the recruitment of mSin3A repressor and 
HDAC. 4- HES and HEY (grey circle) can form hetero-dimers that bind to C boxes and repress 
transcription through the recruitment of TLE and HDACs (Histone Deacetylases). +++ indicate 
higher repression efficiency by HES/HEY heterodimers compared to homodimers. Nucleic 
sequence of the different consensussites is precised on the right.  
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bHLH proteins binds to DNA as dimers with each monomer attached to a specific half-site. 
Hes can bind to N and C consensus sites, while Hey mostly binds B and C consensus sites. Hes 
and Hey can act either as homodimers, or interact with each other to form a more efficient 
DNA-binding heterodimer that fix C consensus site. When forming homodimers Hes recruits 
principally TLE co-repressor protein, while Hey recruits N-CoR/ mSin3A repressor complex.  
Hes repress transcriptional activity mostly through its tetrapeptide, while Hey uses mostly 
its bHLH domain. Hes uses different mechanisms to repress transcriptional activity either by 
direct binding to DNA and the recruitment of HDAC machinery (active repression), or by 
sequestrating other bHLH proteins preventing them to form functional complexes with their 
partners (passive repression), whereas Hey acts mostly by active repression mode. Both Hes 
and Hey control their own expression by direct binding on their respective promoters.Hes-1 
and Hes-5 can have redundant functions on HSCs emergence as demonstrated by the 
absence of phenotype in simple mutant mice in contrast to double mutant mice ((Guiu et al., 
2013). Interestingly, RBPJ-k binding sites were found on gene promoters different from Hes 
and Hey, and the corresponding genes were induced with Notch stimulation establishing the 
existence of supplementary direct targets. For instance, NICD/RBPJ axis directly activates the 
expression of genes with various functions such as cell cycle regulators(ie Cyclin-D3: (Joshi et 
al., 2009)or transcription factor (ie GATA-2: (Guiu et al., 2013)).  
2.1.4 Signal downregulation 
Mastermind induces the recruitment of Cyclin-C-CDK8 that phosphorylates Notch 
intracellular domain on Serine residue of the C-terminal PEST sequence, inducing its 
recognition by Fbw7 E3-Ubiquitin Ligase and its proteosomal degradation (Fryer et al., 
2004)Furthermore, Mastermind can also be ubiquitinylated by UBC9 to downregulate Notch 
signaling. In addition, Hes phosphorylation on PKC consensus sites into the basic region can 
disrupt its DNA-binding (Strom et al., 1997) 
2.1.5 Non canonical Notch signaling 
 
The canonical Notch pathway implies the cleavage of Notch receptors at the cell surface by 
the gamma-secretase complex, its translocation into the nucleus and the activation of hes 
and hey transcription in an RBPJ-k dependent manner. Though, Notch is able to activate 
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signaling pathways and gene transcription by various other mechanisms, termed non-
canonical Notch signaling (Reviewed in (Ayaz and Osborne, 2014)). 
Increasing number of data illustrates the ability of non canonical Notch to activate different 
pathways. For instance, membrane-bound Notch induces AKT phosphorylation by mTORC2 
allowing the survival of T lymphocytesfollowing cytokine deprival, whereas the retention of 
Notch-1 in the nucleus abolished the survival of Hela cells (Perumalsamy et al., 
2009).Cytoplasmic Notch 1 interacts physically with CARMA-1, a component of T cells 
signalosome,thus allowing the activation of NF-?B (Shin et al., 2014a).The comparison 
between Notch and RBPJ-k conditional knock-out in mice evidenced the activation of NFκb 
by Notch independently of RBPJ-? mediated gene transcription during CD4+ T cells 
amplification (Dongre et al., 2014). Moreover, the cooperation between Notch and YY1 
transcription factor activates c-Myc transcription through non RBPJ-k binding-sites in K562 
cells(Liao et al., 2007). 
Besides, Notch signalingcan be activated independently of Notch receptors. For instance, c-
Jun directly activates Hey-2 transcription as attested by promoter assay in K562 myeloid cell 
line, which in turn inhibits GATA-1 transcriptional auto-activation through direct physical 
interaction leading to the inhibition of erythrocytic differentiation of human derived CD34+ 
cells (Elagib et al., 2004). 
2.2 Notch role in HSCs function 
 
Given that mice deficient for the expression of Notch molecular components die before the 
emergence of definitive hematopoiesis, the development of conditional deleted mice 
models was necessary to investigate the role of Notch during hematopoiesis. The effects of 
Notch components’ deletion on HSCs cell fate are detailed in Table 3. 
2.2.1 Through the hematopoietic niche 
 
Notch effect on HSCs can be mediated either by direct contact between niche cells and 
HSCs, or through the modulation of niche cells expansion (Reviewed in (Weber and Calvi, 
2010)).  
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 HSC Osteoblast Endothelial 
cells 
MSPC Macrophages 
Notch 1 X X  X X 
Notch 2 X     
Notch 3 Not expressed     
Notch 4 Not expressed     
Jag-1 Weak X X X  
Jag-2   X   
DL-1  X X X  
DL-4   X X  
Fringe X    X 
 
 
 
Table 2: Expression profile of Notch receptors and ligands into the hematopoietic niche 
(Reviewed in Liu et al., 2010; Weber et al., 2010). MSPC: Mesenchymal stem and 
progenitor cell.  
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As summarized in Table 2, Notch ligands (principally Jag-1, Jag-2, Dll-1 and Dll-4) and 
receptors (Notch 1 and 2) are expressed in HSCs and by diverse cells of the hematopoietic 
niche such as osteoblasts, endothelial and mesenchymal progenitor cells.  
Striking evidence for the implication of Notch in the regulation of HSCs cell fate through the 
niche came from the pan-depletion of Notch signaling through the conditional knock-out of 
Mib-1 (essential for Notch ligands maturation), which induces the development of 
myeloproliferative disorder (MPD), notably characterized by extramedullary hematopoiesis 
with greatly enhanced proportion of HSCs. The development of MPD was due to defective 
microenvironment as attested by its emergence into irradiated mutant mice transplanted 
with wild-type bone marrow cells and its absence into wild-type irradiated mice 
transplanted with mutant bone marrow cells. Although Notch activation was comparable 
into the HSCs enriched population LSK from normal and MPD-developing mice, the 
expression of constitutively active Notch-1 receptor restored the survival and MPD-absence 
of Mib-1 deficient mice (Kim et al., 2008). 
More precisely, Notch effect was mapped to the osteoblastic and endothelial niche 
components. The conditional depletion of Jag-1 in endothelial cells induces decreased 
number of Notch-2 expressing LT-HSCs, as well as their quiescence resulting in their 
exhaustion in serial transplantation assay (Poulos et al., 2013). Conversely, the expression of 
Notch ligands on endothelial cells induced the ex vivoexpansion of HSCs and required the 
direct interaction between HSCs and endothelial cells (Butler et al., 2010). Additionally, the 
loss of Jag-1 expressing osteoblasts reduced HSCs quiescence and self-renewal ability 
(Bowers et al., 2015), while increased production of Jag-1 by osteoblasts induces the 
expansion of NICD-expressing HSCs and this effect required the interaction of HSCs with 
osteoblasts (Calvi et al., 2003).  
Notch may regulate the osteoblastic niche, but with divergent effects depending on age 
and maturation stage (Reviewed in (Weber and Calvi, 2010). On one hand, pan-depletion of 
Notch signaling through the conditional depletion of Presenilin 1/2 (Gamma-secretase 
complex component) in osteoblasts induceslate-onset osteoporosis (decreased bone 
mass)(Engin et al., 2008).On the other hand, Presenilin 1/2 depletion in mesenchymal 
progenitors induced osteosclerosis (increased bone mass)(Hilton et al., 2008). Thus, Notch 
activation seems to inhibit osteoblastic differentiation of mesenchymal progenitors, while at 
later stage Notch would cause osteoclasts differentiation.  
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2.2.2 HSCs emergence 
 
Notch signaling pathway is essential, when cooperating with BMP-4 and Wnt pathways, for 
the emergence of definitive hematopoiesis from hematopoietic clusters into the AGM region 
during development through the regulation of endothelial versus hematopoietic cell fate 
and in close relationship with arterial formation (reviewed in(Gering and Patient, 2010); 
(Ciau-Uitz et al., 2014)). Notch-1, but not Notch-2 (Kumano et al., 2003),as well as Jag-1 
expression in the AGM are primordial for the emergence of HSCs through the control of 
GATA-2 expression (Robert-Moreno et al., 2007). Furthermore, the double mutation of hes-1 
and hes-5 induces total loss of functional HSCs. Further analysis of gata-2 promoter 
evidenced its double regulation by Notch, as Jag-1/Notch-1/RBPJ-k directly binds and 
induces the expression of GATA-2, whereas direct binding of HES-1 on a different region of 
the promoter represses gata-2 transcription. In the AGM, GATA-2 expression is tightly 
regulated by Notch in two opposite ways. On one hand, HES-1 allows the emergence of pre-
hematopoietic cells but inhibits their hematopoietic engagement through the repression of 
GATA-2. On the other hand, Jag-1/ Notch1/RBPJ-k signaling induces the expression of GATA-
2 allowing the emergence of functional HSCs (Guiu et al., 2013). In summary, Notch 
participates to the control of the balance between emergence/differentiation in fetal life.  
2.2.3 HSCs differentiation 
 
The most robust effect of Notch activation in hematopoiesis is its positive role in the 
induction of T-cell development at the expense of B-cell differentiation (Reviewed in 
(Rothenberg, 2014)).This was first indicated by clinical studies showing that 50 and 20% of T-
ALL (T cell Acute Lymphoblastic Leukemia) are associated with Notch-1 mutations either  
inducing increased expression of activated NICD-1 or affecting HD and LNR domains or PEST 
motif, respectively.Notch-1 expression is induced during lymphopoiesis with increased 
expression in T lymphocytes compared to B lymphocytes(Oh et al., 2013). Notch-1 regulates 
almost all steps of T-cells development such as amplification, cell fate decisions between α/β 
and ϒ/δ or T helper and T reg lymphocytes, as well as lymphocytes maturation from double 
negative to double positive CD4 CD8 stage.  
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Table 3: Hematopoietic phenotypes of murine knock-out models of various Notch signaling 
components  
Each lane of the table indicates in the successive columns: the name of the deleted gene, 
its known implication in Notch signaling pathway, the type of deletion (constitutive, 
inducible or cell specific), the main hematopoietic phenotype observed, whether this 
phenotype is hematopoietic cell autonomous and the corresponding reference. 
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While Notch-1 activation induces T-cell development, Notch 1 and Notch 2 inactivation in 
murine models (Table 3) is associated with the development of myeloproliferative disorders 
affecting particularly the bipotent GMP and granulocytes (Klinakis et al., 2011). This is 
further confirmed by exvivo studies demonstrating the inhibitory role of Notch-1 in myeloid 
commitment (Stier et al., 2002). Myeloid commitment is rather favored by the induction of 
Notch-2 expression from HSCs to erythroid progenitors as elegantly demonstrated by 
expression profiling and functional analyses of 4 Notch receptors in murine models (Oh et 
al., 2013)(Figure 14). 
 
2.2.4 HSCs maintenance/ amplification 
 
Several ex-vivo experiments using immobilized Notch ligands Jag-1, DLL-1 or DLL-4 argue 
for a positive role of Notch signaling during HSCs amplification ((Varnum-Finney et al., 2000); 
(Karanu et al., 2000; Karanu et al., 2003). Interestingly, a recent study using fed-batch 
culture strategy (dilution every 24h and replating every 4 days to test feed-back effects) 
assessed the negative effect of myeloid cells on HSCs expansion, while DLL-1 stimulation and 
subsequent STAT-3 activation led not only to the repression of myeloid granulomonocytic 
differentiation, but also allowed delayed expansion of most primitive progenitors CD34+ 
CD90+. Strikingly, the combination of DLL-1 stimulation with fed-batch culture allows the 
expansion of short-term HSCs in sublethally irradiated immunodeficient mice (Csaszar et al., 
2014).   
Notch contribution to HSCs maintenance is subject to divergent opinions. On one hand, 
Notch activity has been positively correlated with HSCs quiescence as Hes-1 transduced LSK 
produced a higher proportion of progenies able to exclude Hoechst label when transplanted 
into lethally irradiated mice (Kunisato et al., 2003). In accordance, the stimulation of HSCs 
ex-vivo by DLL-4 shows increased quiescent/proliferating LSK ratio concomitant to increased 
engraftment ability, short-term maintenance and increased expression of stemness over 
cyclines genes (Catelain et al., 2014). On the other hand, the conditional depletion of Notch 
ligands and receptors or pan-inactivation of Notch transducers through the conditional 
expression of a dominant negative form of MAML or the conditional depletion of RBPJ-k 
evidenced the absence of Notch effect on HSCs frequency and long-term-repopulating  
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Figure 14: Mapping of Notch receptorrs expression and functions 
Hematopoietic tree showing the differential expression of Notch-1 (blue area) in the 
lymphoid and Notch-2 (brown area) in the myeloid branches (relative expression levels are 
indicated by police sizes). The stimulating orrepressive effects of Notch signaling are 
indicated by green arrows or red inhibitory signs, respectively. The positive effect of 
Notchon self-renewal is indicated by curved green arrows and is mainly observed in stress 
conditions (adapted from (Oh et al., 2013)). 
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activity. These studies exclude the implication of Jag-1/Notch-1 during steady state 
hematopoiesis (Maillard et al., 2008; Mancini et al., 2005).Thus, the artificial activation of 
Notch is associated with positive effect on HSCs maintenance, while its repression argues for 
its dispensability in steady state condition. The apparent discrepancy of Notch implication in 
HSCs maintenance might be due to differences in signal intensities and kinetic of stimulation. 
Incidentally, when studying the effect of Notch on leukemia in a murine model of T-ALL, the 
authors evidenced that hyper-stimulation of Notch signaling induced only transient 
maintenance of LT-HSCs while sustained stimulation lead to their exit from quiescence and 
exhaustion (Chiang et al., 2013). 
     Interestingly, a study using conditional deletion of Notch-1 or Notch-2 seems to 
reconcile precedent discrepancy of Notch effect on the behavior of HSCs during either 
steady state or stress condition (Varnum-Finney et al., 2011). Actually, the preferential 
activation of Jag-1/ Notch-2/Hes-1 axis over Notch-1, potentially mediated by the 
maturation of Notch-2 by Fringe glycosyl-transferase, inhibits granulocytic myeloid 
differentiation. Confirming precedent results in conditional depletion models, neither Notch-
1 nor Notch-2 affected the repopulating activity of LSK over serial transplantation, indicating 
the dispensable role of Notch in homeostatic condition. However, Notch-2 signaling allows 
the expansion of ST-HSCs and MPP in stress condition favoring a rapid recovery after 
induced-exit of quiescence or after myelosuppression.  
In summary, Notch participates to the control of the balance between expansion and 
differentiation in adulthood by modulating HSCs niche and gene expression.Notch seems 
dispensable for HSCs maintenance in steady state conditions, while Notch-2 and DLL-1 allow 
rapid expansion of ST-HSCs in stress conditions. Notch delays HSCs differentiation, but 
strong induction of Notch-1 induces T lymphocytic differentiation, while Notch-2 activation 
allows myeloid commitment but represses granulo-monocytic lineages (Figure 14).    
 
2.3 Notch role in erythropoiesis 
 
Notch role in erythropoiesis is difficult to appreciate from incoherent in vitro studies using 
cell lines with inducible expression of constitutively active Notch-1 ICD evidencing either 
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positive role on erythrocytic differentiation in FDCP-mix cells (Henning, 2007), or negative 
role in K562 cells (Ishiko et al., 2005).  
The results from ex-vivo studies are more consistent when using immobilized Notch ligands 
DLL-4 or Jag-1 to stimulate CD34+ human progenitors derived from either cord blood 
(Poirault-Chassac et al., 2010; Sugimoto et al., 2006)fetal liver (Dando et al., 2005)or bone 
marrow (Walker et al., 1999). These studies show a positive effect of Notch signaling on the 
maintenance of erythrocytic progenitors while delaying their differentiation. Interestingly, 
one report used ex-vivo differentiation system to produce erythroblasts from human 
peripheral blood CD34+ cells, wherein SCF stimulation induces the expression of Notch-2 
receptor, at the expense of Notch-1, which interacts with endogenous Jag-1 to delay 
erythrocytic maturation (Zeuner et al., 2011).  
In-vivo studies support the positive role of Notch on erythropoiesis as murine models of 
pan-depletion of Notch signaling, through the conditional depletion of Notch modulators of 
endocytosis Mind-bomb-1 (Kim et al., 2008) or glycosylation (Zhou et al., 2008) show mild-
anemia. Interestingly, using transgenic mice harboring a Hes1-GFP (reporter of Notch 
activated pathway)combined with deletion of either one of the 4 Notch receptors, a recent 
study evidenced the preferential expression of Notch-2 and Hes-1 in CFU-E and the 
association between Hes-1 expressing LSK with erythrocytic transcriptome signature. The 
conditional expression of ICN-2 increased CFU-E progenitors and erythroblasts in the bone 
marrow whereas the conditional depletion of Notch-2 receptor led to the opposite effect 
(Oh et al., 2013).Conversely, another study based on functional and chromatin-
immunoprecipitation analyses on fetal liver derived from mice depleted for Ikaros 
transcription factor revealed the importance of Ikaros-mediated repression of Notch 
signaling for terminal erythroid differentiation (Ross et al., 2012). This study actually 
demonstrated the direct activation of Hes-1 by ICN/RBPJ-k during erythrocytic amplification, 
while erythrocytic terminal differentiation from the pro-erythroblast through the 
normoblast stage required the direct binding of Ikaros and the subsequent recruitment of 
GATA-1 and Ezh-2/ MI-2 complex inducing chromatin compaction and Hes-1 transcriptional 
repression.  
Notch is also crucial for correct response to stress erythropoiesis. Indeed, conditional 
depletion of Nicastrin in the hematopoietic system delayed the recovery of red blood cells 
when acute stress anemia was induced by phenylhydrazine treatment. 
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Furthermore,sublethal irradiation causes increased Hes-1 expression into the bone marrow 
and Notch-2 expression in bipotent PreMegE progenitors. Additionally, Nicastrin -/- 
irradiated mice display virtually absent erythroid progenitors as well as basophilic and 
orthochromatic erythroblasts in the bone marrow. Finally, Notch2 -/- irradiated mice harbor 
small spleen and reduced proportion of erythroid progenitors, while other myeloid lineages 
are not affected, indicating specific effect on stress erythropoiesis(Oh et al., 2013).  
The compilation of these data demonstrates the requirement of Notch-2 signaling for 
normal and stress erythroid progenitors’ expansion, while its repression is needed to allow 
terminal differentiation.   
 
2.4 Notch role in megakaryopoiesis 
 
Notch role in megakaryopoiesis remains difficult to fully appreciate due to contradictory 
results obtained in mice or humanstudies.  
On one hand,in a recent study (Mercher et al., 2008)Dll1 Notch ligand (either recombinant 
immobilized or expressed on the cell surface of OP9 stromal cells) was shown to stimulate 
the production of CD41+ megakaryocytic cells by murine LSK stem cells in-vitro.  The same 
study showed that mice engrafted by LSK stem cells expressing dnMAML1 (a dominant 
negative repressing Notch signaling) displayed decreased production of megakaryocytic 
progenitors,contrarily to mice engrafted by HSC expressing ICN4 (cleaved activated Notch-4) 
which displayed increased production of megakaryocytic progenitors and increased ploidy in 
megakaryocytes. Though, in both inactivation and hyper-activation of Notch cases, blood 
platelets count did not vary.Interestingly, the activation of Notch pathway increased the 
number of MEP at the expense of GMP,reciprocally inhibition of Notch signaling by 
dnMAML1 decreased the proportion of MEP. Surprisingly, the number of multipotent 
progenitors CMP did not vary. Taken together, these data clearly indicate that the 
stimulation of Notch signaling favors megakaryocytic commitment of murine HSCs and 
erythro-megakaryocytic commitment of multipotent CMP at the expense of the granulo-
monocytic lineages. Further studies showed thatthe short-cut allowing the generation of 
megakaryocytes from HSCs requires Notch induced activation of AKT while TPO seems 
dispensable, contrarily to the classical generation of megakaryocytes from CMPs which can 
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be initiated by TPO but is less dependent on AKT activation (Cornejo et al., 2011). More 
recently, part of the already known inhibitory effect of Ikaros on megakaryocytic lineage 
could be attributed to its ability to repress several downstream specific targets of Notch 
signaling, thus further strengthening the importance of Notch pathway in the positive 
control of megakaryocytic lineage specification (Malinge et al., 2013).   
On the other hand(Poirault-Chassac et al., 2010), the stimulation of human CD34+ derived 
from umbilical cord blood or purified bipotent MEP byDLL-4 ligand(either immobilized or 
expressed on OP9 stromal cells)inhibited megakaryocytic terminal differentiation, as 
attested by the production of a reducednumber of CD41+ CD42+ cells, lower ploidy and 
reduced proplatelets formation. Though, the number and proportion of CFU-MK 
megakaryocytic progenitors did not vary. DLL-4 stimulation induced-phenotype was 
correlated with the induction of Hes-1 expression and the concomitant decrease of 
megakaryocytic markers such as Fli-1, NF-E2 and β-tubulin, thus confirming the negative 
effect of DLL4-mediated activation of Notch signaling on terminal megakaryocytic 
differentiation. Importantly, this study also showed, as previously shown for Dll1, that DLL-4 
was also able to induce megakaryocytic differentiation of murine LSK stem cells. Whether 
these differences regarding the effect of Notch signaling on megakaryocytic lineage rely on 
different types of hematopoietic cells or to real differences in the function of Notch between 
human and mouse remains an open question  (Malinge and Crispino, 2010). 
 
2.5 Notch and Megakaryocytic Leukemia 
 
Activating mutations of Notch-1 receptor have oncogenic effect on the development of 
acute T-lymphoblastic leukemia (reviewed in (Van Vlierberghe and Ferrando, 2012)), 
whereas the inactivation of Notch signaling is associated with myeloid leukemia(Table 3). 
For instance, the alternative splicing of Notch-2 transcripts lead to the expression of a 
dominant negative form and the extinction of Hes-1 expression in the majority of AML 
samples (Adamia et al., 2014). 
On the contrary, the constitutive activation of Notch is associated with the development of 
acute megakaryoblastic leukemia (AMKL). Indeed, the fusion oncogene OTT-MAL generated 
by the translocation t(1;22) (p13;q13) transcriptionally activates and physically interacts with 
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RBPJ-k, even in the absence of Notch stimulation. This aberrant activation of Notch signaling 
lead to the hyper-proliferation of the 6133 OTT-activated cell line established from a murine 
model of AMKL and was accompanied by an aberrant megakaryocytic specification. Though, 
the total transformation into AMKL required secondary oncogenic event such as the 
mutation W515L of c-MPL receptor (Mercher et al., 2009). These data are consistent with 
previously described positive effect of Notch on megakaryocytic specification from murine 
HSCs. 
 
 
62 
 
 
Figure 15: SCF and c-Kit receptor proteins structure and isoforms 
A:The 6th exon of SCF transcript (black bar) encodes for a cleavage site. When present, SCF 
long isoform is cleaved producing a soluble and secreted form (s-SCF). Contrarily, the 
alternate spliced isoform lacking the 6th exon, and thus the cleavage site, produces a 
membrane-bound form of SCF (mb-SCF). Signal peptide is represented by hatched line and 
the transmembrane region is represented by orange box. 
B: Schematic representation of c-Kit receptor structure and isoforms. The names of the 
different domains are indicated on the left: c-Kit receptor comprises 5 Ig-Like domains in the 
extracellular part, the transmembrane region (TM) and two tyrosine kinase domains (TK1 
and TK2) separated by a kinase insert domain (KID) in the intracytoplasmic region. 
Alternative splicing events generate several isoforms differing by the presence or absence of 
either GNNK tetrapeptide in the extracellular part or of a serine residue in the KID domain. 
Alternative use of a cryptic promoter allows the production of a truncated protein called tr-
Kit which contains only TK2 and C-terminal tail.   
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3 SCF/c-Kit signaling pathway 
3.1 SCF/c-Kit signaling pathway 
The SCF/c-Kit signaling pathway relies on the activation the Kit receptor by its specific 
ligand SCF. Beside important roles in the control of pigmentation, gut function and 
reproduction, this pathway is one of the most important pathways involved in the control of 
hematopoiesis.  
3.1.1 SCF transcript and protein 
3.1.1.1 Sl locus 
SCF stands for Stem Cell factor, also called Kit-L for Kit Ligand, MGF for Mast Cell Growth 
Factor or SF for Steel factor. SCF is encoded by the Steel locus (Sl) the mutations of which 
lead to very similar phenotypes to that of c-kit mutations in mice(Williams et al., 1990). The 
Sl locus harbors 9 exons and maps on mouse chromosome 10 and on human chromosome 
12.  
3.1.1.2 SCF protein 
SCF is mainly produced by fibroblasts and endothelial cells throughout the body. The 
relative production between soluble and membrane-bound SCF varies greatly between 
tissues. For instance, into the bone-marrow the production of soluble SCF is 4 times more 
abundant than the membrane-bound isoform. The dosage of circulating soluble SCF is 
approximately 3 ng/mL in normal human serum. SCF is highly glycosylated and circulates 
under the form of a non-covalently bound dimers with 4 Cysteine residues forming intra-
molecular disulfide bounds contributing to maintain fully active conformation (Broudy, 
1997). 
3.1.1.3 SCF isoforms 
 SCF exists in two isoforms, one soluble and one membrane-bound which result from 
the alternative splicing of the 6th exon that contains the cleavage site required to generate 
the soluble form (Huang et al., 1992)(Figure 15). Both isoforms are able to activate c-Kit 
receptor. However, a deletion in Sl locusinducing the production of only the soluble form 
causes anemia in Sld mice, thus highlighting the importance of the membrane-bound 
isoform for normal function of c-Kit (Brannan et al., 1991). For instance, membrane-bound 
 
 
64 
SCF induced the proliferation of 32D cells whichwas demonstrated to be specifically 
dependent onc-Kit residue Y728 involved in the binding toPLC-ϒ(Gommerman et al., 2000). 
3.1.2 c-Kit transcript and protein 
3.1.2.1 kit gene 
kit gene harbors 21 exons and maps to chromosome 4 in human and to chromosome 5 in 
mouse.kit promoter has been thoroughly investigated (Cairns et al., 2003)and contains 
multiple binding sites for various transcription factorspositively regulating its expression 
such as SCL (Lecuyer et al., 2002). Most importantly, kit expression requires the concomitant 
activation of several enhancers, which arecontrolled either negatively by GATA-
1(Munugalavadla et al., 2005)or positively by GATA-2 (Jing et al., 2008). 
3.1.2.2 c-Kit protein 
The protein productof kit gene is a tyrosine kinase receptor (RTK) belonging to the subclass 
III (along with PDGFR and FLT3 kinases) which is characterized by an extracellular region 
consisting of five immunoglobulin-like domains (encoded by exons 1 to 9), a single 
transmembrane domain (encoded by the exon 10) and an intracellular domain composed of 
two tyrosine kinase domains (encoded by exons 11-14 and 16-20) separated by an insert 
region (encoded by exon 15)(Figure 15). During maturation, the 110 KD native c-Kit protein 
is heavily glycosylated at different N-glycosylation sites mainly located in the juxta-
membranar region, and thus reaches 145 to 160 KDa when present at the membrane. c-
Kitcontains 9 different ligand-induced phosphorylation sites on either Tyrosine or Serine, as 
well as ubiquitinylation sites essential for receptor internalization and degradation. 
3.1.2.3 c-Kit isoforms 
Alternative splicing of kit gene results in the production of several isoforms differing by the 
presence or absence of the tetrapeptide GNNK in the extracellular part of the 
juxtamembranar region. An additional isoform varies by the presence or absence of a serine 
residue in the kinase insert region. Furthermore, the use of a cryptic promoter in the 16th 
intron of murine kit gene (15th intron in human Kit gene) allows the production of a 
truncated form of the receptor (Tr-kit) that contains only the second part of the kinase 
domain and the C-terminal tail. Tr-kit was initially identified in post-meiotic germ cells of the 
testis (Rossi et al., 1992), but was later found specifically in hematopoietic stem and  
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Figure 16: SCF-dependent activation of c-Kit kinase 
In the absence of its ligand, c-Kit adopts a self-inhibited conformation. SCF dimers interact 
with Ig-like domains 1 to 3, and bring closer two c-Kit monomers. The two monomers 
dimerize through the 4th and 5th Ig-Like domain leading to the activation c-Kit tyrosine kinase 
activity. Activated c-Kit autophosphorylates first on Y568 and 570 then on the 7 remaining 
Tyrosine residues.   
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multipotent cells while its expression was lost in more committed progenitors(Zayas et al., 
2008). Despite the fact that Tr-kit lacks a kinase domain, this isoform is able to signal by 
inducing the formation of a multimeric complex comprising SFK whencontributing to the 
transition from metaphasis to anaphasis during mouse egg activation (Paronetto et al., 
2003).  
3.1.3 Signal transduction 
3.1.3.1 c-Kit kinase activation 
In the inactive state, the juxtamembranar region of c-Kit receptor forms a hairpin loop that 
inserts into the active site avoiding the access to the ATP binding site and thereby 
suppressing the kinase activity (Reviewed in(Lennartsson and Ronnstrand, 2012))(Figure 16).  
SCF ligand, circulating as a homo-dimer, binds to the first three Ig-like domains of c-Kit 
receptor that shapes in a way favorable for the tight maintenance of SCF ligand interaction 
and brings two c-Kit monomers in close proximity. The two monomers dimerize through the 
4th and 5th Ig-like domains, thus achieving the stabilization of c-Kit protein. The proximity 
between the two kinases domains of c-Kit induces their activation and trans-phosphorylation 
initially on the juxtamembranar Tyrosine residues 568 and 570. Next, trans-phosphorylation 
proceeds on the 7 remaining Tyrosine residues located in the kinase insert region (Tyr 703, 
721, 730 and 747) , the kinase domain (Tyr 823 and 900) and the C-terminal tail (Tyr 936). 
3.1.3.2 Downstream signaling 
As illustrated in Figure 18, phosphorylated sites of activated c-Kit receptor function as 
docking sites for the binding of several adaptor proteins and kinases, thus activating 
transduction pathways which controls cell proliferation and survival. The three main 
signaling pathways acting downstream of c-Kit in hematopoiesis are detailed below and 
schematized in Figures 17/ 18. 
 
PI3K/AKT pathway (Figure 17): SCF stimulation allows the activation of phosphoinositide 3 
Kinase (PI3K), through the direct binding of the p85 regulatory subunit of PI3K on c-Kit 
Tyrosine residue 721 or indirectly through the adaptor protein Grb2 on Tyr 936. The 
phosphorylation of PIP2 (Phosphatidyl-inositol 4-5 diphosphate) into PIP3 (Phosphatidyl- 
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Figure 17: Role of c-Kit-activated PI3K/AKT pathway in cell survival 
Activation of c-Kit induces the activation of PI3K (p85 pink sector + p110 pink square) which 
phosphorylates PIP2 into PIP3, allowing the activation of PDK-1 and the recruitment of AKT 
Ser/Thr kinase. PDK-1 and mTOC-2 activates AKT (green rectangle) by phosphorylation. 
Activated AKT (green rectangle with black star) sequestrates FOXO transcription factors 
preventing their translocation into the nucleus and thus the expression of pro-apoptotic 
genes. Activated AKT also sequestrates BAD disrupting its interaction with Bcl-xL. Bcl-xL 
interaction with BAX prevents the release of Cytochrome C (Curved black arrow) from the 
mitochondria (orange circle). Activated PI3K activates S6K and mTORC-1 allowing enhanced 
translation.   
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inositol 4-5 triphosphate) by p110 subunit of PI3K induces the recruitment of AKT a Ser/Thr 
kinase and the activation of PDK-1 (Phosphoinositide dependent kinase). AKT full activation 
is achieved by the phosphorylation on Thr-308 by PDK-1 and on Ser-473 by mTORC-2 
(mammalian target of rapamycin complex-2), thereafter playing a pivotal role in cell survival 
through different mechanisms. The first mechanism involves the mitochondrial pathway as 
activated AKT phosphorylates Bad on Ser-136 disrupting its interaction with Bcl-xL, which in 
turn can inhibit the release of cytochrome C induced by Bax, finally leading to the inhibition 
of apoptosis. The second mechanism involves AKT-dependent phosphorylation of forkhead 
transcription factors (FOXO) inducing their sequestration into the cytoplasm, thus inhibiting 
their nuclear translocation and activation of pro-apoptotic genes. The third mechanism 
involves PI3K-dependent activation of mTORC-1 and S6K which in turn stimulate translation.  
 
MAPK pathway: Mitogen Activated Protein Kinase pathway consists in three layers of 
signaling molecules,with cell-specific combinations, allowing signal transduction from the 
plasma membrane to the nucleus. c-Kit phosphorylation on Tyr 703 and 906 recruits the 
Grb2 adaptor, which is constitutively bound to the Sos (Son of Sevenless) guanine exchange 
factor, the latter being responsible for the recruitment of the small GTPase RAS. SCF 
stimulation induces the recruitment of another RAS guanine exchange factor, named vav-1 
and induces its phosphorylation(Munugalavadla and Kapur, 2005). The proximity between 
Sos and RAS allows the latter protein to proceed to the exchange between GDP and GTP, 
inducing its conformational change and activation. Next, kinases are activated sequentially 
as RAS activates Raf which activates Mek-1 which in turn activates ERK-1 and 2. ERK-1 and 2 
transcription factors translocate to the nucleus and induce the expression of target genes 
such as c-Fos and Elk-1, or act on cytoplasmic substrates such as RSK. c-Kit kinase also 
activates the three other major MAP kinases p38, JNK and ERK-5. 
SFK pathway: The Src family of tyrosine kinases contains eight cytoplasmic kinases, some 
of which are ubiquitously expressed (Src, Yes and Fyn), while others have more restricted 
expression pattern such as Lck, Hck, Lyn, Fgr and Blk in the hematopoietic system (Ingley, 
2008). They contain a unique membrane targeting domain, SH3 (Prolin-rich interacting 
domain), SH2 (phosphorylated Tyrosine interacting domain), a tyrosine kinase domain and a 
C-terminal tail with auto-inhibiting activity. SFK kinases interact directly with activated c-Kit 
receptor on Tyrosine 568/570 residues and their activity is rapidly increased within few  
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Figure 18: Main pathways activated by SCF/c-Kit signaling 
Phosphorylated Tyrosine residues (blue) on activated c-Kit function as docking sites for the 
recruitment of specific adaptors or signaling molecules allowing the activation of at least 
three main pathways. The activation of JAK/STAT pathway is mediated either by JAK2 
activation or through the recruitment and activation of Src family kinases (SFK), leading to 
the nuclear translocation of STATs factors. The PI3K/AKT pathway’s activation results from 
the recruitment either directly of p85 subunit or indirectly through Grb2 adaptor, leading to 
the cytoplasmic retention of FOX factors.The MAPK/ERK pathway activation is mediated 
either by the recruitment of Grb2 adaptor or through SFK leading to the nuclear 
translocation of ILK and JUN factors among others. c-Kit signaling also leads to the activation 
of other MAPK: p38 and JNK. 
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minutes. SFK induces the phosphorylation of c-kit on Tyrosine 900 and enhance its kinase 
activity. SFK participate to several steps downstream of c-Kit signaling, such as the activation 
of AKT in a raft-dependent manner (Arcaro et al., 2007), JNK, p38 and ERK-1/2. SFK 
contribute to the pro-survival effect of SCF on erythroid precursors by suppressing Fas-
mediated apoptosis signals(Endo et al., 2001; Nishio et al., 2001).  Lyn member of SFK family 
can induce JNK and STAT-3 expression in mast cells and contributes to SCF-mediated effects 
on proliferation and migration. Lyn also promotes the cell cycle transition G1/S in the 
megakaryocytic cell line Mo7e(Linnekin et al., 1997).  
 
JAK/ STAT: The Janus kinases are cytoplasmic Tyrosine kinases rapidly activated following 
ligand binding to RTK. JAKs interact and activate by phosphorylation members of the STATs 
family (Signal Transducers and Activators of Transcription). STATs transcription factors forms 
hetero-dimers between different members of the family and translocate to the nucleus 
where they activate gene transcription. JAK-2 is constitutively associated to c-Kit receptor 
and is transiently phosphorylated upon SCF stimulation. JAK-2 participates to SCF-induced 
proliferative response. STAT-1, STAT-5A and STAT-5B are activated by c-Kit kinase activity 
(Brizzi et al., 1999), inducing the enhancement of their DNA-binding. The co-stimulation of 
the megakaryoblastic cell line Mo7e with SCF and IL-9 induces the phosphorylation of STAT-3 
on a serine residue and its nuclear translocation (Gotoh et al., 1996).  
3.1.4 Signal downregulation 
Following activation, SCF/c-Kit signaling is physiologically shut-down by different 
mechanisms allowing suitable signal intensity and duration of stimulation(Figure 19).  
When c-Kit kinase is still at the plasma membrane, PKC (Protein Kinase C) is activated by 
DAG (Diacylglycerol) release. PKC interacts with phosphorylated c-Kit on Tyrosine residue 
570 and phosphorylates Serine 741 and 746 c-Kit residues inactivating its kinase activity. 
SHP-1 also interacts with pTyr-570 of c-Kit and dephosphorylates its Tyrosine residues. SHP-1 
depletion in murine model induces the hyper-proliferation of hematopoietic progenitors 
(Shultz et al., 1997). In addition, SOCS-1 interacts with c-Kit, dephosphorylates JAK kinase 
(Endo et al., 1997)and inhibits SCF induced proliferation of mast cells (De Sepulveda et al., 
1999). 
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Figure 19: Downregulation mechanisms of SCF/c-Kit signaling  
A: Downregulation mediated by kinase inactivation. Kinase inactivation can occur either by 
membrane-recruited PKC (through diacylglycerol DAG) which phosphorylates c-Kit (red 
arrow) or by dephosphosphorylation of c-Kit by SPH1 or JAK2 by SOCS1 phosphatases 
(curved double arrow).  
B: Downregulation mediated by c-Kit internalization and degradation. Activation of c-Kit 
and subsequently SFK, induces the recruitment and activation of the E3-Ubiquitin Ligase CBL 
which then ubiquitinylates c-Kit inducing its internalization and degradation either by the 
lysosome or the proteasome.  
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In few minutes following SCF binding, SFK on Tyrosine residues 568/ 570 of activated c-Kit 
recruits c-CBL E3-Ubiquitin Ligase. The ubiquitinylation of c-Kit causes its 
internalization(Miyazawa et al., 1994) and degradation by the proteasome (D'Allard et al., 
2013)or the lysosome (Zeng et al., 2005). The factors determining the balance between 
lysosomal or proteosomal degradation remains to be determined. Though, it is known that 
the inhibition of c-Kit kinase activity by Masitinib (Dubreuil et al., 2009)induces its lysosomal 
degradation (D'Allard et al., 2013). 
3.1.5 c-Kit proteolytic cleavage 
Membrane-bound c-Kit is cleaved by ADAM-17 (A Disintegrin and Metalloprotease)/ TACE 
(TNF-α converting enzyme) on the 5th Ig-like domain releasing a soluble fragment of 100 KDa 
corresponding to the extracellular domain and which can be detected in human serum. This 
soluble form of c-Kit has been implicated in the survival of mast cells (Cruz et al., 2004), but 
the underlying mechanisms remain elusive. As both soluble and membrane-bound isoforms 
ofc-Kit have the same affinity for SCF, soluble c-Kit may act as a competitor of SCF. 
Alternatively, the cleavage of c-Kit may simply reduce the level of the full-length membrane-
bound isoform available for activation by SCF (Turner et al., 1995). 
3.1.6 c-Kit exosomal secretion 
Interestingly, a few recent studies have shown that c-Kit can be secreted with exosomes 
and this form of secretion can mediate tumorigenesis. For example, when the conditioned 
medium of human mast cell line HMC-1 was harvested, c-Kit protein, but not transcripts, 
was found into exosomes. Furthermore, the culture of the human pulmonary 
adenocarcinoma cell line A549 with HMC-1 conditioned medium induced the activation of 
SCF/c-Kit signaling and the increase of their proliferation (Xiao et al., 2014). Similarly, 
activated phosphorylated c-Kit was detected in high amounts in the plasma of GIST-affected 
patients on the contrary tothe plasma of healthy donors. In vitro studies demonstrated that 
oncogenic activated c-Kit released in CD9-high exosomes are able to transform smooth 
muscle cells into gastric-like Cajal cells with increased invasiveness by allowing them to 
release metalloprotease MMP-1 in a c-Kit signaling dependent manner (Atay et al., 2014). 
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3.2 c-Kit role in hematopoiesis 
3.2.1 In HSCs cell fate 
 
The loss of c-Kit kinase activity in W42 mutant mice which are viable and fertile, on the 
contrary to W mutant mice, is associated with extremely reduced number of HSCs and 
transplantation studies into sub-lethally or lethally irradiated mice suggest intrinsic defects 
of c-Kit deficient mice (Geissler et al., 1981). Sl mutant mice deficient in SCF expression have 
micro-environmental defect which would normally supports regenerative activity of CFU-S/ 
HSCs (McCulloch et al., 1965). Furthermore, the combination of low-dose irradiation with 
treatment by a monoclonal antibody (ACK2) blocking the interaction between SCF and c-Kit 
highly decreased competitive long-term HSCs and allowed for efficient transplant 
engraftment (Xue et al., 2010). These results suggest that the interaction between SCF and c-
Kit modulates HSCs maintenance and engraftment.  
3.2.1.1 HSCs emergence 
Recent studies state the clear contribution of SCF/c-Kit signaling to HSCs emergence during 
fetal life. Indeed, c-Kit plays a critical role downstream of retinoic acid(RA) signaling during 
the emergence of the hemogenic endothelium in the AGM of embryos. Interestingly, the re-
expression of c-Kit, which was lost in RA knock-out mice, was required to activate Notch 
signaling pathway, which in turn allowed the induction of p27 cell cycle regulator finally 
allowing the generation of the hemogenic endothelium and the maintenance of HSCs by 
quiescence (Marcelo et al., 2013).  
A recent study investigatedthe murine placenta in whole embryo culture as a potential 
source of HSCs generation during the transition between AGM and fetal liver and the 
contribution of SCF/c-Kit signaling in this process (Sasaki et al., 2010). Interestingly, the 
inhibition of SCF/c-Kit signaling with ACK2 antibody decreased the transcripts levels of GATA-
2, RUNX-1 (essential factors for HSCs establishment) and c-MYBinto placental hematopoietic 
cluster cells. Furthermore, SCF was shown to be produced by the endothelial cells 
surrounding placental hematopoietic clusters, suggesting their involvement in paracrine 
stimulation of HSC through the activation of SCF/kit signaling.  
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Interestingly, the transition between fetal and adult life is marked by increased 
requirement for SCF without variation of c-Kit expression level and could be rather partially 
explained by differential expression of Ink4 gene (Bowie et al., 2007). 
 
3.2.1.2 HSCs maintenance 
 Loss of c-Kit kinase activity in W41 mutant adult mice reduces the number of total LT-
HSCs into the bone-marrow. Consequently, a 10-fold excess of mutant HSCs was necessary 
to accomplish a level of reconstitution comparable to wild-type HSCs in competitive 
transplantation assay. In addition to the loss of LT-HSCs following serial transplantation, 
these results evidence a major defect of self-renewal in W41 mice. Cell cycle analysis 
revealed increased proportion of S/G2/M and decreased proportion of quiescent LT-HSCs in 
W41 mice (Thoren et al., 2008). This study establishes the crucial role of c-Kit in the 
maintenance of LT-HSCs in steady state conditions. Similarly, the depletion of SHP-2, a 
protein activated by c-Kit signaling, also caused a decrease of bone marrow cellularity and 
major reconstitution defects in competitive reconstitution assay, as well as cell cycle 
deregulation. SHP2 -/- HSCs defect was associated with decreased expression of c-Kit. c-Kit 
expression was dependent on GATA-2 binding on its promoter, SHP-2 phosphatase activity, 
as well as PI3K and STAT-3 activation. Interestingly, this study reveals the existence of a 
kinase/phosphatase/kinase axis essential for HSCs maintenance (Zhu et al., 2011).   
 Consistent with the demonstration of HSCs heterogeneity, HSCs sorting upon c-Kit 
expression levels revealed the association between low levels of c-Kit protein and the 
quiescent state of HSCs (Matsuoka et al., 2011), suggesting that the above mentioned study 
describes a prevalent c-KitLow population. Furthermore, c-KitLow HSCs were responsible for 
the generation of HSCs with higher expression of c-Kit, the former displaying more powerful 
and sustained repopulation ability over serial transplantation assay, suggesting the retention 
of self-renewal ability by c-KitLow HSCs population on the contrary to their HSCs c-KitHigh 
progeny (Grinenko et al., 2014). Additionally, the transition from c-KitLow to c-KitHigh 
population was inhibited by the inhibitor of c-Kit signaling c-CBL (Shin et al., 2014b), 
confirming the requirement of c-Kit signaling activation for the generation of highly 
proliferative HSCs. 
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3.2.1.3 HSCs maintenance through the niche 
SCF contributes to HSCs maintenance into their niche. The conditional depletion of SCF 
induced an important decrease in bone marrow and spleen cellularity and HSCs frequency. 
When using reporter mice for SCF expression, its production was mapped principally to 
endothelial and mesenchymal cells into the bone marrow. The maintenance of HSCs was 
independent of intrinsic cues and the conditional depletion of SCF specifically from the 
endothelial and perivascular cells lineage, on the contrary to the osteoblastic lineage, 
reproduced the defects in HSCs observed in SCF depleted mice(Ding et al., 2012). This study 
suggests the importance of SCF produced by the niche cells in the maintenance of HSCs. 
Interestingly, the matrix metalloproteinase MMP-9 was found to be responsible for the 
cleavage of membrane-bound SCF and its release by stromal cells. The depletion of MMP-9 
delayed the response to myeloablative injury addressed by the percentage of HSCs in S 
phase of cell-cycle, thus suggesting the importance of soluble SCF in HSCs function during 
the response to injury (Heissig et al., 2002). 
3.2.2 SCF/c-Kit role in bipotent MEP 
Few studies specifically investigated the role of c-Kit during the amplification of erythro-
megakaryocytic (E/MK) bipotent progenitors.Ex-vivo progeny analysis of murine HSCs (LSK 
CD150+) expressing different levels of c-Kit revealed that c-KitHigh HSCs generate an 
increased proportion of bipotent E/MK progenitors (preMegE) and unipotent 
megakaryocytic progenitors (MkP), but equivalent number of myeloid progenitors (preGM) 
when compared to c-KitLow HSCs. Theselective and level-dependentrole ofc-Kit during the 
generation of bipotent E/MK progenitors was further confirmed by comparing the progeny 
of sorted c-KitHigh and c-KitLow LSK populations transplanted into lethally irradiated mice(Shin 
et al., 2014b). Furthermore, transgenic mice harboring c-Kit V558Δ; T669I gain-of-
functionmutations show a selective increased frequency and number of bipotent MEPs, 
without significant changes in the proportion of pluripotents CMPs and bipotents GMPs 
(Deshpande et al., 2013). These results evidence the positive role of c-Kit in the amplification 
of bipotents MEPs.  
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3.2.3 SCF/c-Kit role in erythropoiesis 
SCF/c-Kit signaling is crucial for normal erythropoiesis as evidenced by severe anemia in 
mice harboring homozygous mutations on kit(Antonchuk et al., 2004) or Sl(Rajaraman et al., 
2002)locus. Based on physical and functional interactions between c-Kit and EPO-R, SCF and 
EPO act in synergy to stimulate the proliferation and survival of erythroid 
progenitors(Munugalavadla and Kapur, 2005). Moreover, SCF/kit signaling inhibits erythroid 
differentiation and downregulation of c-Kit constitutes a critical step for terminal 
differentiation. 
Convergent studies argue for the pro-survival role of c-Kit during erythroid cells 
amplification. For instance, cytokines starvationinducedapoptosis of erythroid progenitors, 
generated in-vitro from human peripheral blood CD34+, can be partially rescued by SCF 
alone. SCF-induced survival of erythroid progenitors was cancelled by treatment with SFK 
inhibitor PP-2, which also induced a decrease of AKT activity (Endo et al., 2001). Similarly, 
SCF is able to suppress cell death of human primary erythroid progenitors induced by Fas-L 
mimetic molecule (CH11) and allowstheir expansion in a SFK dependent manner. Notably, 
the SFK member has been identified as Lyn which activity is induced by co-stimulation with 
both EPO and SCF (Nishio et al., 2001). Interestingly, co-stimulation of murine erythroid cells 
GIE-ER2 (erythroblastic cell line with inducible expression of GATA-1) by SCF and fibronectin 
peptide containing α4β1 integrin binding site allows their survival in an AKT and Bcl-xL 
dependent manner. In contrast, co-stimulation by SCF and fibronectin containing α5β1 
integrin binding site allows their expansion through the sustained activation of FAK (Focal 
Adhesion Kinase) and ERK pathway(Kapur and Zhang, 2001), thus indicating that survival 
versus proliferation effect of SCF can be modulated by integrin signaling.  
SCF is particularly important during stress erythropoiesis by allowing the massive expansion 
of stress erythroid progenitors in cooperation with EPO, BMP4 and hypoxia (Perry et al., 
2007). Stress erythropoiesis resembles fetal erythropoiesis, notably through the re-induction 
of fetal hemoglobin expression. SCF/c-Kit signaling is also implicated in the re-expression of 
fetal hemoglobin during stress erythropoiesis as shown in sickle cell anemia (Miller et al., 
1992)or in β-thalassemia(Gabbianelli et al., 2008). A recent study performed on human 
primary erythroid progenitors suggests that the induction of ϒ-globin expression by SCF 
relies on the repression of COUP-TFII repressor in an ERK-1/2 dependent manner(Aerbajinai 
et al., 2009). Interestingly, c-Kit expression was found to be lower in erythroid progenitors 
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generated by human CD34+ cells derived from peripheral bloodthan from cord blood. This 
decrease in c-Kit expression was also positively correlated with the decrease in fetal 
hemoglobin expression and inversely correlated with the expression of its inhibitor miR-221 
(Gabbianelli et al., 2010). Taken together, these data indicate a dose-dependent contribution 
of SCF/c-Kit signaling to the expansion of erythroid progenitors and re-expression of fetal 
hemoglobin mediated at least partially through the activation of ERK pathway.  
3.2.4 SCF/c-Kit role in megakaryopoiesis 
Mice harboring partial loss-of-function mutations of c-Kit (Antonchuk et al., 2004)or SCF 
(Zsebo et al., 1990)or even inducible SCF gene deletion (Ding et al., 2012)present only 
discrete decrease or no alteration of platelets count in peripheral blood. However, both Sl/Sl 
and c-Kit Wv/+mutant mice fail to induce stressthrombopoiesis following 5FU 
treatment(Hunt et al., 1992). Accordingly, homozygous c-Kit mutant miceWv/Wv display a 
drastic decrease of megakaryocytic progenitors’ number in the spleen, but not into the bone 
marrow (Antonchuk et al., 2004). Thus, the majority of data indicate that SCF/c-Kit signaling 
is not required for steady state thrombopoiesis, while they clearly state its contribution to 
the amplification of megakaryocytic progenitors in stress conditions. Furthermore, 
numerous studies showed that SCF and TPO synergizes during the amplification of 
megakaryocytic progenitors ex-vivo (Reviewed in (Lee et al., 2014)).  
 
3.3 c-Kit and hematological diseases 
c-Kit activating mutations are involved in several hematological neoplasms as being the 
major cause of mastocytosis and the most frequent secondary mutations found in AML.  
3.3.1 Mastocytosis 
Mastocytosis is almost invariably due to c-Kit activating mutations (reviewed in (Soucie et 
al., 2015)). Mastocytosis is characterized by the deregulated proliferation and accumulation 
of mast cells in various organs and by the release of mast cell mediators. On the contrary to 
other hematologic lineages, the mast cell lineage is characterized by the maintenance of c-
Kit during differentiation and SCF/c-Kit signaling is essential for survival and maturation of 
mast cells. Most of somatic c-Kit mutations in sporadic cases of mastocytosis in adult map to 
the kinase domain (D816V, D816Y and D820G) and promote ligand independent auto-
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phosphorylation. Familial mastocytosis may occur in the absence of c-Kit mutations, while 
half of typical pediatric patients harbor an activating mutation on residue 839 (Longley et al., 
1999). Mastocytosis affecting the dermis can also imply high dosage of soluble SCF (de Paulis 
et al., 1999), probably due to excessive cleavage of the membrane-bound isoform (Longley 
et al., 1993) (Reviewed in (Orfao et al., 2007)). Importantly, the c-Kit D816V mutation 
conferred significant growth advantage when associated with the loss of TET-2 DNA 
demethylating protein in murine mast cells derived from bone marrow (Soucie et al., 2012). 
3.3.2 Acute Megakaryoblastic Leukemia (AMKL) 
c-kit is the most frequently mutated RTK in AML (Acute Myelogenous Leukemia), wherein 
in most of cases it contributes to the deregulation of myeloblasts proliferation (Reviewed in 
(Malaise et al., 2009)). 
AMKL is a heterogeneous subtype of AML and can be sub-classified into two main groups: a 
first group associated with Down-syndrome transient myeloproliferative disease and AMKL 
caused by the expression of a truncated GATA-1 protein (GATA-1s) and a second group 
associated with chromosomal translocation t(1;22)(p13;q13) resulting in the expression of 
the fusion protein OTT-MAL (Reviewed in(Shimizu et al., 2008)).  
c-Kit mutations are rarely found in AMKL but aberrant regulation of GATA-1 target genes 
can affect c-Kit expression level. The proliferation of 6133 cells established from a murine 
model of AMKL with OTT-MAL fusion protein is dependent on SCF (Mercher et al., 
2009)while its inhibition by IKAROS is associated with strong decrease of c-Kit expression 
(Malinge et al., 2013). Similarly, proliferation and survival of the cell line ZPAM, established 
from human patient presenting GATA-1s short isoform, were dependent on SCF and ERK 
activation, whereas SCF withdrawal caused apoptosis (Toki et al., 2009). These results 
suggest positive effect of SCF/c-Kit on megakaryoblastic proliferation without providing 
evidence for causative role of c-Kit signaling activation in the induction of AMKL.   
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4 TPO/c-MPL signaling pathway 
 
c-MPL receptor is mainly expressed in HSCs and megakaryocytic cells. Through activation 
by its specific ligand thrombopoietin (TPO), c-MPL signaling mainly contributes to the 
maintenance of HSCs, as well as to the specification of megakaryocytic progenitors and the 
stimulation of their maturation into platelets.    
 
4.1 c-MPL receptor and TPO ligand 
4.1.1 The ligand Thrombopoietin 
TPO was identified in the 50s as the humoral substance allowing the increase of platelets 
count into the peripheral blood. Numerous attempts to purify the protein failed, until the 
discovery of its receptor c-MPL in the 90s. The use of either affinity column purification (de 
Sauvage et al., 1994) or functional screening of cDNA librariesallowingc-MPL-dependent 
growth after transfection (Lok et al., 1994) allowed the purification of TPO and its cloning by 
different groups in 1994.  
4.1.1.1 TPO protein structure and function 
Circulating TPO is a secreted acidic glycoprotein produced mainly by the liver andto a less 
extent by kidneys. TPO is also produced in bone marrow by stromal cells, endothelial cells 
(Ding et al., 2012) and megakaryocytes (Nakamura-Ishizu et al., 2014a), thus contributing to 
the HSCs niche modulation.  
TPO is a polypeptide of 353 amino-acids (AAs) in humans and 356 AAs in mice. TPO N-
terminal domain contains 21 amino-acids corresponding to signal peptide and a conserved 
extracellular domain with high homology to EPO (Foster and Lok, 1996)(Figure 20). The N-
terminal domain forms 4 helices among which the first and forth are essential for the 
interaction with c-MPL receptor (Pearce et al., 1997). The C-terminal domain is rich in 
Proline, Serine and Threonine residues and massively glycosylated thereby facilitating the 
secretion (Linden and Kaushansky, 2000), as well as the stabilization (Elliott et al., 2003) of 
the protein.  
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Figure 20: Structure of Thrombopoietin ligand TPO and its c-MPL receptor  
A: TPO structure. TPO contains an EPO-domain with a signal peptide and 4 helices. RR: 2 
conserved Arginine. The glycan-domain contains multiple glycosylation-modified residues 
and a Proline-rich domain (yellow box). 
B: c-MPL structure and isoforms. The extracellular domain contains a Signal peptide (SP) 
followed by two Cytokine Receptor Modules (CRM) and a conserved WSXWS. Each CRM 
contains 2 conserved Cysteine residues (C) and Fibronectin type III domain (Blue box). The 
transmembrane region (TM) is followed by a conserved pentapeptide KWQFP. The 
intracellular domain is composed of 2 boxes (orange box). Tr-MPL isoform, generated by 
alternative splicing, contains a signal peptide and an unique intracellular domain (hatched 
box).  
 
  
 
 
81 
4.1.1.2 Regulation of TPO levels  
 
The concentration of TPO in normal human serum is approximately95 pg/L in steady state 
condition. TPO stimulates platelets production and its level increases when platelets number 
decreases as observed in mpl knock-out mice (Gurney et al., 1994). However, this increase in 
TPO level is not due to increased production, but results from the escape of its capture and 
degradation by platelets themselves which express high levels of c-MPL receptor on their 
surface (approximately 30 receptors per platelet) (Broudy, 1997). By this way, platelets mass 
directly controls TPO level thus allowing the maintenance of platelets homeostasis 
(Reviewed in (Deutsch and Tomer, 2013)).  
4.1.2 The receptor c-MPL 
4.1.2.1 c-MPL receptor structure/function  
c-MPL polypeptide is 635 AAs long in humans and 625 AAs in mice. c-MPL belongs to the 
subclass I of cytokine receptors along with EPO-R, GM-CSFR and Interleukins receptors such 
as IL-3R, IL-5R and IL-9R. As schematized in Figure 20, the extracellular domain of 466 AAs (in 
humans and 457 AAs in mice) is conserved among other members of the family and 
comprises a signal peptide of 25 AAs and two cytokine receptor modules (CRM). Each CRM is 
composed of 2 conserved Cysteine residues, a WSXWS motif essential for the interaction 
with TPO and a fibronectin-rich domain with multiple sites of glycosylation. The 
transmembrane region of 22 AAs and the juxtamembrane RWQFP motif are important for 
the maintenance of self-inhibited receptor in the absence of TPO. The intracellular domain 
of c-MPL of 122 AAs (in humans and 121 AAs in mice)is unique when compared to other 
members of the family and is characterized by the absence of kinase or phosphatase activity, 
but rather contains a Pro-X-X-Pro motif into the first box allowing its interaction with JAK 
kinase. The second box is rich in acidic amino-acids. The C-terminal intracytoplasmic end 
harbors phosphorylation sites (detailed in signaling cascade part). c-MPL protein is 
maturated by glycosylation which is important for its expression on the cell surface (Albu 
and Constantinescu, 2011). Of note, the most usually used annotation of c-MPL residues 
starts from the first cytoplasmic residue which will be used from herein. The conversion can 
be performed by the addition of 514 amino-acids.  
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Figure 21: JAK2 structure and activation byTPO/c-MPL  
A: JAK family members are composed of 7 JAK Homology domains (JH). The first domain 
corresponds to the catalytic subunit. JH2 inhibits the activity of JH1 in absence of ligand. The 
FERM domain (band 4.1/Ezrin/Radixin/Moesin) allows the interaction of JAK with c-MPL 
receptor on the motif PSLP into the box-1 (Green box). FERM domain contains JH3 and JH4 
corresponding to an SH2-type domain allowing the interaction with phosphorylated Tyrosine 
residues. 
B: JAK2 activation. In the absence of ligand, JAK2 is constitutively associated with c-MPL 
receptor (in green) in its inactive conformation through the tetrapeptide PSLP. TPO (Orange 
square) interaction with c-MPL allows the activation of JAK2 (star) which in turn 
phosphorylates c-MPL receptor on different residues (pY), the most important being Y112. 
STAT proteins (Black circle) are recruited on phospho-tyrosines residues of c-MPL and are 
activated by JAK2 kinase. 
  
 
 
83 
4.1.2.2 c-MPL isoforms 
mpl locus encodes several alternate transcripts some of which are specific either of 
humans or mice. The only conserved isoform between humans (Vigon et al., 1992) and mice 
(Skoda et al., 1993) encodes a truncated protein called Tr-MPL which contains the signal 
peptide, lacks the transmembrane region and possess a unique sequence of 30 amino-acids 
in the cytoplasmic domain. Tr-MPL is retained into the cytoplasm and acts as a dominant 
negative for the full-length c-MPL by targeting it to lysosomal degradation, resulting in 
decreased cell growth (Coers et al., 2004).  
4.1.3 TPO/c-MPL signaling 
4.1.3.1 c-MPL activation  
In the absence of ligand, c-MPL is expressed at the cell surface as a homo-dimer and adopts 
an auto-inhibited conformation with important contribution of the motif KWQFP. Even in 
the absence of TPO, JAK kinases are constitutively associated with c-MPL through the 
interaction of their FERM domain with the PSLP motif located in box-1 of c-MPL. In this 
inactive configuration, kinase activity of JAK (standing into the JH-1 domain) is inhibited by 
the regulatory domain JH-2 (Reviewed in (Wu and Sun, 2012)) (Figure 21). 
Upon TPO binding, c-MPL receptor dimers undergo a conformational shift allowing the 
close proximity of their two intracytoplasmic domains and subsequent activation of JAK 
kinases. As c-MPL lacks its own kinase activity, TPO signaling transduction is ensured by this 
activation of JAK kinases. TPO induces the activation of JAK-2 and TYK-2 JAK family members, 
though TYK-2 is not essential for TPO signaling (Drachman et al., 1999). Then, JAK-2 induces 
the phosphorylation of c-MPL on its Tyrosine residues 8, 29, 78, 112 and 117 in the 
intracytoplasmic domain. Signal transduction takes place mostly through Y112 residue 
whichfunctions as a docking site for adaptor and signaling molecules. These signaling 
proteins are alsophosphorylated by JAK-2 kinase (Reviewed in (Kaushansky, 2005)). The 
three major signaling pathways activated downstream of TPO/ c-MPL are detailed below and 
illustrated in Figure 22. 
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Figure 22: Main pathways activated by TPO/c-MPL 
Phosphorylated Tyrosineresidues (here only pY112) of c-MPL receptor function as a 
docking site for the recruitment of adaptors and signaling molecules. STATs are recruited on 
c-MPL receptor and activated by JAK-2 allowing their activation and subsequent homo- or 
hetero-dimerization and nuclear translocation (grey or grey and black circles). STATs dimers 
then activate the expression of survival gene BcL-xL and cell cycle regulators p21 and p27. 
Activated SHP2 enhances the formation of p85 (PI3K subunit) and Gab adaptor protein 
allowing the activation of PI3K and subsequently of AKT kinase. AKT sequestrates FOXO3a 
transcription factors, BAD and GSK3-β, thus inhibiting the expression of their target pro-
apoptotic genes FAS, p27 and Cyclin-D1. The adaptor complex SHC/Grb2 recruits GDP 
exchange factors Sos (Son Of Sevenless) allowing the sequential activation of MAP-Kinases: 
RAS, Raf-1 and ERK-1/2 as well as p38. ERK-1/2 activates the transcription factors RUNX-1, 
MYC and JUN allowing the expression of cell cycle regulators such as p19 and p21. 
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4.1.3.2 Signaling pathways activated by TPO/MPL:  
JAK/ STAT pathway 
STATs (Signal Transducers and Activators of Transcription) family members are recruited on 
phosphorylated Tyrosine residues of c-MPL receptor through their SH2 domain and are 
subsequently activated by JAK-2. Following their homo- or hetero-dimerization, STATs 
proteins translocate to the nucleus and bind to their target genes allowing their 
transcription. For example, STATs activation allows the expression of pro-survival Bcl-xL, as 
well as cell cycle regulators such as Cycline-D or p21, p27. STAT transcription factors also 
activate the expression of SOCS 1 and 3 responsible for the extinction of TPO/c-MPL 
signaling.  
 
MAPK pathway 
Rapid activation of the MAPK pathway is ensured by SHC (Src homology 2 domain 
containing)adaptor activationwhich bindsphosphorylated residue pY-122 of c-MPL. SHC 
activation by JAK-2 allows the recruitment of Grb-2 adaptor and exchange factor Sos,leading 
to the activation of Ras. Activated Ras activates Raf-1, which in turn activates p38 and ERK-
1/2 MAP kinases. ERK-1/2 transcription factors translocate to the nucleus and phosphorylate 
their substrates notably Elk1, RUNX-1, MYC and JUN allowing their activation and the 
subsequent expression of cell cycle regulators such as Cycline-D1, c-Myc, p19 INK4 and p21. 
Noteworthy, slow activation of ERK-1/2 can occur independently of JAK-2 but through its 
interaction with pY-78 of c-MPL and subsequently to the activation of Rap-1 and B-Raf 
(Garcia et al., 2001). 
 
PI3K pathway 
SHP-2 docked on pY-112 is activated by JAK-2 and enhances the association between Gab 
adaptor protein and p85 subunit of PI3K allowing its activation. As explained in the chapter 
on c-Kit signaling transduction, PI3K allows the activation of AKT kinase which in turn 
phosphorylates several substrates controlling survival and cell cycle progression. Among 
important AKT substrates, FOXO3a is sequestrated into the cytoplasm allowing the de-
repression of p27 and Fas genes transcription, BAD is inhibited inducing the liberation of the 
pro-survival protein Bcl-2 and GSK-3 is inhibited allowing increased expression of Cycline-D1. 
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Figure 23: Mechanisms of TPO/c-MPL signaling downregulation  
A: Downregulation by kinase inactivation. Kinase inactivation implicates the phosphatase 
SHP which targets JAK/STAT family members, SOCS proteins which target JAK/ STAT for 
degradation by the proteasome and the SFKs family members LNK and LYN which inhibit JAK 
and ERK-1/2, respectively.  
B: Downregulation by internalization and degradation. Following c-MPL activation by TPO, 
c-MPL is ubiquitinylated and the TPO/c-MPL complex is internalized in clathrin-coated pits. 
CBL mediated ubiquitinylation also contributes to induce c-MPL degradation through the 
lysosome or proteasome pathways. The phosphorylated tyrosine residues Y8 and Y78 of c-
MPL favor its interaction with AP2 and clathrin-dependent internalization of the complex, 
whereas phosphorylated residue Y8 targets the TPO/c-MPL complex for lysosomal 
degradation.  
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4.1.4 TPO/c-MPL signaling downregulation 
TPO/c-MPL signaling is downregulated by two different ways: through the inactivation of 
kinase activity and through the degradation of the complex TPO/c-MPL (Figure 23). 
4.1.4.1 Inactivation of kinase activity 
TPO stimulation induces the activation of STAT transcription factors leading to the 
expression of SOCS 1 and 3. SOCS proteins bind directly to the receptor or to the activated 
JAK and STATs through their SH2 domains and inhibit their activity either by competition or 
by proteasomoal degradation (reviewed in (Wormald and Hilton, 2004)). JAK-2 kinase 
activity is also inhibited by phosphatase SHP-1 which binds directly through its SH2 domain. 
The SFK family member LNK was also shown to inhibit TPO signaling through its binding to 
JAK-2 (Bersenev et al., 2008).The SFK LYN was shown to inhibit TPO/c-MPL mediated 
proliferation by inhibiting ERK-1/2, potentially through SHIP phosphatase and without 
affecting JAK-2 phosphorylation (Lannutti et al., 2006).  
4.1.4.2 Internalization and degradation 
Rapidly following TPO stimulation, AP-2 interacts with c-MPL receptor on the motifs RRL 8 
and 78 of the intracellular domain, recruits Clathrin and induce its internalization. The 
recruitment of AP-2 on position 8 of intracellular c-MPL targets the receptor for lysosomal 
degradation (Hitchcock et al., 2008). In parallel, c-MPL can also be ubiquitinylated on its 
Lysine residues 39 and 59 by CBL inducing its degradation by the proteasome (Saur et al., 
2010). 
 
4.2 TPO/c-MPL signaling in the control of hematopoiesis 
 
4.2.1 Role in HSCs function 
Initial studies of mice harboring constitutive loss of either mpl(Alexander et al., 1996; 
Carver-Moore et al., 1996) or thpo(Carver-Moore et al., 1996) genes revealed a significant 
reduction of most multipotent and monopotent progenitors,already suggesting the 
impairment of HSCs function. Since then, several studies have clearly evidenced a role of 
TPO/c-MPL signaling in early amplification of HSCs during fetal life, as well as in maintenance  
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Table 4: HSCs and megakaryocytic phenotypes in mouse models of c-MPL or TPO (thpo) 
knock-out 
Each lane of the table indicates in the successive columns: the name of the deleted gene, 
the main impact either on HSCs quiescence or self-renewal or on megakaryocytic 
differentiation and the corresponding reference. 
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of adults HSCs by self-renewal and quiescence (reviewed in (de Graaf and Metcalf, 2011; 
Deutsch and Tomer, 2013)(Table 4). 
4.2.1.1 In fetal life 
c-MPL transcripts are already detectable in hematopoietic clusters generated by 
AGM.Analyses of fetal liver cells showed that stemness activity segregates with c-MPL+ cells 
and that fetal liver c-Mpl -/- HSCs were unable to engraft into lethally irradiated mice in 
competitive repopulation assay (Solar et al., 1998).  A more recent study performed at 
different times of development confirmed these results and further showed that c-MPL 
deficiency delayed the appearance of these defective long-term self-renewing HSCs in fetal 
liver (Petit-Cocault et al., 2007). 
4.2.1.2 HSCs self-renewal 
In adult mice, the self-renewal of HSCs is also controlled by TPO/c-MPL pathway. Indeed, 
loss of c-MPL dramatically reduced the number of CFU-S generated by bone marrow HSCs 
and impeded their competitiveness for proper long-term reconstitution in irradiated mice 
(Kimura et al., 1998). Similar defects were observed with HSCs expressing a truncated form 
of c-MPL which decreases TPO signaling (Tong et al., 2007). Moreover serial transplantation 
experiments performed in wild type or TPO-/- recipients elegantly confirmed that TPO/c-
MPL signaling is required for long term self-renewal of HSCs (Fox et al., 2002). Altogether, 
these studies conducted in myeloablative conditions suggest a role of TPO/c-MPL in HSCs 
self-renewal after injury. Interestingly, loss of mpl has also been shown to reduce the 
number of bone marrow cells required for lymphomyeloid reconstitution in non-
myeloablative competitive assay, thus confirming functional endogenous HSCs defect. 
Furthermore, concomitant loss of mpl and kit function further reduced the number of bone 
marrow cells required in these non-ablative competitive assays, indicating the cooperation 
between c-Kit and c-MPL during HSCs homing(Antonchuk et al., 2004).        
4.2.1.3 Role in quiescence 
Concordant results obtained by loss or gain of function in vivo and ex-vivo experiments on 
murine models strongly argue for a positive effect of TPO/c-MPL in maintaining HSCs 
quiescence and avoiding their exhaustion.  
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Constitutive loss of TPO induced specific and progressive loss of LT-HSCs from post-natal to 
adult life, suggesting its importance in HSCs maintenance. This effect was associated with 
concomitant increase of HSCs proliferation, as evidenced by increased number of BrdU 
labeled cells, and by reduced proportion of the most quiescent fraction ofHSCs(side-
population or Ki-67Low HoechstLow cells). Excessive proliferation was consistently 
accompanied by decreased expression of several negative regulatorsof cell cycle such as 
p57, p21 and p19 (Qian et al., 2007). Similarly, ex-vivo HSCs treatment with AMM2 (c-MPL 
blocking antibody) decreased p57 and p21 expression and increased c-Myc expression 
counteracting the positive effects of TPO. In vivo, AMM2 treatment reduced the number of 
side population HSC allowing exogenous HSC engraftment without irradiation, while 
concomitant 5-FU treatment was required for successful engraftment in competitive assay, 
thus suggesting efficient quiescence exit. Furthermore, quiescent HSCs were shown to reside 
in c-MPL+ sub-fraction, whereas their shift into proliferation reduced the percentage of c-
MPL+ HSCs and p57 expression into the bone marrow. The quiescence of c-MPL+ HSCs 
requires their physical proximity with the osteoblastic niche which produces TPO(Yoshihara 
et al., 2007). Altogether, these results establish the implication of TPO/c-MPL signaling in the 
maintenance of long-term quiescent HSCs population.  
Interestingly, the continuous injection of low dose of TPO in normal mice induced transient 
increase in quiescent over non-quiescent proportion of LSK HSCs after 4 days due to 
preferential survival of c-MPL+ cells, whereas one-time injection of high dose of TPO 
increased HSCs proliferation as soon as 2 days after treatment (Yoshihara et al., 2007). This 
latter study highlights the duality of the implication of TPO in fine-tuning the 
proliferation/quiescence balance of HSCs.   
4.2.1.4 Role in DNA repair 
A recent study evidenced the positive effect of TPO/c-MPL signaling on the protection of 
murine LSK from DNA damage and chromosomal abnormalities accumulation during 
recovery from irradiative stress on the long-term (de Laval et al., 2013). Indeed, irradiation 
induces DNA double strand breaks (DSB) in LSK from normal mice and the proportion of LSK 
cells harboring DSB increases in mpl -/- mice or in LSK cultured in vitro in absence of TPO. 
Irradiation-induced DSB in WT LSKwas canceled by TPO injection in-vivo or TPO addition ex-
vivo and correlated with TPO-mediated enhancement of DNA repair efficiency by NHEJ (Non-
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Homologous End Joining) mechanism. TPO protective role was also observed when analyzing 
chromosomal abnormalities in metaphasic LSK. Interestingly, loss of c-MPL induced the 
persistence of DSB induced by irradiation in LSK with aging. Furthermore, LSK cells derived 
from irradiated c-Mpl -/- mice failed to reconstitute LSK population in secondary lethally 
irradiated recipients in competitive assay. In contrast, TPO pre-treatment of wild type donor 
mice before irradiation enhances bone marrow chimerism obtained by LSK in competitive 
transplantation. This protective effect was specifically observed 4 months after 
transplantation, thus evidencing long-term protection of HSC. Noteworthy, TPO protection 
mainly concerned immature CD34- cells and could not be explained by enhanced LSK 
proliferation or quiescence.  
A second study (de Laval et al., 2014) evidenced that TPO protective effect during NHEJ 
repair of irradiation-induced DSB was dependent on the formation of a ternary complex of 
DNA-PK (the catalytic subunit responsible for NHEJ) with ERK-1/2 and Iex1 (early actor of 
DNA-repair) which are transcriptionally activated in response to TPO.  
4.2.2 Role in erythropoiesis 
Some studies suggest a positive effect of TPO on erythrocytic progenitors’ production. 
Infection of mice by mpl-transducing-retrovirus induces massive infiltration of erythroblasts 
in spleen and liver, causing hepatosplenomegaly and death (Cocault et al., 1996). The 
injection of TPO (Kaushansky et al., 1995) or the transplantation of TPO-treated (Fibbe et al., 
1995) or mpl-transduced bone marrow cells (Yan et al., 1999)into irradiated mice 
accelerated red-blood cells recovery. The decrease of RBC in double mutant mpl -/- 
kitWvmice when compared to simple mutants (Antonchuk et al., 2004) suggest the synergy 
between TPO and SCF on erythroid cells production. However all these effects might be due 
to the expansion of bipotent or multipotent progenitors rather than specific effect on 
erythroid progenitors(Carver-Moore et al., 1996). Interestingly, the combination of TPO and 
SCF rescued the production of erythroid colonies by EPOR-deficient fetal liver cells (Kieran et 
al., 1996). TPO was also shown to stimulate the development of erythroid colonies derived 
from human peripheral blood mononuclear cells, but this stimulating effect was only 
observed in the presence of serum and was inhibited by either EPO or EPO-R antibodies (Liu 
et al., 1999). On one hand, TPO does not seem to be able to bind EPO-R. Indeed, radio-
labeled TPO did not label human erythroblasts and excess of TPO failed to compete for EPO 
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binding to EPO-R in BaF-3/EPO-R cells (Broudy et al., 1997). On the other hand, BaF-3/EPO-R 
cells were shown to survive and to proliferate in the presence of TPO alone despite the 
absence of c-MPL expression. Intriguingly, the survival of BaF-3/EPO-R cells in TPO alone was 
strongly decreased by siRNA mediated knock-down of EPO-R (Rouleau et al., 2004). Taken 
together, these data suggest that TPO is able to mediate c-MPL-independent survival and 
proliferation of erythroid progenitors in EPO-R dependent but EPO-R binding-independent 
manner.   
 
4.2.3 Role in megakaryopoiesis 
4.2.3.1 Role in normal megakaryopoiesis 
Both TPO -/- and c-MPL -/- mice show severe thrombocytopenia(Table 4). Surprisingly, a 
recent study reported that mice harboring conditional deletion of c-MPL targeted only on 
megakaryocytes and platelets (induced by Cre recombinase expression driven by pf-4 
promoter) paradoxically display megakaryocytosis and thrombocytosis (Ng et al., 2014). The 
excess of megakaryocytes and platelets could derive fromthe markedlyamplifiedc-Mpl 
expressing myeloid progenitors or LSK stem cells. Supporting this interpretation, LSKs fromc-
Mpl pf-4 mice display a strong transcriptome signature indicative of TPO/c-MPL signaling 
activation, whereas paradoxically their circulating TPO levels are not increased. This study 
confirms that massive platelets production can readily occurwithout TPO and suggests the 
unexpected role of platelets and megakaryocytes in limiting available TPO to avoid the 
amplification of c-MPL-expressing myeloid progenitors.  
4.2.3.2 Downstream signaling pathways involved in the dual role of TPO 
during the control of megakaryopoiesis 
TPO/c-MPL signaling stimulates expansion, maturation and polyploidization of 
megakaryocytes. One intriguing but still unresolved question is whether the specific changes 
downstream ofTPO signaling can explainitsdual effects. 
 TPO/c-MPL signaling activates JAK2, STAT1, STAT3, STAT5-A and STAT5-B in 
megakaryocytic cells. Overexpression of a dominant negative mutant of STAT3 induced a 
decrease of megakaryocytic progenitors and platelets recovery after 5FU treatment while 
platelets count remained unaffected, suggesting the role of STAT3 in stress 
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megakaryopoiesis (Kirito et al., 2002). STAT5-A/-B knock-out mice display thrombocytopenia, 
but also overall defects of HSCs function (Snow et al., 2002). In contrast, STAT-1 knock-out 
mice show defective polyploidization of megakaryocytes thus indicating a specific 
requirement of STAT1 for megakaryocytic maturation(Huang et al., 2007) 
Several other studies indicate that the duration and intensity of MAP kinase activation are 
important parameters to control the balance between proliferation and differentiation. 
Indeed, sustained activation of ERK-1/2 by Rap1 and B-Raf induces the expression of Elk-1 
and is required for megakaryocytic maturation of UT7/c-MPL cells (Garcia et al., 2001). 
Similarly, sustained activation of ERK-1/2 by TPA or by forcing constitutively active MEK 
expression induced megakaryocytic differentiation of human K62 cells. Conversely, weak 
activation of ERK-1/2 induced by a mutant form of c-MPL lacking residues 71 and 94 on the 
intracytoplasmic domain in UT7/c-MPL cell line, or transient ERK1/2 inhibition by Bryostatin 
inhibited megakaryocytic differentiation (Rouyez et al., 1997)(Racke et al., 1997). Even 
though the latter studies performed in cell lines suggest the importance of sustained MAPK 
activation for differentiation, studies performed with primary cells reported contradictory 
results.  
On one hand, TPO stimulation of cord blood CD34+ human progenitors induced strong 
activation of MAPK inducing megakaryocytic differentiation. Decreased activation of MEK 
and ERK-1/2 obtained by inhibition of MEK with low dose of PD-098059 increased the 
proliferation of megakaryocytes and delayed their differentiation, as attested by the 
increased proportion of blasts and immature CD34+ CD41+ CD42b- cells (Fichelson et al., 
1999). On the other hand, the treatment of a pure megakaryocytic populationderived this 
time from peripheral blood CD34+ human progenitorswith the same dose of the same MEK 
inhibitor weakly inhibiting MEK and ERK1/2,leads in contrast to increased megakaryocytic 
polyploidization. Furthermore,the increased polyploidization was associated with strong 
increase of PI3K activation and was suppressed by rapamycin treatment (targeting mTOR). 
Thus, this study rather strongly suggests the pivotal role of the axis AKT/mTOR/S6K as the 
major actor of megakaryocytic polyploidization (Guerriero et al., 2006). 
 JAK2 activation level was also recently proposed as another important actor which 
controls the switch between megakaryocytic proliferation and terminal differentiation. 
Indeed, analyses of several spontaneously emerging sub-clones of UT7/c-MPL cells which 
proliferate instead of differentiate in the presence of TPO, revealed a systematic decrease of 
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JAK2 and c-MPL expression. Further experiments revealed that the restoration of 
megakaryocytic differentiation could be obtained by enforced expression of either JAK2 or c-
MPL. Conversely, the stimulation by low dose of TPO or the treatment with low doses of 
JAK2 inhibitor allowed the proliferation of UT7/c-MPL cells. Importantly, low doses of JAK2 
inhibitor was also shown to increase the number of megakaryocytes generated by human 
CD34+ progenitors cells ex vivo, as well as to increase the number of platelets in injected 
mice in vivo(Besancenot et al., 2014). 
 
4.3 Pathological TPO/ c-MPL deregulation in the megakaryocytic lineage 
 
Activating mutations of mpl are associated with myeloproliferative neoplasms (MPN) and 
hereditary thrombocytopenia (HT), whereas c-MPL loss of function is associated with 
congenital amegakaryocytic thrombocytopenia (CAMT).  
In the case of MPN affecting the megakaryocytic compartment, mpl mutations are 
associated with 5% of essential thrombocytemia (ET) and 1% of primary myelofibrosis (PMF), 
whereas JAK2 constitutive activation is found in 50% of these two types of MPN. The most 
common c-MPL mutation is a substitution at the residue W515 which affects the 
juxtamembranar motif KWQFP, thus inducing receptor activation in the absence of TPO and 
subsequent activation of intracellular signaling. The transduction of irradiated mice with 
infected bone marrow cells harboring W515 mutation induced splenomegaly, increased 
expansion of megakaryocytic progenitors into the spleen and platelets count (Malinge et al., 
2008). In the context of PMF and ET associated with JAK2 V617F and MPL W515 mutations, 
JAK2 and c-MPL expression was found decreased, whereas MPL expression was found 
increased in ET without any of these mutations.  
In the case of hereditary mutations of mpl, a recent study investigated the effect of 3 
mutations affecting the domain of interaction with TPO and proposed different mechanisms: 
P106L gain-of-function mutation is retained in the cytoplasm and able to induce cytokine-
independent proliferative signals, whereas loss of function mutation F104S is still expressed 
at the cell surface but lose the capacity of activation by TPO and the R102P loss of function 
mutant form harbors defective glycosylation, cell-surface expression and dimerization ability 
(Stockklausner et al., 2015).  
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5 Tetraspanins 
 
5.1 General presentation of tetraspanins family 
Tetraspanins superfamily (TM4SF) comprises about 30 members and has been implicated 
in various physiological processes, including cell motility, adhesion and fusion, as well as 
tumor progression and metastasis (Reviewed in (Lazo, 2007)). Tetraspanins are cell surface 
proteins with 4 transmembrane regions, one intracellular and two extracellular loops. On the 
cell surface, tetraspanins are unable to transduce intracellular signaling, but rather dimerize 
between each other or with different members of the family and cluster, thus forming 
membrane specialized micro-domainswherein they provide a scaffold for receptors and 
signaling molecules assembly.  
 
5.2 Tetraspanins in hematopoiesis 
Tetraspanins CD9, CD63, CD81, CD82, CD151 are expressed in hematopoietic tissues. Some 
of them were shown to play a role in lymphocytes B and macrophages function(Lazo, 2007). 
Interestingly, CD9 is increasingly expressed during terminal megakaryocytic differentiation 
and preferentially expressed in a specific subset of HSCs displaying erythro-megakaryocytic 
lineage bias and being mostly in a quiescent state (Guo et al., 2013).  
5.2.1 Regulation of HSCs engraftment and quiescence by tetraspanins CD9, CD81 
and CD82 
Several studies reported the contribution of some tetraspanins family members to HSCs 
homing and maintenance. For instance, CD9 transcripts were found to increase in human 
cord blood CD34+ HSCs exposed to SDF-1 stimulation ex-vivo. In addition, sorted CD34+ 
expressing low levels of CD9 are associated with decreased engraftment capacity into the 
bone marrow and spleen of sublethally irradiated NOD/SCID mice, when compared to total 
CD34+ HSCs (Leung et al., 2011).Likewise, whereas quiescent CD34+ HSC are associated with 
polarized expression of CD82 at the cell membrane, this polarized expression of CD82 is lost 
in cycling human G-CSF mobilized stem and progenitor cells (HSPCs) suggesting a positive 
role of CD82 in the maintenance of quiescence and homing capacity of HSPCs (Larochelle et 
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al., 2012). Additionally, Cd81 -/- HSC showed a marked engraftment defect when 
transplanted into secondary recipient mice and a significantly delayed return to quiescence 
when stimulated to proliferate with 5-fluorouracil (5-FU). As observed for CD82, CD81 
proteins formed a polarized patch when HSCs were returning to quiescence. Complementary 
experiments further showed that the clustering of CD81 actually induced a decrease in AKT 
activity allowing nuclear translocation of FOXO-1a and subsequent increase of p19 and 
decrease of Cyclin-D1, thus at least partially explaining cell cycle exit(Lin et al., 2011).  
These data suggest the contribution of tetraspanins in the maintenance of functional HSCs 
during homeostasis, as well as HSCs homing, re-entry into quiescence and self-renewal 
following injury.  
5.2.2 Modulation of c-Kit response to SCF by CD9 
Another interesting study suggests the regulation of c-Kit activation in response to SCF by 
CD9 (Anzai et al., 2002). c-Kit was found physically associated with several tetraspanins 
including CD9, CD63 and CD81 at the cell surface of Mo7e cell line. The colocalization of c-Kit 
and CD9 in Mo7e cells and c-Kit and CD81 in CD34+ cord blood progenitors was also 
observed by immunofluorescence. Co-immunoprecipitation assays further confirmed the 
direct interaction of c-Kit with CD9 and its indirect interaction with CD63 and CD81. 
Interestingly, in contrast to its unbound fraction, the fraction of c-Kit associated with CD9 
was found to be slightly phosphorylated, but lacked kinase activity and was not activated or 
internalized in response to SCF stimulation. This study thus indicates that CD9 is able to 
physically interact with c-Kit and to alter its activity and turnover.  
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Main justification of my project 
Even under stable environments, every type of progenitor only divide a limited number of 
times before irrevocably engaging into terminal differentiation thus suggesting the existence 
of intrinsic mechanisms or internal clocks controlling the balance between proliferation and 
differentiation. One of the main interests of our team is to understand the molecular 
mechanisms underlying these internal clocks using murine bipotent erythro-megakaryocytic 
progenitors (MEP) as a model system. Indeed, MEP are highly unstable progenitors and very 
rapidly commit into monopotent erythrocytic or megakaryocytic progenitors which 
themselves again only divide a limited number of times before terminal erythrocytic or 
megakaryocytic differentiation. Moreover, after commitment towards megakaryocytic 
lineage, thrombopoietin (TPO), the main cytokine controlling megakaryopoiesis, is involved 
in both proliferation and terminal differentiation raising the additional question of the 
mechanisms responsible for this intriguing dual function. One of the strategies developed in 
the team to address these questions has been to use Notch pathway activation as a 
molecular tool to modulate some parameters of these internal clocks controlling 
proliferation/differentiation balance and by this way try to understand how they work. First 
results indeed established that Notch pathway stimulation is actually able to increase the 
number of MEP divisions without losing their bipotency. More recently, we found that Notch 
pathway stimulation is also able to increase the number of divisions of committed 
megakaryocytic progenitors at the expense of their terminal differentiation. In that context, 
the main initial purpose of my work was to try to decipher the mechanisms by which Notch 
pathway sustains bipotency and favors the proliferation of megakaryocytic progenitors at 
the expense of their terminal differentiation.  
 
Specifics aims and working hypotheses 
1- Notch pathway and control of bipotency: testing the role of GATA1-levels  
Previous results of the team established that the mutually exclusive erythro-
megakaryocytic commitment of MEP mainly relies on functional cross-antagonism between 
Fli-1 and EKLF transcription factors which compete for limited amounts of the same partner 
GATA-1. Based on this functional antagonism, we hypothesized that Notch pathway might 
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lower the competition between Fli-1 and EKLF either by increasing GATA-1 levels or by 
modifying its phosphorylation state. The first specific aim of my work has been to test this 
hypothesis by studying the effect of Notch on the expression and phosphorylation of GATA-1 
transcription factor in the murine megakaryoblastic cell line L8057.  
 
2- Notch pathway and control of the proliferation/differentiation balance: deciphering 
mechanisms of c-Kit regulation  
Other results of the team have shown that the stimulating effect of Notch pathway on MEP 
proliferation was strictly SCF-dependent and associated with increased expression of c-Kit 
receptor thus indicating that c-Kit regulation is a critical determinant in the control of 
proliferation/differentiation balance. Based on these results and the known functional 
duality of TPO, the second aim of my work was thus to determine the molecular mechanisms 
controlling the expression of c-Kit by Notch and TPO at both transcriptional and protein 
levels. For that purpose, I choose to conduct this study using G1ME cells which results from 
the spontaneous immortalization of GATA-1 deficient bipotent erythro-megakaryocytic 
progenitors and which proliferation depends on TPO only. The main results of this study 
concern the unexpected contribution of c-Kit to the TPO-dependent proliferation as well as 
the unexpected down regulation of c-Kit by the late megakaryocytic maker CD9. These 
results lead us to propose a new model explaining the functional duality of TPO through the 
dynamic regulation of c-Kit signaling. 
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Figure 1: Schematic 
presentation of the protocol 
used to study the effect of 
Notch signaling on the 
proliferation and 
differentiation of MEP 
Bipotent E/MK progenitors (MEP) are 
purified from murine bone marrow 
cells suspension by flow cytometry 
and seeded in liquid culture in 
presence of a full cocktail of myeloid 
cytokines (EPO, TPO, IL-3, IL-6, IL-11, 
GM-CSF and Flt-3L) either on control 
IgG or on recombinant Notch ligand 
rDll1 in presence or absence of Notch 
inhibitor DAPT with or without SCF. 
Freshly purified MEP (day 0), as well 
as their progeny generated following 
two days in liquid culture are either 
harvested for qRT-PCR analyses or 
seeded in semi-solid medium from which we quantified the number of mixed, erythrocytic and megakaryocytic 
colonies generated. Alternatively, MEPs are maintained 6 days in liquid cultures before cells counting and 
analysis of c-Kit expression by FACS.  
 
Figure 2: Notch signaling stimulates bipotent 
progenitor’s amplification in a SCF-dependent 
manner 
A: Progenitors present in sorted MEP populations before 
(Day 0) or after a two days liquid culture on either IgG or 
rDll1 (with or without DAPT) were numbered by colony 
assay as described in Figure 1. Results are presented as 
piled histograms showing the numbers of the different 
types of colonies (mixed, erythrocytic or megakaryocytic) 
generated from untreated cells (Day 0) and after a two days 
culture on IgG, rDll1 or rDll1 + DAPT (mean and standard 
deviations from 5 independent MEP preparations). 
B: Same experiment as in A, except that MEPs were 
cultured either in presence or absence of SCF. Histograms 
show the fold variations in the relative numbers of mixed 
colonies obtained at Day 2 compared to the initial numbers 
at Day 0.  
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1. Main starting observations 
Here, I will summarize the main results of our team (manuscript 1 in Annex 1) showing the 
SCF-dependent amplification of megakaryocytic-erythrocytic bipotent progenitors induced 
by Notch pathway stimulation and introducing the context of my study. 
The protocol used to study the effect of Notch pathway stimulation on bipotent MEP cell 
fate is presented in Figure 1. Populations highly enriched in MEPs were sorted by FACS from 
murine bone marrow according to published protocol (Akashi et al., 2000). We then 
quantified the number of bipotent, erythrocytic and megakaryocytic progenitors present in 
this initial population (day 0) by counting the numbers of mixed (containing both 
erythrocytic and megakaryocytic cells), pure erythrocytic and pure megakaryocytic colonies 
obtained after seeding in semi-solid medium containing a full myeloid cytokines cocktail. 
Progenitors numbers were then compared to that obtained using the same colony assay 
performed after a 2 days liquid culture starting from the same cells number in the presence 
of coated recombinant Notch ligand rDll1 or IgG used as negative control. Duplicates 
cultures were also performed in the presence of ϒ-secretase inhibitor DAPT or in the 
absence of SCF to control that the changes induced by Notch ligand are due to the activation 
of the Notch pathway and to test their dependency on the SCF/c-Kit signaling respectively. 
Using this protocol, we observed that in absence of Notch stimulation (Day 0 or IgG day2), 
MEPs generated 1/3 of erythrocytic and 1/3 of megakaryocytic monopotent colonies but 
only 1/3 of mixed colonies (Figure 2 A), suggesting the low stability of the bipotent E/MK 
state. In contrast, the 2 days stimulation of MEPs by rDll1 increased the number of mixed 
colonies when compared to the initial number derived from freshly purified MEPs (Day 0) or 
to unstimulated MEPs (IgG) (Figure 2 A), thus indicating the positive effect of Notch on the 
stabilization of MEPs bipotency as well as on their amplification.  
Besides, we found that Notch-induced amplification of MEPs required the addition of SCF 
(Figure 2 B). This observation suggests the cooperation between Notch and SCF pathways 
during the amplification of MEPs.  
Cells counting and FACS analyses of MEP cultures after a 5 days stimulation by rDll1 
revealed the SCF-dependent and selective amplification of c-Kit positive cells, which was a 
Notch-specific effect as it was reversed in presence of DAPT (Figure 3 A). Additionally, this 
SCF-dependent selective amplification of c-Kit positive progenitors was also associated with   
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Figure 3:  Notch modulates c-Kit protein levels in MEPs 
progeny 
MEPs were cultured during 5 days in liquid culture in wells coated either 
with control IgG or with rDll1 ligand and in presence or absence of SCF 
or DAPT. At the end of the culture, cells were numbered and c-Kit 
expression was assessed by flow cytometry. A. Histogram showing the 
proportion of c-Kit positive cells B. Histogram presenting the relative 
median fluorescence intensities of c-Kit in the c-Kit positive population, 
showing that Notch stimulation induces the expression of c-Kit both in 
presence and absence of SCF.  
 
 
 
Figure 4: Variations in transcript levels induced by Notch 
stimulation in MEPs 
Transcripts levels were determined by qRT-PCR in MEP cultured two 
days on control IgG or rDll1 in presence or absence of DAPT as described 
in Figure 1. Histograms show the fold variations observed in the 
presence of Notch ligand rDll1 with or without Notch inhibitor DAPT. 
Means and strandard deviations from 3 independent experiments. 
Statistically significant results are indicated by asterisks.  
 
 
 
Figure 5: Strong induction of bipotent progenitors from 
MEPs subset expressing high levels of CD9 
MEPs were sorted according to their medium (A) or high (B) levels of 
CD9 expression and their responses to Notch ligand were compared 
using the same protocol as described in Figure 2. Results are presented 
as piled histograms showing the numbers of the different types of 
colonies generated from untreated cells (Day 0) and after a two days 
culture in presence of IgG or rDll1 with or without DAPT. Means and 
standard deviations from 3 independent experiments 
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the SCF-independent increase of c-Kit expression per cell as attested by an increased c-Kit 
median of fluorescence in c-Kit positive population which again was reversed by DAPT 
treatment (Figure 3 B). Furthermore, MEPs stimulation by Notch ligand in presence of SCF 
induced an increase in c-Kit transcripts amounts (Figure 4). Taken together, these results 
indicated that the SCF-dependent amplification of MEP induced by Notch pathway activation 
is associated with an increased expression of c-Kit.  
More recently, we observed that sorted MEPs populations are actually heterogeneous and 
can be subdivided in at least two subpopulations considering the level of expression of the 
CD9 tetraspanin. The majority MEPs subset expressing intermediate levels of CD9 (CD9Med) 
closely resembles the unfractioned MEP population (Figure 5 A), while the subpopulation 
highly expressing CD9 is strongly skewed towards megakaryocytic differentiation as attested 
by the very high initial proportion of megakaryocytic colonies generated at Day 0 (Figure 5 
B). Besides, the stimulation of the two subpopulations by Notch ligand rDll1 during two days 
led to a more pronounced increase in the proportion of mixed colonies in CD9High 
subpopulation when compared to CD9Med subpopulation (Figure 5). This observation reveals 
an increased sensitivity of the CD9High megakaryocytic biased MEP subpopulation to the 
stimulation by Notch leading to the amplification of bipotent progenitors.  
In summary, these results indicate that MEPs bipotency is an unstable state which can be 
stabilized by Notch pathway stimulation leading concomitantly to their amplification. This 
effect requires the cooperation between Notch and SCF/c-Kit signaling and is accompanied 
by increased c-Kit transcripts and protein levels. Moreover, the stronger increase of bipotent 
progeny in the CD9High subpopulation of MEPs under Notch stimulation could suggest a 
functional interaction between Notch pathway and the tetraspanin CD9.   
These observations led me to investigate the molecular mechanisms allowing Notch 
pathway to maintain bipotency and to stimulate MEP amplification by trying to answer the 
following questions: 1) is Notch pathway involved in the control of GATA-1 expression 
and/or phosphorylation and is GATA-1 phosphorylation implicated downstream to Notch in 
the stabilization of the bipotent state in MEPs? 2) How Notch pathway activates c-Kit 
expression? 3) Is c-Kit implicated in the balance proliferation/differentiation and what is the 
molecular basis of the functional interaction between Notch and CD9 ? To answer the two 
latter questions, I choose to conduct the study using the TPO-dependent G1ME cells 
resulting from the immortalization of GATA1 deficient murine bipotent progenitors.  
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Figure 6: Working model on the stabilization of MEP bipotency 
A- Cross-antagonism between Fli-1 and EKLF controlling MEP commitment:  
Schematic presentation of the unstable balance between maintenance of MEPs bipotency and their 
commitment towards either erythrocytic or megakaryocytic differentiation based on the functional antagonism 
between Fli-1 and EKLF. EKLF (red circle) and Fli-1 (green circle) transcription factors inhibit each other 
expression, while inducing their own expression and both require their interaction with a common partner 
GATA-1 to induce either erythrocytic or megakaryocytic differentiation, respectively. This functional 
antagonism implies that Fli-1 and EKLF compete for their mutually exclusive interaction with GATA-1 thus 
causing the instability of the bipotent state (illustrated by the narrowness of the black curve plateau). 
Consequently, any small fluctuations in the level of Fli-1 or EKLF will be rapidly amplified causing increased 
capture of GATA-1 and inducing irreversible commitment towards either one lineage. 
B. Hypotheses on the mechanisms possibly involved in the Notch-mediated stabilization of the bipotent 
state. Notch could stabilize the bipotent state (illustrated by the enlarged plateau of the black curve) by 
buffering the tolerated differential expression between Fli-1 and EKLF, before either EKLF or Fli-1 reach a 
sufficient level of expression inducing irrevocable engagement into differentiation. This buffering mechanism 
could be mediated either by enhancing the available quantity of GATA-1 (left panel), or by modulating GATA-1 
phosphorylation affecting in turn the strength of its interactions with Fli-1 and EKLF (right panel).  
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2. Does Notch maintain MEPs bipotency through the regulation of GATA-1 
2.1. Working hypotheses 
We know that the mutually exclusive commitment of MEP towards erythrocytic or 
megakaryocytic differentiation is partly governed by the cross-antagonism between Fli-1 and 
EKLF transcription factors (Bouilloux et al., 2008; Frontelo et al., 2007). EKLF and Fli-1 
transcription factors inhibit each other expression, while inducing their own expression and 
both require their interaction with a common partner GATA-1 to induce either erythrocytic 
or megakaryocytic differentiation, respectively (Figure 6). This functional antagonism 
suggests that Fli-1 and EKLF compete for their mutually exclusive interaction with GATA-1 
thus causing the instability of the bipotent state. Consequently, any small fluctuation in the 
level of Fli-1 or EKLF will be rapidly amplified causing increased capture of GATA-1 and 
inducing irreversible commitment towards either one lineage (Figure 6 A). On the opposite, 
stabilization of the bipotent sate of MEP should be favored by situations allowing to reduce 
the competition between Fli-1 and EKLF for their interaction with GATA-1 (Figure 6 B). 
Based on this model, we hypothesized that Notch pathway induces the maintenance of the 
MEP bipotency by acting directly on GATA1 in either quantitative or qualitative ways 
allowing to lower the competition between Fli1 and EKLF: 
Our first hypothesis was that the Notch pathway could reduce the competition between 
Fli1 and EKLF by increasing GATA1 levels (Figure 6B left panel). 
Our second hypothesis, was that the Notch pathway could modulate the strength of the 
interactions between GATA-1 with Fli-1 or EKLF by modulating GATA-1 phosphorylation 
(Figure 6 B right panel). Several previous studies were also compatible with this second 
hypothesis. One of these studies showed that Notch is indeed able to activate the AKT kinase 
through the repression of its inhibitor PTEN allowing the specification of the megakaryocytic 
lineage directly from murine HSCs (Cornejo et al., 2011). Other studies evidenced the AKT-
dependent phosphorylation of GATA-1 on Serine 310 during erythroid differentiation in MEL 
cells treated with DMSO (Zhao et al., 2006), or in response to EPO in UT7 cell line (Kadri et 
al., 2005). Moreover, another study showed that GATA-1 phosphorylation on serine 310 was 
actually able to favor its preferential interaction with FOG1 instead of RB/E2F and by this  
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Figure 7: Notch does not modulate GATA-1 expression or phosphorylation in L8057 cells 
L8057 megakaryocytic cells were cultured for one day on OP9 or OP9-Dll1 stromal cells and mRNAs or protein 
levels were quantified by qRT-PCR (A) or Western-Blot (B) respectively.  
A.  Culture of L8057 cells on OP9-Dll1 increases the transcript levels of Hey-1 (left histogram) attesting for 
Notch pathway activation and slightly reduces the expression of Gata-1 (right histogram). Means and standards 
deviations from three independent experiments with asterisk showing significant variation (p<0.5%). 
B. Left panel: Typical representative Western-Blot showing the levels of phosphorylation of GATA-1 on Serine 
310, total GATA-1 or β-Actin in the nucleus or cytoplasm of L8057 cells cultured on either OP9 or OP9-Dll1 
stromal cells. Right panel: Histograms showing the relative variations in the signals of GATA-1, phosphorylated 
GATA-1 and pGATA-1/GATA-1 ratios obtained after first standardization to β-Actin signal and then to values 
obtained on OP9 stromal cell. 
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way contribute to proliferation arrest and terminal erythroid differentiation (Kadri et al., 
2009) (Lefevre, Thesis manuscript 2013).   
 
2.2. Study of Notch effect on GATA-1 in L8057 cells 
In order to test the effect of Notch stimulation on GATA-1 expression, I choose to conduct 
the study in the murine megakaryoblastic cell line L8057 (Ishida et al., 1993). First, I assessed 
their ability to respond to Notch stimulation. For that purpose, L8057 cells were co-cultured 
on murine OP9 stroma cells engineered to express Notch ligand Dll-1 (OP9-Dll1) or on 
control OP9 cells (OP9). Following 24 h of co-culture, L8057 cells were harvested and the 
expression of Notch target gene Hey-1 was assessed by qRT-PCR. As expected Hey-1 
transcript levels in L8057 cells significantly increased by 4 fold in OP9-Dll1 compared to OP9 
cocultures (Figure 7A left panel) thus attesting the activation of the Notch pathway.  
Having validated the activation of Notch pathway, I then used the same coculture 
conditions to study the effect of Notch pathway activation on GATA-1 expression in L8057 
cells. qRT-PCR analyses showed that the activation of Notch pathway in L8057 cells was 
accompanied by a slight and significant decrease of Gata-1 transcripts (15 % decrease on 
OP9-Dll1 compared to OP9 cocultures) (Figure 7 A right panel). Furthermore, cells lysates of 
L8057 cells harvested in the same conditions were fractioned into either nuclear or 
cytoplasmic fraction and used to quantify GATA-1 protein levels by Western blot. 
Quantification of Western-Blots signals revealed that the stimulation of L8057 cells by OP9-
Dll1 induced a 15 % significant decrease of GATA-1 protein levels in the cytoplasmic fraction, 
whereas it did not affect the protein levels of GATA-1 in the nuclear fraction (Figure 7 B). 
Interestingly, parallel analyses performed on native bipotent MEP, revealed that their 
stimulation by recombinant ligand Dll1 during two days was also associated with a slight 
decrease of Gata-1 transcripts levels which was reversed by DAPT treatment (Figure 4). 
  In order to test the second hypothesis, I used the same lysates of L8057 cells harvested 
after co-culture on either OP9 or OP9-dll1 to quantify the levels of GATA-1 phosphorylated 
on residue 310 by Western-Blot analysis using a pSer 310 GATA-1 specific antibody. This 
analysis showed that the coculture of L8057 cells on OP9-Dll1 did not induce any significant 
change in the levels of phosphorylated GATA-1 or in the proportion of phosphorylated 
GATA-1 (pS310/total GATA-1 ratios) neither in the cytoplasm nor in the nucleus. However,  
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Figure 8: GATA-1 phosphorylation on S310 is dispensable for the stimulation of MEPs 
amplification induced by Notch pathway activation. 
MEPs derived either from wild-type (grey bars) or GATA-1S310A knock-in mice (Black bars) were purified and 
compared for their ability to increase the number of bipotent progenitors upon Notch pathway activation 
following the protocol described in Figure 1. Histograms show the relative variations in the number of mixed 
colonies obtained before (Day 0) and after 2 days of culture on either IgG, rDll1 with or without DAPT. Mean 
and standard deviations from three independent experiments showing no significant variations.  
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Notch activation induced a slight but significant decrease of GATA-1 phosphorylation in 
cytoplasmic but not in the nuclear fraction roughly following the variation observed on total 
GATA-1 protein levels (Figure 7 B). 
We hypothesized that Notch activation induces the increase of GATA-1 expression levels 
and modulates its phosphorylation on S310 residue. Contrarily to this hypothesis, our results 
showed that Notch activation in L8057 cells slightly decreased GATA-1 transcripts and 
cytoplasmic GATA-1 protein levels to the same extent but did not change GATA1- protein 
levels in the nucleus. Moreover, we found that Notch activation in L8057 cells did not 
modulate the proportion of phosphorylated GATA-1 neither in the cytoplasm nor in the 
nucleus.  
 
2.3. Study of the implication of S310 phosphorylated GATA-1 in Notch-mediated 
maintenance of MEPs 
In order to directly assess the real implication of GATA-1 phosphorylation in the Notch-
mediated maintenance of MEP bipotency, we took advantage of a murine knock-in model 
expressing a mutated form of GATA-1 in which Serine 310 has been change into Alanine thus 
disabling GATA1 phosphorylation on that residue (Rooke and Orkin, 2006) (kindly provided 
by S. Chretien).  
As described before in Figure 1, MEP from either wild-type or GATA-1S310A mice were 
purified and cultured on either IgG or Notch ligand rDll1 with or without Notch inhibitor 
DAPT. Following two days of stimulation, MEP progeny was seeded in semi-solid medium 
and colonies obtained were classified and counted. Again, we observed that Notch 
activation increased the proportion of mixed colonies when compared to freshly purified 
MEPs (Day 0) or unstimulated MEPs (IgG). This Notch-mediated maintenance and 
amplification of bipotent progeny of MEP persisted even in MEP derived from GATA1S310A 
mutant mice with no significant difference when compared to MEPs derived from wild-type 
mice (Figure 8). These results thus indicate that the phosphorylation of GATA-1 on its serine 
residue 310 is dispensable for Notch-mediated maintenance and amplification of the 
bipotent progenitors MEP.  
Altogether these data indicate that, contrarily to our initial hypotheses, Notch activation 
does not increase GATA-1 protein levels or phosphorylation in L8057 cells. Moreover, loss of  
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GATA-1 phosphorylation on S310 does not alleviate the positive effect of Notch activation on 
native MEP maintenance and amplification. Based on these results, we conclude that the 
Notch-mediated amplification of MEP cannot be explained by increased GATA-1 protein 
levels or by changes in GATA-1 protein phosphorylation on S310 residue.   
 
3. Study of the mechanisms by which c-Kit expression upregulation by 
Notch 
The strong SCF-dependency of the Notch-mediated amplification of MEP prompted us to 
investigate the molecular mechanisms controlling c-Kit expression by Notch pathway. 
Moreover, knowing the functional duality of TPO in stimulating both proliferation and 
differentiation of megakaryocytic progenitors, we choose to extent our study of c-Kit 
regulation also in response to TPO. Given the very small number of MEP available from 
murine bone marrow (0.1% of total bone marrow cells), I choose to  perform this study of c-
Kit regulation using immortalized bipotent G1ME cells (Stachura et al., 2006). Before 
performing this study, I first verified the pertinence of this cellular model by controlling its 
erythro-megakaryocytic bipotency and its ability to mimic the upregulation of c-Kit observed 
in native MEP upon Notch activation.  
 
3.1. Validation of G1ME cells as a cell model for the study of c-Kit regulation in 
bipotent progenitors 
 
3.1.1. Verification of G1ME cells ability to differentiate towards E/MK lineages 
 G1ME bipotent progenitors cells were established from Gata-1 deficient murine embryonic 
stem cells immortalized in the presence of TPO (Stachura et al., 2006). Initial 
characterization of G1ME cells evidenced their expression of pluripotent markers such as c-
Kit and GATA-2, as well as megakaryocytic markers such as CD9, CD41 and CD61, with no 
detectable expression of other hematopoietic lineages markers such as erythroid (Ter119), 
lymphoid (B220 and IL-7R ), or granulo-monocytic ( Mac-1 and Gr-1). Quite interestingly, the 
re-expression of GATA-1 transduced by retroviral infection allows G1ME cells to resume their  
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Figure 9: G1ME cells are still able to resume terminal erythroid and megakaryocytic 
differentiation upon GATA-1 re-expression 
G1ME cells were infected by either retrovirus MIGR (transducing GFP) or MIGR-GATA-1 (transduction GFP and 
GATA-1). GFP positive infected cells were flow-sorted then re-seeded in a medium containing SCF, EPO, TPO, IL-
3, IL-6 and IL-11. Their differentiation along the erythroid or megakaryocytic lineages was monitored by flow 
cytometry through the analysis of Ter119 or CD42b markers, respectively.  
 A.   Schematic presentation of the retroviral vectors harboring either GFP alone (MIGR) or the coding sequence 
for GATA-1 coupled to GFP through an IRES sequence (MIGR-GATA1). The restoration of GATA-1 expression 
only in MIGR-GATA1 infected cells was checked at day 1 post-sorting by qRT-PCR as presented in the histogram. 
 B. FACS contour plots of the expression of GFP and either Ter119 (upper panels) or CD42b (lower panels) 
obtained after 2 and 4 days, respectively following infection with either MIGR (left panels) or MIGR-GATA1 
(right panels) retroviruses. Gate P5 corresponds to GFP positive cells expressing significant levels of either 
Ter119 or CD42b when compared to control labeling with fluorescent IgG control isotypes.  
C. Kinetic evolution of the ratios of the Ter119 (grey curve) and CD42b (black curve) median fluorescence 
intensities (MFI) between cells infected with MIGR-GATA1 and control MIGR retroviruses during the 3 days 
following infection. 
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differentiation only in erythrocytic and megakaryocytic lineages as assessed by the induction 
of Ter-119 erythroid marker and CD42b megakaryocytic marker observed by flow-cytometry.  
First, I checked the phenoptype of G1ME cells (kindly provided by T. Mercher) by FACS 
analyses. As described in the initial study (Stachura et al., 2006), we observed that G1ME 
cells resembles E/MK bipotent progenitors as they express c-Kit, while they don’t express 
CD34 and Sca-1 stem cells markers. Furthermore, they do express early megakaryocytic 
markers such as CD41 and CD61 as well as late megakaryocytic marker such as CD9, but no 
CD42b was detected. The double labeling of G1ME cells for erythroid markers CD71 and 
Ter119 showed that they are CD71+ Ter119 low. We also checked for the absence of 
granulo-monocytic markers Mac-1 and Gr-1 in G1ME cells cultured in TPO (data not shown).  
I also tested the ability of G1ME cells to engage into both erythroid and megakaryocytic 
differentiation following their infection by retroviral vector transducing only GFP expression 
(MIGR) or by the same vector transducing both GATA-1 and GFP (MIGR-GATA1) (provided by 
T. Mercher). In a first experiment, transduction efficiency was determined by analyzing GFP 
expression by flow cytometry which revealed only transient persistence of GFP marker (data 
not shown), probably due to the overwhelming growth of GATA-1 -/- G1ME cells (Stachura et 
al., 2006). In a second experiment, G1ME cells were infected by MIGR or MIGR-GATA1 
retroviral vectors followed by FACS-sorting of GFP positive cells that were seeded in a G1ME 
medium supplemented by full cocktail of erythro-megakaryocytic cytokines (SCF, EPO, TPO, 
IL-3, IL-6 and IL-11). We first checked by qRT-PCR at day 1 post-sorting the presence of 
GATA-1 transcripts in G1ME GFP+ cells infected by MIGR-GATA1 vector, whereas GATA-1 
transcripts remained undetectable in G1ME GFP+ cells infected by MIGR control vector 
(Figure 9 A). Next, the expressions of the erythroid marker Ter119 and of the late 
megakaryocytic marker CD42b were monitored by flow cytometry during three days 
following the sorting of G1ME-GFP+ infected cells. This kinetic analysis showed that the 
median fluorescence of the megakaryocytic marker CD42b continuously increased in G1ME 
cells expressing GATA-1 when compared to their MIGR counterparts, whereas the median 
fluorescence of Ter119 was increased by 2 fold and was sustained at the same level during 
the three days following the sorting (Figure 9 C).  
These results thus validated the ability of G1ME cells to engage into both erythroid and 
megakaryocytic lineages upon the restoration of GATA-1 transcription factor expression. 
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Figure 10: Notch activation upregulates c-Kit expression in G1ME cells 
G1ME cells were cultured during two days in wells coated either with control IgG or recombinant Notch ligand 
rDll1 in presence or absence of ϒ-secretase inhibitor DAPT, then harvested for the analysis of c-Kit transcripts 
and protein levels using qRT-PCR and FACS or Western-Blot, respectively.  
A. Histogram showing the relative levels of c-Kit transcripts normalized to β-Actin and to IgG control condition.  
B. Histogram showing the relative levels of c-Kit protein following quantification of Western-Blot signals of total 
c-Kit normalized to β-Actin and to IgG control condition. 
C. Histogram showing the relative median of fluorescence intensities of c-Kit protein determined by FACS 
analyses. Results are presented as relative values calculated after deduction of background fluorescence and 
normalization to the IgG control condition. 
For all histograms, (A, B, C) means and standards deviations from three independent experiments are 
presented and significant variations compared to control IgG indicated by an asterisk (Student t test p<0.5%). 
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3.1.2. Validation of the ability of G1ME cells to induce c-Kit expression upon Notch 
activation 
To test their ability to activate Notch pathway, G1ME cells were cultured either on control 
IgG or on Notch ligand rDll1 during two days and the expression of Notch target genes, Hey-
1 and Hes-1, was monitored by qRT-PCR. Hey-1 transcripts were detected neither in control 
IgG nor in rDll1-stimulated G1ME cells (data not shown). By contrast, Hes-1 transcripts were 
detected at low level in unstimulated G1ME cells cultured on IgG and increased up to 7 fold 
in response to rDll1, this increase being reversed by DAPT treatment (Table 1).  
This result thus attests that G1ME are able to activate the Notch pathway when they are 
cultured on Notch ligand rDll1.   
Having validated the ability of G1ME cells to activate Notch pathway, I used the same 
culture protocol to investigate the effect of Notch activation on the expression of c-Kit at 
both mRNA and protein levels. qRT-PCR analyses revealed that the stimulation of G1ME cells 
by rDll1 ligand induced a significant 4 fold increase  of c-Kit transcripts levels which was 
reversed by DAPT treatment (Figure 10 A). The analysis of c-Kit expression by Western-Blot 
revealed a 2 fold increase in c-Kit protein levels, though this effect was not significant (Figure 
10 B). Finally, FACS analyses revealed that the stimulation of G1ME cells by rDll1 ligand 
induced a significant increase of the mean of florescence of c-Kit when compared to 
unstimulated G1ME cells (IgG) which was reversed in the presence of DAPT (Figure 10 
C).These results thus validate that G1ME mimics the upregulation of c-Kit mRNA and c-Kit 
protein expression at the cell membrane which are observed upon Notch activation in native 
MEP.   
To complete the characterization of the Notch response of G1ME cells, we combined 
additional qRT-PCR (Figure 11C) and FACS analyses (Figure 11A and B) to document the 
effect of Notch activation on the expression of the TPO receptor c-MPL as well as of the two 
other late megakaryocytic markers PF4 and CD9 in the same culture conditions.  
We noticed that rDll1 induced a 2 fold decrease of the expression of c-MPL at the cell 
membrane which was however not reversed in the presence of DAPT (Figure 11A). 
Moreover, this decrease of c-MPL protein expression was associated with no significant 
variation in the levels of c-MPL transcripts (Figure 11C). 
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Figure 11: Notch stimulation increases c-Kit and decreases late megakaryocytic genes 
expression.  
G1ME cells were cultured for two days either on recombinant Notch ligand rDll1 or control IgG in 
medium containing TPO and in the presence or absence of ϒ-secretase inhibitor DAPT as indicated. A: 
Median Fluorescence Intensities (MFI) of c-Kit, c-MPL and CD9 expression determined by FACS 
analyses (relative values standardized to the IgG condition). B: Same data as in A but presenting the 
ratio of median of fluorescence intensities of CD9 over c-Kit normalized to IgG control condition. C: 
mRNAs levels determined by qRT-PCR and normalized to β-actin (relative values standardized to the 
IgG condition). Mean and standard deviations from 3 independent experiments. Statistically 
significant differences from the IgG condition are indicated by asterisks (p<0.05 in Student t test).  
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More interestingly, we found that rDll1 induced a significant 30% decrease of the 
expression of CD9 at the cell membrane (Figure 11A) as well as a 20% decrease of CD9 mRNA 
levels (Figure 11C) which were both reversed in the presence of DAPT. This result revealed 
an intriguing divergent regulation of c-Kit and CD9 upon Notch activation raising the 
possibility that c-Kit and CD9 could modulate each other expression. 
Knowing that CD9 expression strongly increases during terminal megakaryocytic 
differentiation, its decreased expression induced by rDll1 could reflect the inhibition of 
spontaneous megakaryocytic differentiation of G1ME cells. Supporting such a possibility, we 
found that rDll1 induced a significant 30% decrease in transcript levels of another late 
megakaryocytic gene Pf4 (Figure 11C) which again was reversed in the presence of DAPT. In 
contrast, CD41 and Fli-1 transcript levels, known to be activated earlier than CD9 and pf4, 
did not changed significantly in response to Notch activation (Table 1). These results tend to 
suggest that activation of the Notch pathway is involved in the repression of late 
megakaryocytic genes such as Cd9 and Pf4 that are spontaneously activated in G1ME cells 
cultured in presence of TPO. 
In summary, these first analyses showing that G1ME cells are still able to differentiate 
exclusively into either erythroid or megakaryocytic cells as well as to mimic the behavior of 
native MEP in the upregulation of c-Kit expression upon Notch activation validate the use of 
these cells as a pertinent cellular model to study the regulation of c-Kit expression by Notch 
pathway. Moreover, these first results obtained on G1ME cells raise several interesting new 
questions regarding the putative interferences between c-Kit and CD9 expression as well as 
the putative implication of c-Kit in modulating the dual control of their proliferation or 
differentiation by TPO.  
 
3.2. Study of c-Kit transcriptional regulation by Notch 
In order to understand the molecular mechanisms allowing Notch pathway to induce c-Kit 
expression, I adopted a two steps strategy. First, I tried to get the best evidence that the 
upregulation of c-Kit does occur at the transcriptional level. Secondly, I investigated several 
transcription factors known to be involved in the regulation of c-Kit by analyzing their 
putative differential expression and/or recruitment on c-Kit gene chromatin in response to 
Notch activation.  
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Figure 12: Notch regulates c-Kit expression at the transcriptional level 
 A .G1ME cells were cultured on IgG or rDll1 ligand with or without DAPT inhibitor during two days and the 
expression of c-Kit primary transcripts was quantified by qRT-PCR. Histogram presenting data normalized to the 
non-stimulated IgG condition with means and standards deviations from three independent experiments. 
Significant variations between rDll1 and IgG, as well as between rDll1 and rDll1+DAPT are represented by 
asterisk (p< 0.001% in Student test). 
 B. Schematic map showing the positions (in Kb) of the regions amplified using different primers in and around 
c-Kit gene.   
C. G1ME cells were co-cultured either on OP9 or OP9-Dll1 stromal cells, harvested and analyzed by ChIP assay. 
Chromatin was precipitated by RNA POL-II antibody or control rabbit-IgG (CTRL IP). Enrichments in the RNA POL 
II chromatin of c-Kit gene enhancers (-114, +4.7, +72.9), promoter (c-Kit 0) or at regular intervals inside the 
coding sequence were quantified by qPCR. Enrichment data were normalized to the input amount of chromatin 
and to negative control for POL II binding on region (-146) Kb. RNA POL II enrichment on Rpl18 promoter was 
also analyzed as positive control for RNA POL II binding. Means and standards deviations are derived from 3 
independent experiments.  
D.  Same protocol and presentation as in B except that the highly proliferating ESRE2 erythroid cells were used 
as positive control to test the efficiency of RNA POL II antibody in ChIP assay. Chromatin was precipitated using 
either RNA POL II antibody (Black bars) or rabbit control antibody (white bars) and qPCRs were performed on c-
Kit gene and positivecontrol genes encoding proteins implicated in ribosome biogenesis (Rpl18 and Npm1) 
supposed to be highly transcribed.  
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3.2.1. Evidence for the transcriptional upregulation of c-Kit gene 
To test the hypothesis that the upregulation of c-Kit mRNA is due to increased transcription 
of the c-Kit gene, I used qRT-PCR to quantify the upregulation of unspliced c-Kit primary 
transcripts. Indeed, unspliced primary transcripts are very rapidly degraded following 
transcription and for that reason their levels are a good indicatior of instantaneous 
transcription rate. Thus, we designed specific primers amplifying a region in the first intron 
of c-Kit gene and used these primers to quantify c-Kit primary transcripts in G1ME cells. Our 
results showed that the stimulation of G1ME cells by rDll1 induced a three fold increase in c-
Kit primary transcripts when compared to unstimulated cells cultured on IgG, this increase 
being cancelled by DAPT treatment (Figure 12 A). These results strongly suggest that Notch 
actually regulates c-Kit expression directly at the transcriptional level. 
In a different approach aimed to strengthen this conclusion, we tried to evidence an 
increase in the density of RNA Polymerase II (POL II) present on the promoter and along the 
c-Kit gene using chromatin immunoprecipitation assay (see methods). For that purpose, 
G1ME cells were cultured during two days on either OP9 or OP9-Dll1 stromal cells and 
harvested. Then, chromatin was cross-linked and immunoprecipitated using either RNA-POL 
II specific antibody or control rabbit antibody (used to estimate background level of 
immunoprecipitated chromatin due to unspecific antibody binding). Following crosslink 
reversion and DNA purification, I quantified by q-PCR the relative amounts of DNA amplified 
from c-Kit promoter or regularly interspaced regions inside c-Kit gene contained in POL II  
(Figure 12 B) or control chromatin and then calculated the relative enrichment of RNA POL II 
in these different regions following normalization to a negative non transcribed region 
outside c-Kit gene (-146 Kb upstream region). Unfortunately, the results of these RNA POLII 
ChIP analyses  showed very low and non significant enrichments of RNA POL II on the 
promoter and all the regions tested inside c-Kit gene in both unstimulated (cultured on OP9) 
or Notch stimulated (cultured on OP9-Dll1) G1ME cells. In the same experiment, an 8 fold 
enrichment of RNA POL II was clearly detected on the promoter of the highly active RPL18 
ribosomal protein gene which further increased up to 25 fold in Notch-stimulated G1ME 
cells thus attesting successful RNA POL II chromatin immunoprecipitation (Figure 12 C). In 
control experiments we used the same RNA POL II antibody to quantify RNA POL II 
recruitment on c-Kit gene in the SCF-dependent ESRE cells (Extensively Self-Renewing  
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Gene IgG rDll1 rDll1 + DAPT 
Hes-1 1 15 .6 ± 3 0.81 ± 0.24  
c-Myc 1 1. 29 ± 0.05  1. 04 ± 0.25 
Gata-2 1 1. 24 ± 0.07  1. 27 ± 0.25 
Pten 1 1.21 ± 0.1  1. 24 ± 0.1 
Jak-2 1 1.2 ± 0.29 1.24 ± 0.45 
Tal-1 1 1.15 ± 0.19 1.26 ± 0.29 
Itga2b 1 1.1 ± 0.23 1 ± 0.32 
Tr-Mpl  1 0. 96 ± 0.29 1.11 ± 0.18 
miR-221 1 0.91 ± 0.19 1 ± 0.27 
Fli-1 1 0.84 ± 0.11 0.98 ± 0.18 
miR-451 1 0.78 ± 0.58 0.73 ± 0.94 
 
Table 1: Gene expression variation according to stimulation by Notch ligand rDll1 
G1ME cells were cultured during two days either on control IgG or on Notch ligand rDll1 in presence or absence 
of Notch inhibitor DAPT. The expression of the indicated genes (left column) was quantified by qRT-PCR. ΔCt of 
designated genes were normalized on β-Actin and IgG condition. Means and standard deviations from 3 
independent experiments. Significant variations of rDll1 compared to IgG, or of rDll1+DAPT compared to rDll1 
are shown by grey background. 
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Erythroid progenitors) expressing higher levels of c-Kit. In that case, a clear RNA POL II 
enrichment was observed on c-Kit promoter but this enrichment remained quite low as 
being only 4 fold above background and thus indicating a low loading of RNA POL II on the c-
Kit gene (Figure 12 D).   
Even if we could not quantify changes in RNA POL II recruitment on c-Kit gene by ChIP 
assay, we concluded from the induction of c-Kit primary transcripts that Notch pathway 
activation in G1ME cells upregulates c-Kit expression at the transcriptional level.  
 
3.2.2. Looking for Notch-dependent regulation of known transcriptional 
regulators of c-Kit 
As an attempt to identify the molecular actors allowing the induction of c-Kit gene 
transcription by Notch pathway, I adopted a gene/protein candidate strategy focused on 
several already known direct regulators of c-Kit gene transcription. For each candidate, I 
looked for putative changes in their expression using qRT-PCR and, when possible, directly 
quantified their enrichment on c-Kit gene using ChIP assays.  Positive regulators candidates 
consisted in GATA-2 (Jing et al., 2008) and SCL (Lecuyer et al., 2002) which make part of the 
same complex that binds c-Kit gene on enhancer regions at position (-114), +5, +58 and +73 
Kb (Jing et al., 2008) (Figure 13 A). Besides, knowing that Notch stimulation in G1ME cells 
induced the expression of Hes-1 which encodes for a transcriptional repressor, I analyzed the 
modulation of expression of c-Kit repressor such as miR-221 (Gabbianelli et al., 2010) or 
GATA-2 repressor miR-451 (Pase et al., 2009). miR-221 was an interesting candidate as it was 
shown to be negatively regulated by Notch pathway during angiogenesis (Nicoli et al., 2012). 
qRT-PCR analyses in G1ME cells stimulated during two days (rDll1) or not (IgG) by Notch 
revealed that none of these candidates’ expression was modulated by Notch stimulation or 
by DAPT treatment (Table 1).  
In a second complementary approach, I used ChIP assay to quantify the recruitment of 
GATA-2 and SCL on c-Kit promoter and enhancers in G1ME cells after a 2 days culture on 
either OP9 or OP9-Dll1 stromal cells. Chromatin was immuno-precipitated either by GATA-2 
or SCL specific antibodies or by control rabbit antibody as described for previous RNA POL II 
ChIP assays. As above, primers amplifying the -146 Kb region were used as negative control 
for the binding of these two transcription factors. No significant recruitment of GATA-2  
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Figure 13: ChIP analyses of GATA-2 and SCL binding on c-Kit gene 
Same protocol as in Figure 12 B except that immuno-precipitations were performed either using 
GATA-2 (B) or SCL specific antibodies (C) or control rabbit-IgG (CTRL IP).  
Histograms show the relative enrichments of the different region for GATA-2 (A) or SCL (B) binding 
calculated after normalization to input chromatin and to the negative binding control region -146 Kb. 
Means and standards deviations from two independent experiments.  
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(Figure 13 A) or SCL (Figure 13 B) was detected on the c-Kit promoter and all along the c-Kit 
gene neither in unstimulated nor in stimulated G1ME cells. In contrast, strong enrichments 
indicating binding of both GATA2 and SCL were clearly detected on the -114 Kb enhancer in 
unstimulated cells (15 and 14 fold enrichments, respectively). Intriguingly however, these 
recruitments of GATA2 and SCL on the -114 enhancer were decreased in stimulated cells 
(down to 9 fold enrichment). Thus, although these results could confirm the expected 
binding of GATA2 and SCL to the -114 Kb c-Kit enhancer, we concluded that the 
transcriptional upregulation of c-Kit gene induced by Notch activation cannot be explained 
by the increased recruitment of either one of these two transcription factors.  
In summary, we were able to show that the positive regulation of c-Kit by Notch originates 
at least partially at the transcriptional level but we failed to explain this increased 
transcription by an increased recruitment of the two known positive transcription regulators 
GATA2 or SCL. At this step of our study, we were aware that the pursuit of our investigation 
of additional candidates’ regulators might be frustrating and possibly endless. Having no 
evident alternative to this candidate approach, we thus decided to refocus our project to 
investigate the putative contribution of c-Kit to the TPO-dependent proliferation of G1ME 
cells as well as the putative regulation of c-Kit by CD9.  
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Figure 14: c-Kit is implicated in G1ME cells proliferation 
A and B. G1ME cells were cultured in the presence of recombinant 
TPO with or without increasing doses of c-Kit inhibitors ISCK-03 (1.5 
to 10 μM) (A) or Masitinib (0.15, 1 or 3 μM) (B) or control DMSO 
during 4 days. Cell concentration and cell viability were assessed 
every day of the kinetic and cell concentration was kept at 2.5 105 
cells/ mL. The cumulated number of viable cells generated from the 
initial number of cells seeded was calculated based on the 
amplification factor from day to day. Mean and standard deviations 
from 3 independent experiments. Statistically significant 
differences of the cumulated number of cells at day 4 between the 
different conditions are indicated by asterisks (* p < 1%). C. G1ME 
cells were submitted to 2 rounds of transfection at 24 hours 
interval with either c-Kit siRNA or control luciferase siRNA and re-
seeded in medium containing TPO with or without 3 μM Masitinib.  
Figure shows the cumulated number of viable cells over 4 days 
after the first transfection. 
 
 
 
 
Figure15: SCF does not contributes to the TPO-dependent 
proliferation of G1ME cells 
A: Quantification by Elisa immunoassay of SCF concentration in the 
supernatant of G1ME cells cultured in the presence of recombinant TPO 
during 24 hours compared to control medium without G1ME cells. Hatched 
area indicates the 95 % confidence interval of themean background value 
detected in control medium devoid of SCF. Mean and standard deviations of 4 
independent experiments showing no significant difference of SCF 
concentration between normal medium and G1ME supernatant. 
B: Proliferation curves of G1ME cells in the presence of recombinant TPO and 
either control IgG2bk or increasing doses of c-Kit blocking monoclonal 
antibody ACK2. Mean and standard deviations of three independent 
experiments showing no difference in the total number of cells generated 
after 4 days in the presence of control IgG2bk or ACK2 c-Kit antibody.  
  
 
 
124 
4. Study of c-Kit regulation by TPO, Notch and CD9 and its implication in 
G1ME cells proliferation/differentiation balance 
 
TPO induces both proliferation and differentiation of megakaryocytic progenitors but the 
mechanisms underlying the switch between these two opposite effects remain poorly 
understood. Besides, the repression of c-Kit corresponds to a critical event signing the 
initiation of terminal differentiation of hematopoietic progenitors. These considerations 
prompted us to take advantage of the TPO-dependent proliferation of G1ME cells to 
investigate the putative contribution of c-Kit signaling in modulating the proliferative or 
differentiating effect of TPO.  As reported above (Figure 11), we also noticed an intriguing 
divergent variations in the membrane expression levels of c-KIT and CD9 following the 
activation of Notch pathway in G1ME cells. This intriguing observation prompted us to 
investigate the putative involvement of CD9 in the down regulation of c-Kit. The results of 
these investigations are presented in a manuscript (manuscript 2) in which we propose a 
new model that could explain the dual function of TPO based on a dynamic regulatory 
interplay between TPO signaling, c-Kit and CD9. The full version of this manuscript is 
presented in the next section from which the main results are summarized in the following 
paragraphs. 
First, I investigated the actual implication of c-Kit in G1ME cells proliferation and survival. 
For that purpose, I adopted two different strategies either the inhibition of c-Kit activity 
using specific chemical inhibitors or the inhibition of c-Kit expression by specific siRNA 
targeting c-Kit transcripts. The two strategies showed convergent results, as both the 
treatment of G1ME cells by ISCK03 or Masitinib inhibitors as well as the reduction of c-Kit 
expression by specific siRNA induced a dose dependent decrease of cell proliferation (Figure 
14) with minimal effect on cell survival. These results demonstrate the active implication of 
c-Kit in G1ME cells proliferation.  
Given that G1ME cells proliferate in the presence of TPO only but not in the presence of 
SCF, we were interested to identify the mode of activation of c-Kit. For that purpose, I 
looked for the putative secretion of SCF by G1ME cells. However, ELISA immuno-assay 
performed on G1ME cells conditioned medium revealed no detectable levels of SCF (Figure  
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Figure 16: Stimulation of G1ME cells by TPO 
induces c-Kit receptor phosphorylation 
G1ME cells were starved for 6 hours without TPO then re-
stimulated by TPO during 5, 10, 15 or 30 minutes, followed 
by Western-Blot analysis of Y719 phosphorylated c-Kit, total 
c-Kit and β-Actin. NS: Non Starved cells; S: Starved cells. 
Upper part shows typical Western-Blot obtained after 
revelation of the same membrane with specific antibodies 
directed against either phosphorylated c-Kit on tyrosine 
Y719, or total c-Kit or β-Actin used as loading control. 
Histogram shown in lower part displays the variations of 
phosphorylated or total c-Kit or the ratio of phosphorylated 
over total c-Kit signal normalized to the ratio determined in the starved condition (mean and standard 
deviations from three independent experiments).  
 
 
 
 
 
 
Figure 17: Masitinib 
stimulates 
polyploidization of G1ME 
cells 
FACS dot-plots for EdU 
incorporation and DNA 
content.G1ME cells were 
cultured in the presence of Cos-
TPO conditioned medium with 
or without Masitinib as indicated. Cell cycle analyses were performed by FACS after EdU pulse labeling followed 
by double labeling for EdU incorporation by Click-it reagent coupled to Alexafluor-647 and DNA content by 
propidium iodide. Numbers indicate the percentage of cells identified in the different phases of cell cycle 
including cells undergoing polyploidization (EdU labeled cells with DNA content higher than 4 N). 
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15 A). Moreover, blocking SCF to c-Kit interaction using ACK2 monoclonal c-Kit antibody did 
not affect G1ME cells proliferation (Figure 15 B), thus excluding a paracrine mechanism. 
Thus, we hypothesized that TPO is able to directly activate c-Kit. To test this hypothesis, I 
analyzed by Western-Blot the levels of phosphorylation of c-Kit in response to TPO 
stimulation following G1ME cells starvation. These analyses demonstrated a significant 
increase in the proportion of Y719 phosphorylated c-Kit protein in response to TPO 
stimulation (Figure 16). To our knowledge, this result is the first demonstration that TPO can 
directly activate c-Kit phosphorylation. 
At this step, these results established the implication of c-Kit in the TPO-dependent 
proliferation of G1ME cells. In order to determine whether c-Kit may be also implicated in 
the repression of G1ME cells differentiation, cells were treated with the c-Kit inhibitor the 
Masitinib and their cell cycle status was analyzed by FACS following the double labeling for 
EdU incorporation as well as DNA content using PI (Propidium Iodide). This analysis revealed 
that Masitinib actually stimulates the polyploidization of G1ME cells as indicated by an 
increased proportion of 4N cells still undergoing DNA synthesis (Figure 17). These results 
indicate that c-Kit participates to G1ME cells proliferation as well as restricts their 
spontaneous megakaryocytic differentiation.  
Finally, I tested the hypothesis of a direct inhibition of c-Kit by CD9. For that purpose, 
G1ME cells were transfected by CD9 specific siRNA or control anti-Luciferase si-RNA and 
analyzed by flow cytometry the expression of c-Kit and CD9. I observed a strong negative 
correlation between CD9 and c-Kit expression as attested by the reciprocal decrease of CD9 
and increase of c-Kit median of fluorescence (Figure 18). These results demonstrate that CD9 
levels negatively regulate the levels of c-Kit expressed at the cell surface of G1ME cells.  
  In summary, this study allowed us to determine that c-Kit participates to the proliferation 
of G1ME cells following its activation not by its canonical ligand SCF, but directly by TPO. 
Furthermore, c-Kit restricted the low tendency of G1ME cells to differentiate along the 
megakaryocytic lineage. Additionally, this study evidenced that CD9 levels negatively 
regulate the levels of c-Kit expressed at the cell surface of G1ME cells.  
Based on these results, we suggest a new model that could explain the dual function of 
TPO during the switch between proliferation and differentiation of megakaryocytic 
progenitors. According to this model, the proliferation of megakaryocytic progenitors would 
proceed under TPO-mediated c-Kit stimulation until reaching a threshold level of CD9  
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Figure 18: CD9 actively contributes to reduce 
c-Kit levels 
G1ME cells were submitted to two rounds of 
transfection at 24 hours interval with either CD9 
siRNA or control luciferase siRNA and re-seeded 
in medium containing TPO. The figureshows the 
compilation of data from three independent 
transfection experiments showing the striking 
correlation between the fold reduction of CD9 
median of fluorescence and the fold increase in c-
Kit median of fluorescence relative to si-
Luciferase control condition.  
 
 
 
 
Figure 19: Working 
model of the dual control 
of c-Kit by TPOduring 
megakaryopoiesis 
Our results showed that 
part of the proliferative 
effect of TPO is mediated 
through the activation of c-
Kit signaling that 
concomitantly contributes 
to inhibit CD9 expression 
and polyploidization, while 
c-Kit itself is under the negative control of CD9. Based on these findings, we suggest that TPO 
stimulates the proliferation of megakaryocytic progenitors while progressively increasing CD9 
expression until reaching a threshold level sufficient to inhibit c-Kit allowing in turn proliferation 
arrest and terminal differentiation. 
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sufficient to lower the expression of c-Kit at the cell surface and thereby to suppress the 
proliferative effect of TPO at the benefit of terminal differentiation (Figure 19).   
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MANUSCRIPT2: 
c-Kit activation contributes to the TPO-
dependent proliferation of 
megakaryocytic progenitors while c-Kit 
expression is limited by CD9  levels 
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Abstract: 
Despite the known dual contribution of Thrombopoietin (TPO) to both proliferation and 
terminal differentiation of megakaryocytic progenitors, the molecular event(s) controlling the 
switch between proliferation and differentiation remain poorly understood.  In the present 
study, we addressed this question by exploring the contribution of c-Kit signaling to the TPO-
dependent proliferation of G1ME cells (GATA1 deficient MEP progenitors immortalized in 
the presence of TPO). Using c-Kit signaling inhibitors Masitinib and ISCK03 or siRNA 
mediated knock down of c-Kit expression, we demonstrated that c-Kit signaling significantly 
contributes to the proliferative effect of TPO. In agreement with this finding, we showed that 
stimulation by TPO actually activates c-Kit phosphorylation in the absence of exogenous or 
secreted SCF. Moreover, we showed that CD9 expression and polyploidization of G1ME cells 
in the presence of TPO are induced by Masitinib, thus indicating that TPO-mediated c-Kit 
activation also contributes to limit their differentiation. Finally, we showed that siRNA 
mediated knock down of CD9 increased membrane expression of c-Kit in a strikingly dose-
dependent manner. Taken together, these results indicate that TPO alone is able to activate c-
Kit phosphorylation which in turn contributes to stimulate proliferation and concomitantly to 
inhibit polyploidization while c-Kit expression itself is limited by CD9 levels. Based on these 
results, we suggest that the proliferation of megakaryocytic progenitors proceeds under TPO-
mediated c-Kit stimulation until reaching a threshold level of CD9 sufficient to lower the 
expression of c-Kit at the cell surface and thereby to suppress the proliferative effect of TPO 
at the benefit of terminal differentiation.   
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Introduction 
 
During megakaryopoiesis, committed megakaryocytic progenitors undergo several divisions 
before terminal differentiation associated with polyploidization (1). Both proliferation and 
differentiation steps are under the main control of thrombopoietin (TPO) that acts through its 
specific receptor c-MPL (1-4). The molecular mechanisms underlying this dual function of 
TPO as well as the signal(s) inducing commitment from proliferation to terminal 
differentiation remain poorly understood.  
One important change in the signaling events downstream to TPO/c-MPL allowing terminal 
differentiation is the sustained activation of the MAPK/ERK pathway that has been shown to 
be required for polyploidization (5-7). However, the underlying mechanisms controlling this 
change in signalization remains unknown.  
Another important cytokine involved in the proliferation step of megakaryocytic progenitors 
is Stem Cell Factor (SCF) acting through its specific receptor c-Kit (8).  While SCF and TPO 
synergize to stimulate the proliferation of megakaryocytic progenitors (9), terminal 
differentiation actually coincides with the drastic down-regulation of c-Kit expression at both 
transcriptional and protein levels (10). Moreover, several evidences indicate that c-Kit 
signaling not only contributes to stimulate proliferation but also concomitantly inhibits 
differentiation. Indeed, knock down of c-Kit accelerates the differentiation of megakaryocytic 
progenitors generated by human CD34+ pluripotent stem cells in vitro as well as terminal 
differentiation of K562 cells induced by PMA (10). Transcriptional repression of c-Kit gene 
can be at least partially explained by the repressive effect of GATA-1 which levels increase 
during progression towards terminal megakaryocytic differentiation (11). Similarly, a recent 
study has shown that the human ZNF16 transcription factor which levels also increase during 
progression towards megakaryocytic differentiation is also actively involved in the active 
repression of c-Kit transcription (10). Unfortunately, given the lack of conservation of Znf16 
in mouse (12), it remains currently unknown whether a similar factor is also involved in c-Kit 
repression during murine megakaryopoiesis. Interestingly, other recent studies have shown 
that hematopoietic stem cells (HSC) displaying the highest levels of c-Kit expression turned 
out to be strongly biased towards megakaryocytic differentiation (13). All together these data 
indicate that while c-Kit actively contributes to the proliferation step of megakaryocytic 
progenitors and its increasing levels accompany their progression towards terminal 
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differentiation, an active program is concomitantly activated that leads to its transcriptional 
repression and is required to allow terminal differentiation. Whether additional changes 
accompanying progression towards megakaryocytic differentiation further contribute to 
switch off c-Kit signaling remains an interesting possibility. For example, CD9 whose 
expression increases during progression towards megakaryocytic differentiation (14, 15), has 
been shown to sequester a fraction of c-Kit receptors into tetraspanin network thus rendering 
it unresponsive to SCF stimulation in MO7e cells (16).  
In the present study, we used the GATA1 deficient G1ME cells (17) that proliferate in the 
presence of TPO only, as a cellular model to investigate the putative contribution of c-Kit 
signaling to the proliferative effect of TPO as well as the putative contribution of CD9 in the 
negative regulation of c-Kit. We showed that a significant part of the proliferative effect of 
TPO is actually mediated through the activation of c-Kit receptor that concomitantly 
contributes to inhibit polyploidization and that CD9 actively contributes to reduce c-Kit 
expression. Based on these results, we suggest that TPO dynamic control of proliferation and 
terminal differentiation during megakaryopoiesis relies on its dual property to activate c-Kit 
signaling contributing to proliferation instead of differentiation and to activate CD9 allowing 
the inhibition of c-Kit once a sufficient threshold level of CD9 is reached.  
 
Material and Methods 
Cell culture 
G1ME cells (GATA-1 -/- Megakaryocyte Erythrocyte) were kindly provided by T. Mercher. 
G1ME cells were derived from GATA-1 deficient murine embryonic stem cells and 
immortalized in the presence of TPO the only cytokine needed for their proliferation and 
survival (17). G1ME cells were cultured in α-MEM Glutamax medium (GIBCO. Life 
Technologies) supplemented with 20 % fetal calf serum (PAA) and 1 % Peni-Streptomycin 
(PAA) in the presence of either 1% of Cos7-TPO conditioned medium (Kindly provided by T. 
Mercher) or 20 ng/ mL of murine recombinant TPO. Cells were cultured in 5 % CO2 at 37°C 
and maintained between 5 105 and 1.5 106 cells/ mL by daily dilution. Inhibition of c-Kit 
signaling was performed by adding either chemical inhibitors Masitinib (18) (Clinisciences). 
[4-t- butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03; Sigma) (19-21) or c-Kit 
blocking antibody ACK2 (eBioscience). 
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Proliferation assay 
Cell concentration was determined by double counting on hemocytometer. Cell viability 
was assessed by Trypan Blue exclusion (Sigma). Each day of the kinetic, 2.5 105 G1ME cells 
of each condition were reseeded in new wells. The cumulative numbers of viable cells were 
calculated from the increase of cell density determined after each passage.  
 
Starvation and re-stimulation assays 
A 5 to 6 hours starvation time was determined in pilot experiments as the maximal time 
allowing no more than 5% of starvation-induced cell death of G1ME cells as determined by 
Trypan blue exclusion in complete medium without TPO. Equal numbers of starved cells 
were harvested and resuspended in complete medium supplemented with 1 % TPO-
conditioned medium or with 20 ng/mL of murine recombinant TPO for 5/ 10/ 15/ 30 minutes 
of re-stimulation at 37°C. Re-stimulation was stopped by adding ice-cold PBS containing a 
full cocktail of protease inhibitors (Complete mini EDTA-free tablets Roche) and phosphatase 
inhibitors (1 mM sodium pyrophosphate. 25 mM sodium beta-glycerophosphate and 50 mM 
of sodium fluoride (Sigma)).  
 
Western-Blot 
Whole cell lysates were prepared by lysing equal number of cells for each condition in 
Laëmmli lysis buffer supplemented with a full cocktail of protease inhibitors (Complete mini 
EDTA-free tablets. Roche) and phosphatase inhibitors (1 mM sodium pyrophosphate, 25 mM 
sodium beta-glycerophosphate and 50 mM of sodium fluoride). Proteins were denatured 5 
minutes at 95 °C and stored at (-80 °C) until analysis. Proteins were separated on pre-casted 
4-12% SDS-PAGE (Biorad) then transferred on PVDF membrane using Trans-Blot Turbo 
Transfer System (Biorad). Membranes were pre-incubated for 1 hour in blocking solution (5 
% bovine serum albumin (BSA) in TBS-T) followed by overnight incubation at 4 °C with 
appropriate dilutions of c-Kit (Cell Signaling # 3074) or Y719 phospho-c-Kit (Cell Signaling 
# 3391) rabbit antibodies. After three washes in TBS-T (Tris Buffered Saline: 50 mM Tris pH 
7.6. 300 mM NaCl and 0.1 % Tween-20), membranes were then incubated for 1 hour at room 
temperature (RT) with Goat anti-Rabbit coupled to horseradish peroxidase and washed three 
times in TBS-T. Signals were revealed using Clarity ECL substrate (Biorad) and recorded on 
Chemidoc instrument (Biorad) and quantified using the Image Lab software (Biorad). After c-
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Kit signals recording, membranes were stripped 12 minutes at 50°C under shaking in strip 
buffer (62.5 mM Tris/HCl pH 6.8. 2% SDS and 100 mM β-mercaptoethanol). Stripped 
membranes were then preincubated for 30 minutes in 5 % nonfat-milk, incubated 1 hour at 
RT with anti-β-Actin (Millipore #MAB 1501) mouse antibody revealed and recorded as 
described above after 1 hour incubation at RT with Goat anti-Mouse secondary antibody 
coupled to horseradish peroxidase.  
 
SCF dosage by ELISA  
The supernatants of 2.105 G1ME cells cultured during 24 or 48 hours were harvested and 
SCF levels were determined on 100   L duplicate aliquots using commercial SCF mouse 
Elisa kit (ab100740; Abcam) following the recommendations of the manufacturer. Optical 
density at 450 nm was recorded on a Viktor luminometer (Perkin Elmer) and SCF 
concentration in each sample estimated by reference to standard curve established using 
murine recombinant SCF.  
 
Flow cytometry 
2.105 cells were washed twice in PBS containing 0.5 % BSA (Sigma) and 2 mM EDTA 
(PBE). Following 10 minutes of blocking with murine Fc-Block (Milteny), cells were 
incubated during 30 minutes with anti-CD117-PE, anti-CD117-APC, anti-CD9-PE, anti-CD9-
APC or anti-CD110-PE fluorescent antibodies or with the corresponding fluorescent control 
IgGs. All antibodies were purchased from eBioscience. Labeled cells were washed and re-
suspended in PBE buffer before analysis on FACS Aria II instrument (Becton Dickinson). 
Fluorescence signals were recorded on 10 000 viable labeled cells and analyzed using 
BDFACS-DIVAv5 and Flow Jo softwares.  
 
Cell cycle analyses 
Cells were plated in duplicate 48 hours before treatment then cultured in presence or 
absence of EdU (5-ethynyl-2'-deoxyuridine) at 10 μM during one hour. Cell cycle analysis 
was then performed using the Click-iT® EdU Alexa Fluor® 647 Flow Cytometry Assay Kit 
following the recommendations of the supplier (Molecular Probes, Life Technologies). 
Briefly, labeled cells were harvested, fixed and permeabilized to allow the detection of EdU 
by picolyl azide which is coupled to Alexa-Fluor-647 dye. After a 30 minutes treatment with 
RNase at 1 mg/mL, propidium iodide was added at 50 μg/mL just before analysis on FACS 
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Aria II flow cytometer (Becton Dickinson). Cell cycle analyses were performed using Flow Jo 
software.  
 
RNA extraction and qRT-PCR 
RNA was extracted from 105 cells using RNeasy Plus Micro Kit (Qiagen # 74034) following 
the manufacturer’s recommendations. 100 ng of RNA were reverse transcribed using 
QuantiTect Reverse Transcription kit (Qiagen # 205313) followed by qPCR using 
LightCycler 480 SYBR Green Master I kit (Roche) on Mx 3000 version 6.22 thermocycler 
and analyzed on Mx-Pro-3000P software (Stratagen). Sequences of qRT-PCR primers are 
given in supplementary Table S1. 
 
siRNA transfection 
5.105 G1ME cells resuspended into 100 μL of Amaxa kit V reagent (Lonza) were 
transfected with 20 μM siRNA using program G-16 on Nucleofector device (Lonza). Cells 
were resuspended in full medium which was changed after 4 hours. After 24 hours, the same 
round of transfection was performed. At the indicated times following first transfection, cells 
were counted, their viability assessed by Trypan blue exclusion and then were harvested for 
qRT-PCR and flow cytometry analyses. 
 
Statistics 
Data were analyzed using Student t-test. Differences were considered significant if p-value 
was below 5 %. 
 
Results 
 
1- c-Kit signaling contributes to the TPO-dependent proliferation of G1ME cells 
As previously reported by others (17), we found that G1ME cells were unable to survive and 
to proliferate in the presence of SCF only (Figure S1). However, this result did not exclude 
the putative contribution of c-Kit signaling to the proliferation of G1ME cells in response to 
TPO. In a first approach to address this possibility we investigated the effect of the two 
specific c-Kit inhibitors ISCK03 (19-21) and Masitinib (18) on the proliferation and viability 
of G1ME cells in the presence of TPO (Figure 1). The addition of increasing low doses of 
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ISCK03 (ranging from 1 to 10   M) led to a progressive decrease of G1ME cells proliferation 
reaching a 60% reduction of viable cells generated after a 4 days culture in the presence of 10 
  M ISCK03 (Figure 1A). Likewise, the addition of increasing low doses of Masitinib 
(ranging from 0.15 to 3 μM) led to a significant and dose-dependent decrease of G1ME cells 
proliferation reaching a 60% reduction of cumulated viable cells number generated after a 4 
days culture in the presence of 3   M Masitinib (Figure 1B). Western blot analyses confirmed 
the presence of phosphorylated c-Kit protein at tyrosine residue 719 attesting of c-Kit 
activation and this phosphorylation was reduced by a treatment with c-Kit inhibitors ISCK03 
(10   M) and Masitinib (3   M) (0.4 and 0.45 fold decrease compared to untreated cells. 
respectively; Figure 2B). Interestingly, FACS analyses further showed that Masitinib (Figure 
2A, right panel) but not ISCK03 (Figure 2A, left panel) also led to a marked reduction (> 
50%) of c-Kit levels expressed at the cell surface. In a second complementary approach, we 
decided to investigate the effect of reducing c-Kit expression directly at the transcriptional 
level by RNA interference. For that purpose, G1ME cells were submitted to two rounds of 
transient transfection at 24 hours interval using c-Kit specific siRNA or control luciferase 
siRNA. During the three days following the second transfection, cell proliferation was 
assessed and c-Kit transcripts and c-Kit cell surface levels were quantified by q-RT-PCR and 
FACS analysis, respectively (Figure 3). This protocol allowed us to obtain a transient 
downregulation of both c-Kit mRNA (Figure 3C) and c-Kit protein membrane levels (Figure 
3D) which were both maximal (-60%) at 48 hours following the first round of transfection 
and approximately returned to initial levels at 96h. This transient downregulation of c-Kit was 
found associated with a significant reduction in the cumulated total number of viable cells 
generated during the two days following the second transfection (Figure 3A and 3B) with 
minimal reduction of cell viability (5 % decrease compared to untreated cells; data not 
shown). Combining c-Kit siRNA transfection with Masitinib treatment at 3 μM led to a 
greater reduction of c-Kit expression that was associated with greater reduction of cell 
proliferation (Figure 3A and 3B). Taken together, these results established that G1ME cells 
cultured in the presence of TPO displays activated c-Kit and that c-Kit activation significantly 
contributes to their proliferation despite the absence of added SCF.  
 
 
 
 
 
139 
2- TPO activates c-Kit receptor phosphorylation 
Having established the contribution of c-Kit activation to the TPO-dependent proliferation of 
G1ME cells in the absence of added SCF, we tried to identify the origin of this c-Kit 
activation. One first possibility could be that c-Kit was activated through the secretion of SCF 
by G1ME cells. However, immuno-detection of SCF failed to reveal any significant SCF 
levels above 0.2 ng/mL (corresponding to the lower limit of SCF detection by Elisa test) in 
the conditioned medium of G1ME cells cultured in the presence of TPO (Figure 4A). Most 
importantly, addition of ACK2 c-Kit antibody, known to block the binding of SCF to c-Kit 
receptor (22), did not affect G1ME cells proliferation (Figure 4B). We therefore investigated 
the alternative possibility that TPO itself could contribute to c-Kit activation. For that 
purpose, we performed kinetics analyses of c-Kit phosphorylation on tyrosine 719 in G1ME 
cells that have been re-stimulated by either SCF or TPO after a 6 hours period of starvation in 
the absence of cytokine. Our results clearly showed the transient increase in c-Kit 
phosphorylation in response to TPO (Figure 5A) with a maximal of 5 fold mean increase after 
5 minutes of TPO re-stimulation followed by gradual return to basal levels during the next 10 
minutes. Transient increase in c-Kit phosphorylation was also observed in response to SCF 
with similar kinetics and no significantly different maximal mean of stimulation (Figure 5B). 
These results thus indicated that TPO actively contributes to c-Kit activation.  
 
3- c-Kit activation restricts megakaryocytic differentiation  
Having shown that c-Kit activation contributes to the TPO-dependent proliferation of G1ME 
cells, we next wanted to know whether c-Kit activation could also restrict their 
megakaryocytic differentiation. Terminal megakaryocytic differentiation involves two main 
aspects including increased transcription of late megakaryocytic genes and polyploidization. 
We therefore investigated whether c-Kit inhibition by Masitinib could stimulate the 
expression of late megakaryocytic genes and polyploidization in G1ME cells cultured in the 
presence of TPO. Interestingly, Masitinib treatment significantly increased Pf4 transcripts in 
G1ME cells (Figure 6A). Progression towards polyploidization was assessed by looking for 
cells with DNA content higher than 4 N and still undergoing DNA synthesis. For that purpose 
we performed pulse incorporation with EdU followed by its labeling as well as DNA content 
labeling using propidium iodide before FACS analyses (Figure 6B). Untreated G1ME cells 
contained at most 0.3 % of EdU labeled cells with DNA content higher than 4N (Figure 6B 
 
 
140 
left panel). In clear contrast, the low frequency of polyploid cells increased by more than 5 
fold reaching 1.7 % when G1ME cells were treated by Masitinib (Figure 6B right panel). 
Taken together, these results thus indicated that c-Kit inhibition by Masitinib drives G1ME 
cells towards megakaryocytic terminal differentiation. 
 
4- CD9 levels actively contribute to reduce c-Kit expression 
A previous study performed in MO7e megakaryoblastic cells showed that a significant 
fraction of c-Kit receptor present at the cell surface is actually trapped into tetraspanins 
network notably composed of CD9 and that this fraction cannot be activated by SCF in 
contrast to the untrapped fraction (16). Moreover, when compared to the SCF-dependent cell 
lines EML (23) and ESRE2 (24), SCF-unresponsive G1ME cells appeared to display the 
highest level of CD9 and lowest level of c-Kit expression (Figure S2). Given these 
observations, we sought to determine whether CD9 could be actively involved in the negative 
regulation of c-Kit. To address this question, G1ME cells were submitted to two rounds of 
transient transfection using CD9 specific siRNA or control luciferase siRNA at 24 hours 
interval and c-Kit and CD9 expression levels were quantified by FACS during the next three 
days. This protocol allowed us to obtain efficient but transient downregulation of CD9 
expression (Figure 7A) which progressively recovered initial levels. Interestingly, this 
transient decrease in CD9 expression was accompanied by a transient but significant increase 
of c-Kit expression two days following the first round of transfection (Figure 7A). Most 
interestingly, by compiling the results of several transfection experiments we found a striking 
correlation between the extent of CD9 decrease and the extent of c-Kit increase (Figure 7B). 
These results thus indicated that CD9 actively contributes to limit c-Kit expression at the cell 
surface of G1ME cells.  
 
Discussion 
G1ME cells result from the spontaneous unlimited outgrowth of bipotent MEP progenitors 
derived from Gata1 -/- ES cells induced to differentiate in the presence of TPO (17). 
Importantly, G1ME cells are still fully competent to terminally differentiate into both 
erythroid and megakaryocytic lineages upon re-expression of GATA1 (17). For these reasons 
G1ME cells remain a pertinent and useful model to understand the control of proliferation and 
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differentiation of bipotent MEP progenitors (17). In that context, our present study provides 
several new original findings showing the SCF-independent dual contribution of c-Kit in 
stimulating proliferation at the expense of terminal megakaryocytic differentiation 
downstream to TPO as well as its unexpected down regulation by CD9.  
Several experimental evidences demonstrate that c-Kit activation does contribute to the 
stimulation of proliferation in response to TPO and in a SCF-independent manner. Indeed. the 
inhibition of c-Kit activity using either one of two different c-Kit specific chemical inhibitors 
ISCK03 and Masitinib (Figure 1) and most importantly the direct knock-down of c-Kit 
expression by specific siRNA (Figure 3) both induced a significant reduction of the TPO-
dependent proliferation of G1ME cells. On one hand, the absence of detectable levels of SCF 
in the supernatant of G1ME cultures, as well as the absence of significant effect of ACK2 
(anti-c-Kit antibody blocking the binding to SCF) (22) strongly indicate that the c-Kit 
contribution to cell proliferation is not mediated by its direct activation by secreted SCF. On 
the other hand, our results showing the transient phosphorylation of c-Kit at tyrosine residue 
Y719 upon re-stimulation of starved cells by TPO clearly indicate that TPO does contribute to 
c-Kit activation. Taken together our results strongly suggest that TPO-dependent proliferation 
is at least partially mediated through the activation of c-kit signaling. However, the additional 
contribution of low level of constitutive c-Kit activation cannot be formally excluded.. This 
raised in turn the question of how TPO leads to c-Kit activation. Interestingly, a few number 
of  ligands other than SCF have been reported to be able to activate c-Kit including EPO (25), 
IL3 (26) or IL33 (27). In all cases, physical proximity of c-Kit with the specific receptors of 
these alternative activating ligands could be documented and would supposedly favor the 
trans-phosphorylation of c-Kit at the plasma membrane. Intriguingly, TPO has also been 
reported to stimulate the EPOR-dependent proliferation of BAF3/EPOR cells in the absence 
of its own receptor c-MPL thus suggesting that TPO can bind and activate EPOR (28). 
Nevertheless, previous studies failed to evidence the direct binding of TPO or its ability to 
compete with EPO for the binding to EPOR (29). Although the physical and functional 
cooperation between EPOR and c-Kit are already well established, further experiments are 
still required to investigate the physical proximity between c-Kit and c-MPL as well as 
whether c-Kit activation by TPO is initiated by the binding of TPO to c-MPL, EPOR or 
possibly to another receptor. 
Our finding that Masitinib slightly enhances Pf4 transcript levels and induces G1ME cells 
polyploidization is an indication that TPO-mediated c-Kit activation not only stimulates 
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proliferation but could also contribute to inhibit terminal megakaryocytic differentiation. This 
finding is in agreement with a previous study showing that another tyrosine kinase receptors’ 
inhibitor Dasatinib also enhances megakaryocytic differentiation in vivo(30). One important 
remaining question is to determine whether this stimulation of megakaryocytic differentiation 
by Masitinib or Dasatinib is really due to c-Kit inhibition or to the inhibition of another kinase 
such as Lyn kinase as previously suggested (30-32). Actually, the repressive effect of Lyn on 
megakaryocytic differentiation, as well as the inhibition of Lyn by Dasatinib and Masitinib is 
well established (31, 32). However, two recent studies cast some doubt on the real functional 
inhibition of Lyn by Masitinib at least in erythroid cells. Indeed, if Lyn is inhibited by 
Masitinib and given that Lyn kinase down-regulates c-Kit (33), one would expect that 
Masitinib leads to the up-regulation of c-Kit, though the quite opposite effect has been 
reported in the erythroid cell line UT7-EPO (34). In agreement with this latter study,  we also 
observed the down regulation of c-Kit in response to Masitinib treatment of G1ME cells. 
Moreover, Masitinib has been shown to accelerate terminal erythroid differentiation in the 
presence of EPO highlighting an interesting parallel with the stimulating effect of Masitinib 
on megakaryocytic differentiation that could be related to the common property of EPO and 
TPO to activate c-Kit. We therefore favor the interpretation that the stimulation of 
megakaryocytic differentiation by Masitinib is probably not mediated through the inhibition 
of Lyn, but additional experiments are still required to firmly establish the implication of c-
Kit inhibition.  
The third major original finding of our study is the intriguing implication of CD9 in the down 
regulation of c-Kit present at the cell membrane. The evidence for this implication is based on 
a clear-cut dose-dependent increase of c-Kit expression that was induced by CD9 knock-down 
when using specific siRNA (Figure 7). Interestingly, a previous study already reported that a 
fraction of c-Kit receptor can be trapped into tetraspanin network including CD9 in MO7e 
megakaryoblastic cells (16) and showed that this trapped fraction of c-Kit displayed low 
constitutive phosphorylation but no kinase activity and was unresponsive to SCF stimulation. 
Besides, CD9 is known as the major component of exosomes and recent studies reported that 
c-Kit can be secreted with exosomes by different types of cells (35-38). Moreover, exosomal 
secretion of several other known interactors of CD9, like  -catenin (39) or EGFR (40) have 
been shown to be modulated by changes in CD9 levels whereas loss of CD9 has been 
associated with a decreased production of exosomes (39). All together, these data suggest the 
exciting possibility that CD9 levels might modulate c-Kit levels present at the membrane 
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through the regulation of its secretion by exosomes. Importantly, a very recent study 
evidenced a surprising decrease in CD9 membrane expression during primary myelofibrosis 
megakaryopoiesis and demonstrated the implication of CD9 in dysmegakaryopoiesis and in 
reciprocal interactions between stroma and progenitors in this pathology (41). Our present 
study raises the other intriguing possibility that these pathological consequences of reduced 
CD9 levels may be related to the upregulation of c-Kit and/or altered exosomes secretion by 
megakaryocytic progenitors or even altered exosome-mediated exchanges between 
megakaryocytic progenitors and stroma cells.  
In summary, the three most important findings of this study are that TPO-induced c-Kit 
activation contributes to stimulate proliferation and at the same time to restrict terminal 
megakaryocytic differentiation, whereas CD9 which is massively increased during terminal 
differentiation is involved in the down regulation of c-Kit. Based on these findings, we 
suggest the working model wherein terminal megakaryocytic differentiation may be induced 
once progenitors reach a threshold level of CD9 sufficient to stop the proliferation effect of 
TPO through the down regulation of c-Kit (Figure 8).  
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Legends to figures 
 
Figure 1 
c-Kit specific inhibitors reduce TPO-dependent G1ME cells proliferation 
G1ME cells were cultured in the presence of recombinant TPO with or without increasing 
doses of c-Kit inhibitors ISCK03 (1.5 or 10 μM) (A) or Masitinib (0.15. 1 or 3 μM) (B) or 
control DMSO during 4 days. Cell concentration and cell viability were assessed every day of 
the kinetic, allowing the maintenance of cell concentration at 2.5 105 cells/mL. The cumulated 
number of viable cells generated from the initial number of cells seeded was calculated based 
on the amplification factor from day to day. Means and standard deviations from 3 
independent experiments. Statistically significant differences in day 4 cell numbers between 
the indicated conditions (brackets) are indicated by asterisks (* p < 1%; ** p < 0.5%; *** p < 
0.05%).  
 
Figure 2 
Masitinib but not ISCK03 reduces c-Kit expression at the plasma membrane 
A: G1ME cells were cultured in the presence of TPO from Cos7 conditioned mediumand in 
the presence or absence of c-Kit inhibitors ISCK03 at10   M (left panel) or Masitinib at 3 μM 
(right panel) and c-Kit expression levels were determined by FACS analysis every day during 
4 days. Each panel presents the superposed fluorescence profiles of c-Kit labeling obtained at 
day 4 for untreated (dark-grey areas) or treated (light-grey areas) cells as well as profiles 
obtained after labeling with isotype control IgG of the same untreated  or treated cells (white 
areas). Histogram shows the relative levels of c-Kit Median fluorescence intensity (MFI) in 
untreated (white boxes) cells or cells treated with either 10   M ISCK03 (black boxes) or 3 
  M Masitinib (grey boxes). 
B: Western blot analysis showing the decrease of c-Kit phosphorylated at position Y719 in 
G1ME cells cultured for 4 days in the presence of TPO and either 10   M ISCK03 (left panel) 
of 3   M Masitinib (right panel). Numbers below each panel indicate the relative decrease in 
pY719-cKit signal standardized to  -actin signal (used as loading control) in treated 
compared to untreated cells (mean from two independent experiments).  
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Figure 3 
Knock down of c-Kit reduces G1ME cells proliferation in response to TPO 
G1ME cells were submitted to 2 rounds of transfection at 24 hours interval with either c-Kit 
siRNA or control luciferase siRNA and re-seeded in medium containing TPO from Cos7 
conditioned medium with or without 3 μM Masitinib. A: Proliferation curve presenting the 
cumulated number of viable cells over 4 days after the first transfection. B. C .D: Relative 
decreases of the cumulated number of viable cells (B), of c-Kit mRNA levels (C) and of c-Kit 
mean fluorescence levels (D) determined after 48, 72 and 96 hours following the first 
transfection. Results are expressed as relative values (means and standard deviations from 3 
independent experiments) standardized to the values obtained in control condition 
(transfection with luciferase siRNA without Mastinib). Significant variations from this control 
condition are indicated by asterisks. * p<5%; ** p<1%. 
 
Figure 4 
Exogenous SCF does not contribute to the proliferation of G1ME cells in response to 
TPO 
A: Quantification by Elisa immunoassay of SCF concentration in the supernatant of G1ME 
cells cultured in the presence of recombinant TPO during 24 hours compared to control 
medium without G1ME cells. Hatched area indicates the 95 % confidence interval of the 
mean background value detected in control medium devoid of SCF. Means and standard 
deviations of 4 independent experiments showing no significant difference of SCF 
concentration between normal medium and G1ME cells supernatant. 
B: Proliferation curves of G1ME cells in the presence of recombinant TPO and either 
control IgG2bk or increasing doses of c-Kit blocking monoclonal antibody ACK2. Means and 
standard deviations of three independent experiments showing no difference in the total 
number of cells generated after 4 days in the presence of control IgG2bk or ACK2 c-Kit 
antibody.  
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Figure 5 
Stimulation of G1ME cells by TPO induces the phosphorylation of c-Kit receptor  
G1ME cells were starved for 6 hours without TPO then re-stimulated by TPO from cos7-
conditioned medium (A) or recombinant SCF (B) during 5, 10, 15 or 30 minutes, followed by 
Western-Blot analysis of Y719 phosphorylated c-Kit, total c-Kit and β-Actin. NS: Non 
Starved cells; S: Starved cells. 
A: Kinetics analysis of c-Kit phosphorylation in response to TPO. Upper part shows typical 
Western-Blot obtained after revelation of the same membrane with specific antibodies 
directed against either phosphorylated c-Kit on tyrosine Y719, or total c-Kit or β-Actin used 
as loading control. Histogram shown in lower part displays the variations of the ratio of 
phosphorylated over total c-Kit signals normalized to the ratio determined in the starved 
condition (means and standard deviations from three independent experiments). Significant 
variations compared to starved condition are indicated by an asterisk (p< 5%). 
B: Kinetics analysis of c-Kit phosphorylation in response to SCF. Same legend as in A. Result 
from 5 minutes re-stimulation by TPO is included for comparison. 
 
Figure 6 
Masitinib stimulates Pf4 late megakaryocytic gene expression and polyploidization  
G1ME cells were analyzed after a 2 days culture in the presence of TPO from Cos7 
conditioned medium with or without Masitinib as indicated. mRNA levels were determined 
by qRT-PCR and cell cycle analyses were performed by FACS after EdU pulse labeling 
followed by double labeling for EdU incorporation by Click-it reagent coupled to Alexafluor-
647 and DNA content by propidium iodide.  
A: Relative levels of mRNAs encoding late megakaryocytic genes Pf4 and Cd9 normalized to 
    actin and standardized to the control condition with IgG without Masitinib (means and 
standard deviations from 3 independent experiments).  
B: FACS dot-plots for EdU incorporation and DNA content. Numbers indicate the percentage 
of cells identified in the different phases of cell cycle including cells undergoing 
polyploidization (EdU labeled cells with DNA content higher than 4 N). 
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Figure 7 
CD9 actively contributes to reduce c-Kit levels 
G1ME cells were submitted to two rounds of transfection at 24 hours interval with either CD9 
siRNA or control luciferase siRNA and re-seeded in medium containing TPO from Cos7 
conditioned medium. 
A: Evolution of the relative values of the median fluorescence of CD9 (grey boxes) or c-Kit 
(black boxes) following transfection with CD9 siRNA normalized to values obtained in 
control condition following transfection with luriferase siRNA (white boxes). Means and 
standard deviations from 3 independent experiments. Significant variations compared to 
control are shown by asterisks (p< 0.05 in Student t-test). 
B: Compilation of data from three independent transfection experiments showing the striking 
correlation between the fold reduction of CD9 and the fold increase in c-Kit.  
 
Figure 8 
Working model of the dual control of c-Kit by TPO during megakaryopoiesis 
Our results showed that part of the proliferative effect of TPO is mediated through the 
activation of c-Kit signaling that concomitantly contributes to inhibit CD9 expression and 
polyploidization while c-Kit itself is under the negative control of CD9. Based on these 
findings, we suggest that TPO stimulates the proliferation of megakaryocytic progenitors 
while progressively increasing CD9 expression until reaching a threshold level sufficient to 
inhibit c-Kit expression, in turn allowing proliferation arrest and terminal differentiation.  
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Supplementary Figures and Table 
 
Target Forward Primer  Reverse Primer  
?-actin 5’-TGGGAATGGGTCAGAAGGACTC-3’ 5’-CTGGGTCATCTTTTCACGGTTG-3’ 
c-Kit 5’-GGGCTAGCCAGAGACATCAG-3’ 5’-AGGAGAAGAGCTCCCAGAGG-3’ 
c-Mpl 5’- CCGAGCTCGCTACAGCTT- 3’ 5’- CTGTAGTGCGCAGGAAATTG -3’ 
Cd9 5’- GCTCGAAGATGCTCTTGGTC -3’ 5’- GCTCGAAGATGCTCTTGGTC -3’ 
c-Myc 5’-TCCTGTACCTCGTCTGATTCC-3’ 5’-CTCTTCTCCACAGACACCACATC-3’ 
Fli-1 5’-GACTCTGTCAGGAGAGGAGC-3’ 5’-GTCATTTTGAACTCCCCGTTG -3’ 
Gata1 5’-TTCTTCCACTTCCCCAAATG-3’ 5’-AGGCCCAGCTAGCATAAGGT-3’ 
Gata2 5’-GAATGGACAGAACCGGCC-3’ 5’-AGGTGGTGGTTGTCGTCTGA-3’ 
Hes1 5’-CTACCCCAGCCAGTGTCAAC-3’ 5’-CGCCTCTTCTCCATGATAGG-3’ 
Itga2b 5’-AAGCTCTGAGCACACCCACT-3’ 5’-CTCAGCCCTTCACTCTGACC-3’ 
Jak-2 5’-GATGGCGGTGTTAGACATGA-3’ 5’-TGCTGAATGAATCTGCGAAA-3’ 
Pf4 5’- AGTCCTGAGCTGCTGCTTCT -3’ 5’- CAGCTAAGATCTCCATCGCTTT- 3’ 
Pten 5’-AATTCCCAGTCAGAGGCGCTATGT-3’ 5’-GATTGCAAGTTCCGCCACTGAACA-3’ 
Tal-1 5’-CGGAGGATCTCATTCTTGCTTAG-3’ 5’- CTAGGCAGTGGGTTCTTTGGG -3’ 
tr-Mpl 5’-GAGGACTGGAAGGAGACTGAGGCA-3’ 5’-AGGTTGCAGTCCTCTGTAGTCCAT-3’ 
 
Table S1 
Primer sequences used in qRT-PCR:  
Target Reverse  Forward  
c-Kit siRNA.1 5’-CCGUGACAUUCAAGCUUUAdTdT-3’ 5’ –UAAACGUUGAAUGUCACGGdTdT-3’ 
c-Kit siRNA.2 5’-CUGUCUAGAAUUUACUCAAdTdT-3’ 5’ –UUGAGUAAAUUCUAGACAGdTdT- 3’ 
CD9 5’-GAGCAUCUUCGAGCAAGAAdTdT -3’ 5’-UUCUUGCUCGAAGAUGCUCdTdT-3’ 
 
Table S2 
siRNA sequences 
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Figure S1 
G1ME cells do not survive or proliferate in the presence of SCF alone. G1ME cells were 
cultured during two days either without any cytokine. or in the presence of SCF (100 ng/ mL) 
or TPO (1% conditioned medium) either alone or combined.  
A: % of cell survival assessed by Trypan Blue exclusion at day 2. 
B: Cumulated numbers of viable cells during the 2 days culture in the different conditions 
(means and standard deviations from 3 independent experiments). 
 
Figure S2 
Inverse variations of c-Kit and CD9 levels between different hematopoietic cells lines. 
ESRE (Extensively Self-Renewing Erythroid murine progenitors) (24) and EML (lympho-
myeloid multipotent murine cell line) (23) cells were maintained as previously described in 
their corresponding medium whereas G1ME cells (17) were maintained in the presence of 1% 
Cos-7 conditioned-medium TPO. A: Median of fluorescence intensities (MFI) of CD9. B: 
Median of fluorescence intensities of c-Kit . C: CD9/c-Kit MFI ratios.  
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The main interest of our team is to decipher the molecular mechanisms controlling the 
proliferation/differentiation balance of bipotent and monopotent progenitors. During my 
thesis, I investigated whether Notch maintains the bipotent state of MEP by acting on the 
transcription factor GATA1 and whether Notch interacts functionally with TPO and c-Kit 
pathways during the control of the proliferation versus megakaryocytic differentiation 
balance.  
1. GATA1 Implication downstream of Notch in the control of MEP bipotency 
and amplification 
Before the start of my work, the team evidenced a positive effect of Notch pathway on 
bipotent MEP progenitors amplification. The first aim of my study was to investigate GATA1 
expression and phosphorylation levels implication in this Notch effect. In a first approach, I 
explored whether Notch was able to regulate GATA1 in L8057 cells. In a second approach, I 
investigated GATA1 phosphorylation requirement in Notch-dependent maintenance of MEP 
bipotency and amplification.  
Notch activation in L8057 cells did not induce the expression neither the phosphorylation 
of GATA1. Besides, taking advantage of a murine knock-in model expressing a non-
phosphorylable form of GATA1 (S310A) (Rooke and Orkin, 2006), I excluded a GATA1 
phosphorylation contribution to Notch-effect on MEP bipotency maintenance. 
  Nevertheless, contrarily to our starting hypothesis, I observed a negative regulation of 
GATA1 transcripts and protein levels in Notch-stimulated L8057 megakaryoblastic cells. We 
also observed a GATA1 downregulation in Notch-stimulated MEP. Thus, convergent results 
between L8057 and MEP suggest that instead of increasing the expression levels of GATA1 
and its availability for its partners Fli-1 and EKLF, Notch reduces GATA1levels.  
This observation makes one wonder whether GATA1 decreased levels contributes to Notch 
effect on the amplification of MEP and whether alternative mechanisms could explain 
GATA1 modulation by Notch, allowing both erythroid and megakaryocytic differentiation 
restriction.  
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1.1 Is GATA1 downregulation implicated in E/MK bipotent progenitors 
amplification? 
Different studies argue for the contribution of a decreased GATA1 expression in MEP 
proliferation. Indeed, GATA1 decreased expression due to the deletion of a Gata1 enhancer 
region in the Gata1ΔNeoΔHS murine model induced an increased generation of bipotent 
progeny derived from fetal liver MEP in semi-solid medium when compared to MEP from 
wild-type mice (Kuhl et al., 2005). Moreover, Gata1 gene total deletion in murine embryonic 
stem cells allowed the immortalization of the E/MK bipotent G1ME cells in presence of TPO 
(Stachura et al., 2006). Furthermore, Gata1 depletion, this time using doxycycline inducible 
RNA interference, again allowed the immortalization of the bipotent cells G1ME2 in 
presence of TPO and SCF (Noh et al., 2015).  
Nevertheless, the molecular mechanism explaining the contribution of decreased 
expression or even GATA1 absence to the amplification or immortalization of bipotent E/MK 
progenitors remains an open question.  
The c-Myc transcription factor is a potential candidate as it is negatively regulated by 
GATA1 (Noh et al., 2015; Rylski et al., 2003) and positively regulated by Notch (Weng et al., 
2006), however its expression did not vary in Notch-stimulated G1ME cells (Table 1).  
Alternatively, we have more arguments to propose a putative involvement of c-Kit. Indeed, 
we found in our study that c-Kit is both positively regulated by Notch and implicated in 
G1ME cells proliferation (detailed in the next paragraphs). In addition, other studies have 
shown a repression of c-kit expression by GATA1 in erythroid cell line (Munugalavadla et al., 
2005). Based on these observations, it seems possible that c-Kit de-repression due to 
Notchstimulation and subsequently decreased GATA1 levels may contribute to E/MK 
bipotent progenitors amplification.   
1.2 Alternative mechanisms of Notch-dependent regulation of GATA1 
activity? 
Interestingly, one study reported the negative effect of Notch effector HEY2 on GATA1 
transcriptional activity using GATA-dependent reporter assay performed in K562 cells (Elagib 
et al., 2004). The other Notch effector HES1 has been reported to inhibit GATA1 activity by 
impeding its recruitment of p300 acetylase (Ishiko et al., 2005). In these two different 
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studies, the Notch effectors HES1 and HEY2 interact physically with GATA1 thus inhibiting its 
transcriptional activity.  
Based on these observations, we propose a new hypothesis implicating GATA1 in the 
control of Notch-mediated blockade of MEP differentiation: the interaction between HES or 
HEY with GATA1 could induce its sequestration and avoid its interaction with its Fli-1 and 
EKLF partners responsible for the engagement into megakaryocytic and erythrocytic 
differentiation, respectively.  
One experiment allowing to test this hypothesis could be to perform co-
immunoprecipitations to analyze whether HES or HEY physically interact with GATA1 and 
whether this interaction modulates the formation of the differentiation complexes GATA1/ 
EKLF or GATA1/ Fli-1. In order to approach physiological conditions, this experiment should 
be performed in bipotent cells such as G1ME2 cells. Indeed, GATA1 expression restoration in 
these cells approximates physiological levels when compared to fetal liver, and this enables 
more efficient differentiation even in vivo(Noh et al., 2015).  
2. c-Kit implication downstream of Notch in the proliferation versus 
differentiation balance control 
Similarly to c-Kit upregulation by Notch observed in MEP, I validated G1ME cells as 
responsive to Notch stimulation since it induced a HES1 expression increase that was 
accompanied by c-Kit transcripts and protein levels increase. Furthermore, as in MEP 
wherein Notch-mediated amplification required SCF/ c-Kit signaling cooperation, I 
demonstrated in G1ME cells the c-Kit contribution to cell proliferation. These observations 
raised the questions of c-Kit mechanism of regulation by Notch and whether c-Kit 
upregulation in GATA1 absence can explain Notch-mediated amplification of bipotent cells. 
2.1 By which mechanism Notch regulates c-Kit gene transcription? 
In order to determine the level of regulation of c-Kit by Notch, I analyzed c-Kit primary 
transcripts levels as an early marker of c-Kit gene transcriptionactivation. I observed that 
Notch-stimulated G1ME cells express higher levels of c-Kit primary transcripts suggesting 
that c-Kit regulation by Notch is at the transcriptional level. I tried to confirm this result by 
performing RNA POL II ChIP analyses, though weak enrichment signals on c-Kit gene 
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hampered this demonstration, whereas positive controls on other promoters showed high 
enrichment attesting for POL II antibody efficiency. The use of a different POL II antibody 
could maybe enhance enrichment signals on c-Kit gene. Another approach could be to 
analyze by ChIP assay for trimethylated Lysine 4 Histone H3 enrichment on c-Kit gene that 
represents a  good evidence of gene transcription activation. 
After that, I tried to identify c-Kit regulators modulated by Notch and able to explain its 
upregulation. Using qRT-PCR and ChIP assays, I excluded the contribution of the two most 
known c-Kit regulators, GATA2 and SCL, as mediators of Notch during c-Kit up-regulation in 
G1ME cells as their transcript levels and their enrichment on c-Kit gene were not increased 
upon Notch activation. Thus, c-Kit regulation mechanism by Notch remains an open 
question. 
Based on available data in the literature, we propose two mechanisms explaining Notch-
induced c-Kit upregulation based either on direct activation by RBPJκ or on the repression of 
a c-Kit negative regulator by HES1. 
Analyses of ChIP-seq data (Wang et al., 2011) generated in lymphoid T-ALL cell lines 
following RBPJκ immunoprecipitation revealed its enrichment on c-Kit promoter. Based on 
these data, one possibility could be that RBPJκ directly bind to its specific sites on c-Kit 
regulatory elements thus favoring c-Kit gene transcription in MEP. We could test this 
hypothesis by analyzing by ChIP assayRBPJκ enrichment on c-Kit regulatory elements in 
Notch-stimulated G1ME cells.  
Alternatively, we could test whether c-Kit upregulation by Notch is dependent on HES1 by 
analyzing whether this upregulation is cancelled by a Hes1 transcripts targeting siRNA.  
Among putative c-Kit repressor candidates, the ZNF16 human transcription factor has been 
recently reported (Chen et al., 2014a). A first experiment could be to test whether the 
stimulation of K562 cells by Notch modulates the transcripts levels of Znf16, then whether 
Notch modulates the enrichment of ZNF16 on c-Kit regulatory elements by ChIP assay. 
However, being not conserved in mice, ZNF16 could not explain the observed c-Kit 
upregulation in G1ME cells.    
A more interesting candidate is GATA1 that was described as a c-Kit repressor in an 
erythroid cell line (Munugalavadla et al., 2005). By performing GATA1 ChIP assay, we could 
test whether this mechanism is conserved in bipotent G1ME2 cells following doxycycline 
withdrawal and whether Notch stimulation reduces GATA1 enrichment on c-Kit regulatory 
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elements. A stronger evidence would be to show that c-Kit expression is dependent of the 
GATA1 levels modulated in G1ME2 cells following their treatment with different doses of 
doxycycline.    
2.2 Does c-Kit de-repression contribute to Notch-mediated 
amplification of bipotent cells? 
Based on our finding that c-Kit contributes to G1ME cells proliferation and that Notch 
induces the expression of c-Kit as well as the previously described repression of c-Kit by 
GATA1, it seems possible that Notch-induced amplification of bipotent cells is mediated by 
GATA1 repression and subsequent induction of c-Kit.  
GATA1 expression in G1ME cells needs to be restored in order to explore c-Kit implication 
downstream of Notch and GATA1. However, I tried this experiment once and observed that 
HES1 is repressed upon GATA1 restoration (data not shown), which is in agreement with 
another study that reported the same effect during erythroid differentiation (Ross et al., 
2012). GATA1 restoration in G1ME cells was described recently to reach supra-physiological 
levels (Noh et al., 2015), this suggest that GATA1 restoration in G1ME cells could masks 
Notch effect on c-Kit, thus limiting the usefulness of G1ME cells in the study of c-Kit role 
downstream of Notch and GATA1. On the contrary, in G1ME2 cells, doxycycline withdrawal 
allows GATA1 to be restored at physiological levels and one could expect that GATA1 
restored levelscould be modulated by different doses of doxycycline, thus rendering the 
G1ME2 cells a more powerful model.   
Thus, one experiment to test the contribution of c-Kit downstream of Notch and GATA1 in 
bipotent cells proliferation could be to analyze whether doxycycline dose-dependent GATA1 
increase is accompanied by a dose-dependent decrease of c-Kit expression levels as well as 
more restricted differentiation. Of further interest, we could test whether G1ME2 are 
responsive to Notch stimulation and whether this stimulation favors cell proliferation in the 
presence of lower dose of SCF.  
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3. The role of c-Kit downstream of TPO, Notch and CD9 in the control of the 
proliferation/ differentiation balance 
3.1 TPO activates c-Kit and c-Kit contribute to G1ME cells TPO-
dependent proliferation 
The convergent results of the two different strategies using either chemical inhibitors of c-
Kit or RNA interference led us to conclude to a c-Kit contribution in G1ME cells proliferation. 
As G1ME cells are cultured in absence of SCF, this observation raised the question of the 
origin of c-Kit activation. Using ELISA and proliferation assays in the presence of the ACK2 
monoclonal antibody that blocks the interaction between c-Kit and SCF, we observed that 
SCF is not secreted by and does not contribute to G1ME cells proliferation. As G1ME cells are 
cultured in presence of TPO only, this observation prompted us to examine whether TPO 
could actually be responsible for c-Kit activation. In order to examine c-Kit activation, I 
measured by Western-Blot the Y719 phosphorylated over total c-Kit ratio in G1ME cells 
starved and re-stimulated by TPO. I observed that c-Kit is phosphorylated upon TPO 
stimulation when compared to starved condition.  
Overall, these results suggested that c-Kit was directly activated by TPO and that c-Kit 
participated to G1ME cells proliferation. However, these observations raise the question of 
whether c-Kit kinase is actually activated upon TPO-stimulation and whether this activation 
is required for TPO-dependent proliferation of G1ME cells. 
Indeed, I assessed for c-Kit activation only by analyzing the levels of phosphorylation on 
Y719 residue. This result should be complemented by a kinase assay or by detecting using 
co-immunoprecipitation assay in TPO stimulated G1ME cells the interaction between c-Kit 
and its partners recruited exclusively on activated receptor such as the p85 subunit of PI3K. 
In addition, the clear contribution of c-Kit activated kinase in TPO-dependent G1ME cells 
proliferation would ultimately require to analyze whether the proliferation is abolished in 
G1ME cells expressing a dead-kinase mutant and cultured in presence of TPO. 
Nevertheless, our finding that TPO induces c-Kit intracellular phosphorylation raises the 
question of the mechanisms allowing c-Kit activation.  
Interestingly, c-Kit activation by other cytokines than SCF has already been reported such 
as by IL3 (Ye et al., 2011), IL33 (Drube et al., 2010) and EPO (Munugalavadla and Kapur, 
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2005). In all cases, the documented physical interaction between c-Kit and the 
corresponding receptors was supposed to facilitate c-Kit trans-phosphorylation. These 
observations suggest a potential c-Kit activation through physical interaction with c-MPL. Of 
further interest, TPO has been reported to activate EPOR (Rouleau et al., 2004), suggesting a 
potential c-Kit activation by the c-MPL/ EPOR complex. 
These hypotheses could be tested by two different strategies: a classical biochemical 
approach of co-immunoprecipitation, or an imaging approach using Proximity Ligation Assay 
(PLA) or Fluorescence Resonance Energy Transfer (FRET). 
In addition, based on the previously reported non-canonical AKT signaling activation by 
Notch while still at the cell surface (Perumalsamy et al., 2009), we cannot exclude that Notch 
could be able to activate c-Kit in a non-canonical fashion directly at the cell membrane.  
Moreover, since tetraspanins are known to play a clustering role (Hemler, 2003; Larochelle 
et al., 2012), CD9 could be responsible for Notch, c-Kit and c-MPL clustering at the cell 
surface, thus forming signaling platform allowing c-Kit activation by these receptors. This 
hypothesis could be tested using an RNA interference strategy targeting Cd9 and a 
subsequent co-immunoprecipitation in non-denaturating conditions to analyze the 
maintenance or not of a physical interaction between these receptors.   
3.2 Does c-Kit repress megakaryocytic differentiation? 
Given the TPO role in megakaryocytic differentiation and our findings that TPO activates c-
Kit which contributes to G1ME cells proliferation, as well as c-Kit downregulation 
requirement during differentiation, we questioned whether c-Kit also contributes to restrict 
megakaryocytic differentiation of G1ME cells. To address this question, we analyzed whether 
c-Kit inhibition by Masitinib affects two aspects of megakaryocytic differentiation: 
expression of megakaryocytic genes and polyploidization. We found that Masitinib 
treatment increased polyploid cells proportion (EdU positive and DNA content higher than 
4N) and increased late megakaryocytic marker PF4 expression when compared to untreated 
cells. These results suggest that c-Kit restricts the slight and spontaneous megakaryocytic 
differentiation of G1ME cells.  
However, complementary experiments are required to determine whether Masitinib effect 
on megakaryocytic differentiation is mediated by c-Kit repression and more various 
approaches are required to appreciate megakaryocytic differentiation.  
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Even if Masitinib was used at low dose (Dubreuil et al., 2009) we cannot exclude a potential 
effect on another tyrosine kinase such as Lyn. Indeed Masitinib was already reported as an 
inhibitor of Lyn kinase (Lannutti and Drachman, 2004) and Lyn inhibition using either 
another tyrosine kinase inhibitor Dasatinib (Mazharian et al., 2011) or in knock-out mice 
(Lannutti et al., 2006) also increased megakaryocytic differentiation. For this reason, we can 
suspect that megakaryocytic differentiation observed in presence of Masitinib could be due 
to Lyn kinase and not c-Kit kinase inhibition. Nevertheless, Lyn was reported as a down-
regulator of activated c-Kit (Kosmider et al., 2009). Thus, if Masitinib repressed Lyn instead 
of c-Kit, we would expect Masitinib to increase c-Kit expression, the inverse of what we and 
others (D'Allard et al., 2013) have observed. Moreover, c-Kit repression using either 
Masitinib in UT7/EPO cells (D'Allard et al., 2013) or by overexpressing its repressor ZNF16 in 
K562 cells  (Chen et al., 2014a) accelerated erythroid or both erythroid and megakaryocytic 
differentiation, respectively. For these reasons, it seems more likely that the observed effect 
of Masitinib on megakaryocytic differentiation is mediated by c-Kit downregulation.  
Because we observed that Masitinib induced G1ME cells polyploidization and PF4 late 
megakaryocytic marker expression, we concluded that c-Kit restricts G1ME cells 
megakaryopoiesis. Nevertheless, we could complement the demonstration of c-Kit 
contribution to the repression of megakaryocytic differentiation by clarifying potential 
Masitinib off-target effect using ISCK03 inhibitor or even specific anti-c-Kit siRNA in a more 
pertinent cell model that expresses GATA1 and undergoes efficient differentiation such as 
G1ME2 cells or megakaryocytic progenitors. Furthermore, in these cells, we should assess 
for megakaryocytic differentiation by complementary methods such as the quantification of 
more megakaryocytic markers either by qRT-PCR, or FACS acetylcholinesterase staining.  
3.3 By which mechanism does CD9 repress c-Kit? 
We aimed to decipher the inverse correlation observed between c-Kit and CD9 expression 
levels following Notch stimulation. I adopted a siRNA strategy targeting Cd9 transcripts and 
observed that CD9 down-modulation induced an increase of c-Kit expression at the 
membrane. This observation evidenced a new role for the tetraspanin CD9 in c-Kit receptor 
level negative regulation and allowed us to propose a new model explaining the dual role of 
TPO in megakaryopoiesis.  
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This result also raises the question of the CD9 mode of action allowing c-Kit removal from 
the plasma membrane. We propose two mechanisms of CD9 action that could either induces 
c-Kit internalization or induces its internalization followed by exosomal secretion. Based on 
the following studies, we find more plausible c-Kit secretion into exosomes. 
Similarly to our finding that CD9 and c-Kit expression levels at the membrane are inversely 
correlated, a study recently reported that CD9down-modulation in a non-metastatic 
pancreatic cell line increase the cell surface expression of EGF-Receptor, associated with 
increased cell proliferation (Tang et al., 2015). Furthermore, CD9 expression levels down-
modulation using doxycycline-inducible specific siRNA or the inhibition of exosomes-
production using the inhibitor GW4869 decreased the production of β-catenin containing 
exosomes. Moreover, CD9 is a known marker of exosomes and a recent study showed that 
bone-marrow derived dendritic-cells from CD9 -/- mice produced less exosomes when 
compared to their wild-type counterparts (Chairoungdua et al., 2010). These studies 
highlight the importance of CD9 levels in the modulation of exosomes production and the 
control of signaling components expression through exosomal discharge. Besides, the 
secretion of wild-type c-Kit protein by mast cells has been reported and this secretion 
induced SCF/ c-Kit activation in lung-recipient cells inducing their proliferation (Xiao et al., 
2014). Similarly, the secretion of oncogenic hyper-activated c-Kit protein has also been 
detected in CD9-positive exosomes derived from GIST-patients (gastrointestinal stromal 
tumor) and induced the transformation of muscle cells in vitro(Atay et al., 2014).  
These observations strengthen our hypothesis that CD9 repress c-Kit expression at the cell 
surface by inducing its secretion in exosomes.  
One first essential step to demonstrate this hypothesis is to determine whether G1ME cells 
supernatant contains exosomes that could be purified by ultracentrifugation (Thery et al., 
2006) and whether c-Kit is carried by these exosomes following Western-Blot analysis of its 
expression in both exosomal fraction and total cell lysate.  
Second, we could test whether this mode of secretion of c-Kit is actually dependent on CD9 
using specific anti-Cd9 siRNA to quantify both the number of exosomes produced and c-Kit 
presence into these exosomes. Another approach would be to inhibit exosomes production 
and test whether c-Kit expression at the cell surface is increased. To do so, among the 
different pathways controlling vesicles trafficking, ceramide pathway inhibition using 
GW4869 (Trajkovic et al., 2008) has already been reported as cancelling CD9-dependent 
 
 
174 
exosomal secretion of β-catenin by HEK 293T cells (Chairoungdua et al., 2010) and of miR-
214 by hepatic stellate cells (Chen et al., 2014b). Thus, this inhibitor should be a useful tool 
to assess a putative ceramide/ CD9-dependent exosomal export of c-Kit.  
Besides, similarly to our finding that Masitinib treatment of G1ME cells decreased c-Kit 
expression at the cell surface, another study (D'Allard et al., 2013) reported the same effect 
and evidenced that Masitinib induces lysosomal degradation of c-Kit. However, we know 
that following endocytosis, internalized proteins are targeted either to lysosomes or to 
multivesicular bodies that will fuse with the cell membrane to liberate exosomes. Thus, we 
cannot exclude the hypothesis that Masitinib induces exosomal secretion of a fraction of 
internalized c-Kit. To test this hypothesis, we could quantify the number of exosomes 
produced in presence of Masitinib.  
Of further interest, given that Notch represses CD9 expression and the contribution of CD9 
in the control of exosomes production, it seems possible that, in parallel to its repressive 
effect on GATA1 and positive effect on c-Kit gene transcription, Notch could increase c-Kit 
expression by repressing CD9 and subsequently the production of c-Kit containing-
exosomes. This hypothesis could be tested by measuring the number of exosomes produced 
following Notch stimulation of G1ME/ G1ME2 cells.   
3.4 Is c-Kit repression by CD9 implicated in megakaryocytic 
differentiation increase? 
Interestingly, a recent study associated CD9 expression levels deregulation with unefficient 
megakaryocytic differentiation in primary myelofibrosis (PMF) patients who present an 
accumulation of CD41low CD9low megakaryocytes and decreased cell surface expression of 
CD9 in in vitro CD34+ derived-megakaryocytes and in platelets in vivo. Furthermore, CD9 
decreased expression in megakaryocytic progenitors derived from PMF patients was 
correlated with deficient communication between megakaryocytes and their stroma 
(Desterke et al., 2015). These observations raise the question of whether the communication 
between megakaryocytes and their stroma partly relies on exosomes secretion.  
Based on our finding that c-Kit activation contributes to bipotent cells proliferation, 
whereas it restricts megakaryocytic maturation and given that CD9 levels are progressively 
increased during megakaryopoiesis, we propose that progression into terminal 
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megakaryocytic maturation is partly allowed by the CD9-dependent discharge of c-Kit from 
the cell surface by exosomes.  
An experiment allowing to test the implication of CD9-dependent exosomal secretion of c-
Kit during megakaryocytic differentiation would be to analyze whether CD9 siRNA-mediated 
knockdown could reduce exosomes number and the levels of associated c-Kit and whether 
this effect would be accompanied by accelerated megakaryocytic differentiation of G1ME2 
cells or megakaryocytic progenitors.  
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Figure 1: Summary of the proposed hypotheses explaining the positive effect of Notch on 
the amplification of bipotent MEP progenitors 
Regulation network summarizing some results obtained during my thesis (solid and double arrows) 
and subsequently presumed mechanisms (dotted arrows) participating to the maintenance of a 
bipotent state interpreted as a blockade of differentiation and increased proliferation. Positive 
effects are presented by green arrows and negative effects either on expression or activity are 
presented by red inhibition symbol. During my thesis, I evidenced that Notch represses the 
expression of GATA1 (1) and CD9 (3), while inducing c-Kit expression (2). I also evidenced the 
negative regulation of c-Kit by CD9 (4). My results suggest that c-Kit contributes to bipotent cells 
amplification while restricting their differentiation (5). Besides, previous studies described the 
requirement for GATA1 interaction (double way arrow) with FLI-1 or EKLF to induce megakaryocytic 
or erythrocytic differentiation, respectively. Other studies reported that HES/HEY Notch effectors 
interact with GATA1 inhibiting its transcriptional activity. Based on these data, we propose that on 
one hand Notch effectors HES/HEY interacts with GATA1 which becomes unable to interact with its 
partners FLI-1 and EKLF thus repressing both erythrocytic and megakaryocytic differentiation of 
bipotent progenitors and allowing the maintenance of the bipotent state. On the other hand, Notch 
effectors HES/HEY would indirectly activate c-Kit by repressing either GATA1 or CD9 thus allowing 
bipotent cells amplification. 
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GENERAL CONCLUSION 
During my thesis, I investigated the molecular mechanisms allowing the Notch pathway to 
maintain MEP bipotency by restricting their differentiation and favoring their amplification. 
My thesis work evidenced Notch role in both GATA1 and CD9 expression levels decrease and 
positive regulation of c-Kit at the transcriptional level. Further investigation suggested a 
major c-Kit contribution to TPO-dependent bipotent cells proliferation and restriction of 
their megakaryocytic differentiation. Additionally, I evidenced a new role of the CD9 
tetraspanin in repressing c-Kit cell surface levels.  
As recapitulated in Figure 1, these results suggest different modes of action of the Notch/c-
Kit axis on bipotent cells maintenance. We presume that MEP differentiation repression 
would allow the sequestration of GATA1 by HES/ HEY Notch effectors, thus inhibiting its 
formation of differentiating complexes with FLI-1 or EKLF. On the other hand, both Notch 
and c-Kit allows E/MK bipotent cells amplification and we propose different modes of c-Kit 
activation by Notch, either directly through ICN/ RBPJ or indirectly through HES/ HEY Notch 
effectors. HES and HEY being transcriptional repressors, they can induce c-Kit expression by 
repressing a negative regulator of c-Kit such as CD9 or GATA1.  
In summary, my thesis work highlighted Notch and TPO signals integration on the 
regulation of GATA1, c-Kit and CD9 and their role in favoring bipotent cells proliferation 
while restricting their megakaryocytic differentiation.  
Based on these observations we propose that while maturing under TPO stimulation, 
megakaryocytes increase their expression of CD9 which in turn causes a progressive c-Kit 
discharge from the plasma membrane. This decrease of c-Kit expression would eventually 
contribute to suppress proliferative at the benefit of differentiating signals and promote the 
irrevocable engagement into terminal maturation.  
Besides, megakaryocytes membrane was shown to be continuously blebbing and releasing 
microparticles (Flaumenhaft et al., 2009). In addition to the formation of membrane 
extensions called pro-platelets that are shed to generate circulating platelets in normal 
conditions, in stress-condition and independently of TPO, megakaryocyte membrane is 
ruptured allowing the production of enlarged stress-platelets (Nishimura et al., 2015).  
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Figure 2: Megakaryocytes are highly active secreting cells 
We already know that megakaryocytes are able to secrete micro-vesicles by continuous membrane 
blebbing, platelets by pro-platelets shedding, stress-platelets by membrane rupture, as well as 
platelet-like particles. In addition, our results suggest that megakaryocytes may also produce 
exosomes (Dotted rectangle).  
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Additionally, based on the studies presented in the previous section, our studies suggest 
that megakaryocytic progenitors would be able to secrete exosomal vesicles.  
Interestingly, these observations highlight the very active and diversified modes of 
secretion by megakaryocytes (Figure 2). Moreover, platelets and platelet-like-particles have 
been shown to be released by megakaryocytic cell line and incorporated by hepatocyte cell 
line inducing their proliferation (Kirschbaum et al., 2015). Furthermore, CD9 has been 
implicated in the communication between megakaryocytes and their stromal environment 
(Desterke et al., 2015).  
Overall, these data suggest that during their progression toward megakaryocytic 
maturation, megakaryocytes continuously release vesicles that influence either their direct 
microenvironment or even in later stage stress or normal platelets influence the balance 
proliferation/ differentiation of more distant tissues.   
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1. Co-culture on OP9 or OP9-Dll1 
L8057 cells (Ishida et al., 1993) were cultured in half IMDM half RPMI-1640 (PAA) medium 
supplemented by 15% of fetal calf serum, 1% of Penistreptomycin (PAA) and 1% of L-
Glutamine (PAA) and were maintained between 2.5 105 to 1.5 106 cells/ mL by dilution every 
two days. OP9 and OP9-Dll1 (De Smedt et al., 2004) cells were cultured in α-MEM medium 
supplemented by 20% of fetal calf serum (PAA), 50 μM of β-mercaptoethanol, 0.2 % of 
sodium bicarbonate and 1 % of Penistreptomycin. OP9 and OP9-Dll1 cells adherent cells 
were maintained between 5.104 cells/ mL and 106 cells/ mL, diluted following trypsinization 
and numeration twice per week and thrown after 11 passages. All cells were cultured at 37°C 
and 5% CO2. OP9 or OP9-Dll1 adherent cells were plated at 105 cell/ mL the day before 
L8057 were seeded at 1:1 ratio. The day following their seeding, L8057 cells were harvested 
following their detachment from adherent OP9 cells by flushing then potentially remaining 
adherent cells were allowed to re-adhere during 30 minutes at 37°C and L8057 suspended 
cells were harvested again. Further exclusion of OP9 cells was performed by filtering the 
harvested L8057 cells on cellular sieve of 40 μm (Corning). L8057 cells were counted, then 
proceeded for either RNA or protein extraction. OP9 contamination was also estimated by 
quantification of Gfp expression by qRT-PCR.  
2. Extraction of nuclear and cytoplasmic proteins 
L8057 cells were harvested, counted and washed in PBS supplemented by protease (Roche) 
and both Ser/ Thr and Tyr phosphatases inhibitors (1 mM sodium pyrophosphate (Sigma), 25  
mM sodium beta-glycerophosphate (Sigma) and 50 mM of sodium fluoride (Sigma)). 
Following their centrifugation, pellets were suspended in a proportional volume (5 times 
pellet volume) of Hepes buffer (10 mM pH 7.6, 3 mM of MgCl2, 10 mM KCl, 5 % of Glycerol 
and 0.5 % of NP-40) supplemented by protease and phosphatases inhibitors and incubated 
on ice during 10 minutes, centrifuged at 6000 rpm for 5 minutes then cytoplasmic extracts 
were harvested to be stored at (-80 °C). Cell pellets were then suspended in a proportional 
(3 times pellet volume) volume of Hepes buffer supplemented by protease and phosphatase 
inhibitors and 300 mM instead of 10 mM of KCl. Following 45 minutes incubation on ice and 
centrifugation at 6000 rpm for 5 minutes, nuclear protein extracts in the supernatant were 
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harvested and stored in aliquots at (-80 °C). The concentration of protein extracts was 
quantified by Bradford assay and equal amount of proteins was charged per condition.   
3. Lentiviral infection 
MIGR and MIGR-Gata1 retrorviral vectors were generously provided by . Concentrated 
preparations of retroviruses were prepared at the platform U3444 (Gerland, Lyon) and 
stored at (-80°C) before use. 5 10^4 G1ME cells (Stachura et al., 2006) per condition were 
seeded in 96 culture plates. The next day, G1ME cells were transduced either by MIGR or 
MIGR-GATA1 retroviruses at M.O.I 20 in presence of 4 μg/mL of polybrene. GFP expressing 
cells were sorted the following day (Considered as Day 0) at the Flow Cytometry platform 
(AniRA Gerland, Lyon) and were seeded in their culture medium complemented by a full 
cocktail of E/MK cytokines (mSCF 50 ng/mL, huEPO 2 U/mL, mTPO 20 ng/mL, mIL3 20 ng/mL, 
mIL6 5 ng/mL mIL11 10 ng/mL). On day 1 post sorting, G1ME cells were harvested for qRT-
PCR analysis and on day 1, 2 and 3 post sorting, cells were harvested for Ter119 and CD42b 
labeling and FACS analysis.   
 
4. G1ME cells stimulation by Notch coated rDll1 ligand 
Cultures were performed as described previously (Poirault-Chassac et al., 2010) .Briefly, 24-
well plates were pre-coated by a mix of 10 μg/ mL of goat F(ab’)2 anti human IgG1 Fc specific 
(Rockland) and 25 μg/ mL retronectin (Takara) resuspended in phosphate buffered saline 
(PBS) for 2 hours at 37°C. After two washes in PBS, wells were blocked by 1% of bovine 
serum albumin (BSA) (Sigma) in PBS for 1 hour and washed once. Wells were coated by 10 
μg/ mL of either recombinant IgG1 or DLL1 (Adipogen) for 2 hours and then washed twice 
with PBS. Coated plates were kept overnight with full-medium at 37°C, 5% CO2 before cells 
seeding. G1ME cells were seeded at 2.5 105 cells/ mL in presence or absence of 10 μM of ϒ-
secretase inhibitor DAPT (Sigma) and diluted by half at 24 h. At 48 hours post-stimulation, 
cells were counted, viability was assessed, and equal number of cells per condition was 
harvested for RNA extraction, flow cytometry and Western-Blot analyses.  
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5. Chromatin Immuno-Precipitation (ChIP) 
G1ME cells were harvested following 2 days of co-culture on OP9 or OP9-Dll1, filtered and 
counted and then proceed for classical ChIP (Letting et al., 2004) .Briefly, cells were fixed in 
1% Formaldehyde (Sigma) during 10 minutes and the reaction was stopped by the addition 
of 125 mM of Glycine (Sigma). Following centrifugation, cell pellets were washed three times 
in PBS supplemented by protease inhibitors (Roche) and dried cell pellets were conserved at 
(-80 °C). ChIP was performed following manufacturers’ instructions (Millipore # 16-157). 
10^7 cells per condition was lysed in lysis buffer, then sonicated three times during 3 
minutes at 3W and 15V with 3 minutes of pause between each cycle (Bioblock scientific 
VibraCell 72405). Following centrifugation at 13200 rpm, a fraction was kept for check 
sonication efficiency and the remainder was diluted and pre-cleared using ProteinA/ Agarose 
salmon sperm beads during 30 minutes on rotation at 4°C. A fraction was kept for input 
control and the remainder was proceeded overnight for immuno-precipitation either with 
rabbit Ig control (Millipore # 12-370) or with the following antibodies PolII (scbt # sc-9001), 
GATA-2 (scbt # sc-9008) or SCL (a kind gift of C. Porcher) before the addition of ProteinA/ 
Agarose salmon sperm beads. Beads were washed successively by High Salt, low salt, LiCl 
and TE buffer (Millipore, # 16-157). Precipitated DNA was eluted twice using elution buffer 
containing 10% SDS and 100mM of Sodium bicarbonate. Crosslink was reversed by the 
addition of 200mM of NaCl (Sigma) and incubation 4 h at 65°C. The reaction was stopped by 
the addition of TE buffer (Tris pH 6.5 40 mM; EDTA 10 mM) and proteins digested by 
Proteinase K (Roche) enzyme allowed to react 1h at 45°C before storage at (-20 °C). 
Immunoprecipitated DNA was extracted by phenol/ chloroforme (Sigma) method, the DNA 
pellet was visualized by the addition of Glycogen (Roche), washed in Ethanol 70° and 
suspended in water (Sigma). qPCR was performed using the primers detailed in the table 
below.  
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Gene Forward Reverse 
Gata1 HS -3.5 5'-CCGGGTTGAAGCGTCTTCT-3' 5'-TCAGGGAAGGATCCAAGGAA-3' 
Rpl18 promoter 5'-ATAGAGTGTTCCCGCATTGCG-3' 5'-TCAGCGAGCTTACCATGATGG-3' 
c-Kit - 146 5'-AGAAGGTGCCCCGAGTGTATAA-3' 5'-GCACAGCTCCTTACCTTGCAAT-3' 
c-Kit -114 5'-TGCCAGGCTAATGTGTTGTC-3' 5'-ATAAGAAGGCGGCTGTTCTG-3' 
c-Kit -35.8 5'-AGAGAACCGAAGGTCGGATAC-3' 5'-TTGATGGAAGCATTAGAAAAAGAATTT-3' 
c-Kit -21.1 5'-GATCAAAGATAATGACCCCAAGTGA-3' 5'-GGGAGGAATCAGTTATTTTGAGGTTT-3' 
c-Kit 0 5'-CTCCAGGCTAATGTGGTTGTC-3' 5'-ATAAGAAGGCGGCTGTTCTG-3' 
c-Kit + 4.7 5'-GGCTGGAAACCACTGCCTTA-3' 5'-AGCCTTGCCTGTGCTTAAGC-3' 
c-Kit + 9.7 5'-CCGGGTGGGCCTGAGT-3' 5'-GGCATGGGCTTACAGTGTCA-3' 
c-Kit + 16.2 5'-TCTTGGTGAATGGTCGGATAC-3' 5'-AACTGTTGCGGGGCATTAT-3' 
c-Kit + 33.1 5'-TGGCAGTCCTGGTTGTAGCA-3' 5'-GCTGCAAGCATGCGATCA-3' 
c-Kit + 58.1 5'-GCAGTTCTCCAGGTTGAGTCAGA-3' 5'-GGAGGAGTTAGGGAATATGTCGATAG-3' 
c-Kit + 60.2 5'-GAACAGTGGACTCGTAGGAGCAT-3' 5'-AGAGAGGCCCAGCGTATGG-3' 
c-Kit + 72.9 5'-AACTGAAGCGAGTACAGCATTCC-3' 5'-TGCTTTTGCTTGTGTACTGTTAACTG-3' 
c-Kit + 77.8 5'-CACGCGCTATGCACATCCT-3' 5'-TGCCCAGCACATGACAACTT-3' 
6. Micro-RNA extraction and qRT-PCR 
Small RNA and total RNA were extracted using miRNeasy micro kit (Qiagen) following the 
manufacturers’ instructions. RT and qPCR primers for miR-221, miR-451 and U6 were 
purchased from Applied Biosystems (Life Technologies). RT was performed usingTaqMan 
microRNA Reverse Transcription Kit (# 4366596) and qRT-PCR was performed using TaqMan 
Universal PCR Master Mix, both from Applied Biosystems (Life Technologies). 
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Target Forward Primer  Reverse Primer  
 -actin 5’-TGGGAATGGGTCAGAAGGACTC-3’ 5’-CTGGGTCATCTTTTCACGGTTG-3’ 
c-Kit 5’-GGGCTAGCCAGAGACATCAG-3’ 5’-AGGAGAAGAGCTCCCAGAGG-3’ 
c-Kit 
Intron 1 
5'-TGGGAAAAGCCAACAGCTAC-3' 5'-GAAAGAGCGGCAGACAAGAG-3' 
c-Mpl 5’- CCGAGCTCGCTACAGCTT- 3’ 5’- CTGTAGTGCGCAGGAAATTG -3’ 
Cd9 5’- GCTCGAAGATGCTCTTGGTC -3’ 5’- GCTCGAAGATGCTCTTGGTC -3’ 
c-Myc 5’-TCCTGTACCTCGTCTGATTCC-3’ 5’-CTCTTCTCCACAGACACCACATC-3’ 
Fli-1 5’-GACTCTGTCAGGAGAGGAGC-3’ 5’-GTCATTTTGAACTCCCCGTTG -3’ 
Gata1 5’-TTCTTCCACTTCCCCAAATG-3’ 5’-AGGCCCAGCTAGCATAAGGT-3’ 
Gata2 5’-GAATGGACAGAACCGGCC-3’ 5’-AGGTGGTGGTTGTCGTCTGA-3’ 
Hes1 5’-CTACCCCAGCCAGTGTCAAC-3’ 5’-CGCCTCTTCTCCATGATAGG-3’ 
Itga2b 5’-AAGCTCTGAGCACACCCACT-3’ 5’-CTCAGCCCTTCACTCTGACC-3’ 
Jak-2 5’-GATGGCGGTGTTAGACATGA-3’ 5’-TGCTGAATGAATCTGCGAAA-3’ 
Pf4 5’- AGTCCTGAGCTGCTGCTTCT -3’ 5’- CAGCTAAGATCTCCATCGCTTT- 3’ 
Pten 5’-AATTCCCAGTCAGAGGCGCTATGT-3’ 5’-GATTGCAAGTTCCGCCACTGAACA-3’ 
Tal-1 5’-CGGAGGATCTCATTCTTGCTTAG-3’ 5’- CTAGGCAGTGGGTTCTTTGGG -3’ 
tr-Mpl 5’-GAGGACTGGAAGGAGACTGAGGCA-3’ 5’-AGGTTGCAGTCCTCTGTAGTCCAT-3’ 
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Key points  
 
- Notch favors erythrocytic commitment and stimulates SCF-dependent self-renewal of 
bipotent and committed erythrocytic and late megakaryocytic progenitors. 
- Megakaryocytes can be induced to resume cell divisions and regenerate megakaryocytic, 
erythrocytic and bipotent progenitors upon Notch activation.  
 
 
Abstract 
 
The aim of this study was to reinvestigate the controversial contribution of Notch 
signaling to megakaryocytic lineage development. For that purpose, we analyzed the progeny 
of purified megakaryocyte-erythroid progenitors (MEP) in short-term cultures performed on 
recombinant Notch ligand rDll1. Upon short Notch activation, MEP generated an increased 
number of Kit+/CD41Low progenitors expressing increased levels of Kit. Moreover, Notch 
activation reduced both the number of differentiated megakaryocytic cells and their 
expression of CD41 and CD42b. Colony assays showed that Notch favored both the 
expansion of bipotent progenitors and their erythrocytic commitment as well as the expansion 
of committed erythrocytic and late megakaryocytic progenitors. We identified a CD9High MEP 
subset that spontaneously generated almost exclusively megakaryocytic progeny including 
single megakaryocytes and few megakaryocytic colonies. Colony assays and single cell 
progeny analyses showed that upon Notch activation, this CD9High subset generated an 
increased number of megakaryocytic, erythrocytic, bipotent and even granulo-monocytic 
colonies at the expense of single megakaryocytes. These results evidence that Notch 
contributes to the self-renewal of all bipotent and committed erythrocytic and megakaryocytic 
progenitors and strengthen the emerging view that committed megakaryocytic progenitors 
actually remain competent to resume cell divisions and regenerate alternative lineages until 
the very last division before terminal megakaryocytic polyploidization.  
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Introduction 
 
Notch signaling is involved in many proliferation/differentiation and/or lineage commitment 
decisions during development, including hematopoiesis [1-3]. Notably, Notch1 is required for 
the generation of the first definitive hematopoietic stem cells (HSC). Notch1 is also required 
for T-cell lineage development occurring at the expense of B-cell lineage [4]. Moreover, 
deregulated Notch signaling induces T-cell leukemia in mouse and human [5].  
Concordant in vitro results have shown that stimulation by Notch ligands (Jag1, Jag2, Dll1 or 
Dll4)[6-12], as well as enforced expression of Notch intracellular domain (NICD) [7] or that 
of its target HES1 [13] stimulate HSC self-renewal at the expense of their differentiation [14]. 
In apparent contradiction, most in vivo studies have shown that the steady state number of 
HSCs is not affected by the suppression of Notch signaling by either conditional deletion of 
Notch1[15], Notch2 [16], Notch1 and Notch2 [17], RBP-Jk [18], Jag1 [19] or Hes1 nor by 
enforced expression of the pan-Notch inhibitor dnMAML [20]. However, deletion of Notch2 
(but not Notch1) reduces the rate of bone marrow reconstitution including repopulation of 
HSCs after injury thus suggesting a specific role for Notch2 during stress hematopoiesis [16].  
Whether Notch also controls lineage commitment and/or self-renewal divisions of multipotent 
and/or committed monopotent progenitors remains more controversial. Recent studies showed 
that Notch activation induces selective apoptosis of granulo-monocytic (GMP) progenitors 
[21] while loss of Notch signaling induces myelo-monocytic leukemia in mouse and chronic 
myelo-monocytic leukemia (CMML) in human [21-25]. On the opposite, other studies have 
shown that Notch activation increases the number of CD41+ megakaryocytic cells generated 
by murine Lin-/Sca-1+/c-Kit+ (LSK), common myeloid (CMP) or MEP progenitors indicating 
the positive contribution of Notch to the megakaryocytic specification [26]. Further studies 
have shown that Notch pathway activates AKT that in turn suppresses the inhibitory action of 
FOXO factors on Notch targets during megakaryocyte development particularly in CMP [27]. 
Intriguingly in both of these studies [26,27], the positive effect of Notch on megakaryocytic 
development was systematically associated with an increased MEP and a decreased GMP 
numbers that were interpreted as the successive contributions of Notch to the megakaryocytic 
commitments of CMP and MEP. However, intriguingly, Notch does not promote 
megakaryocytic commitment of human CD34+ pluripotent cells but inhibits terminal 
megakaryocyte maturation in contrast to what is observed in mouse [28]. These discrepancies 
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were tentatively attributed to differences in the contribution of Notch to the control of 
megakaryocytic lineage between mouse and human [29]. Similarly, contradictory results have 
also been reported regarding the role of Notch during erythropoiesis with some studies 
indicating increased apoptosis [30,31] and many others indicating either inhibition of 
erythrocytic differentiation [32-35] and/or increased self-renewal of committed erythrocytic 
progenitors [35,36].  
The aim of this study was to reinvestigate the real impact of Notch signaling in 
megakaryocytic lineage development. For this purpose, we took advantage of purified 
bipotent MEP progenitors, which offer the precise deciphering of megakaryocytic 
commitment, expansion and differentiation through progeny analysis. Moreover, to avoid the 
side effects associated with the use of Dll1-expressing cells, MEP progenitors were shortly 
activated in vitro with recombinant Notch ligand rDll1,  
 
Material and methods 
Mice 
Mice (genetic background C57BL/6J-129) were bred and maintained under specific-
pathogen-free conditions at the ALECS-SFP animal facilities of the Faculté de Médecine 
Lyon-Est (Université Claude Bernard, Lyon1, France) and experimentations were performed 
according to procedures approved by the local animal care and experimentation 
authorities(Ministère Délégué de la Recherche etdes Nouvelles Technologies, agreement no. 
4936; Direction des ServicesVétérinaires, agreement no 69266317 and 7462).  
Flow cytometry  
Bone marrow cells (BMC) were flushed from femurs and tibiae in Iscove's Modified 
Dulbecco's Medium (IMDM) containing 2 % fetal calf serum (FCS), treated with red blood 
cells ACK lysing buffer (Lonza) and filtered through a 40   m cell strainer (BD Biosciences) 
to obtain single-cell suspensions. BMC suspensions were labeled with a cocktail of 
biotinylated lineage antibodies (Lineage cell depletion Kit, Miltenyi Biotec) supplemented 
with biotinylated anti-Sca-1 (BD Pharmingen), anti-CD3 (BD Pharmingen), anti-IL7R 
(eBiosciences), anti-Ter119 (eBiosciences) and anti-CD19 (Serotec). Lin-/Sca1- cell 
suspensions were isolated by magnetic depletion of lineage and Sca-1 positive cells using LS 
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columns (Miltenyi Biotec). For MEP preparation, Lin-/Sca1- cells were further labeled with 
streptavidin-PE-Cy7 (BD Pharmingen) for the elimination of residual biotinylated stained 
cells and with anti-c-Kit-APC (BD Pharmingen), anti-CD34-FITC (e-Biosciences) and anti-
Fc -RII/III-PE (BD Pharmingen) antibodies and sorted with gating window Lin-/Sca1-/Kit+ 
Fc -RII/IIIlow/CD34low (Figure S1) as previously described [37] using FACSAria cell sorter 
and DIVA software (BD Biosciences). MEP subsets expressing different levels of CD9 were 
sorted using anti-cKit-efluor 450 and anti-CD9-APC antibodies. For cell cycle analyses, 
sorted CD9High and CD9Med MEP were centrifuged at 400g for 10 minutes, fixed using 
Foxp3/Transcription Factor Staining Buffer Set (eBioscience), treated with DNAse free 
RNAseA (100   g/mL for 30 min at room temperature) and labeled using FITC mouse anti-
human Ki-67 Set (BD Pharmingen) and 50   g/mL propidium iodide followed by FACS 
analysis.  2N and 4N CD9High and CD9Med MEP subsets were sorted after labeling using anti-
CD9-APC and anti-cKit-PerCP-efluor 710 (eBioscience) antibodies followed by DNA 
staining with Hoechst 33342 (20   g/mL Eurogentec) during 45 min at 37°C just before 
sorting.  
Colony assays 
Colony assays were performed by duplicate seeding of 1000 or 2000 cells into 3 mL final 
volume of MethoCultR M3234 (StemCell Technologies) supplemented with 30% FCS, mIL3 
(10 ng/mL), mSCF (50 ng/mL), mFlt3l (5 ng/mL), mGM-CSF (5 ng/mL), mIL11 (50 ng/mL), 
huEPO (4 U/mL) and mTPO (50 ng/mL) allowing the growth of all types of myeloid 
progenitors. Mixed erythro-megakaryocytic, erythrocytic, megakaryocytic and myeloid 
colonies were scored under microscope after 7 days of culture at 37°C, 5% CO2. All cytokines 
were purchased from PeproTech except huEPO (kindly provided by F Nicolini). 
Batch cultures of progenitors on recombinant rDll1 and control IgG1. 
Cultures were performed as previously described with minor modifications [10]. Briefly, 
wells of untreated culture plates were pre-coated for 1 h at 37°C with 10   g/mL of goat 
F(ab’)2 anti-human IgG1 Fc specific (Rockland) and of 25   g/mL Retronectin (Takara) in 
phosphate buffered saline(PBS). Wells were washed twice with PBS, blocked with 1 % 
bovine serum albumin (BSA) in PBS, incubated with 10   g/mLof either IgG1 or rDll1 
(Adipogen) in PBS for 2 h at 37°C and washed extensively with PBS. Coated wells were 
seeded at day 0 with 2000 progenitor cells in 1 mL of IMDM medium supplemented with 
10% FCS, mIL3 (10 ng/mL), mSCF (30 ng/mL), mFlt3l (25 ng/mL), mGM-CSF (10 ng/mL), 
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mIL11 (25 ng/mL), huEPO (4 U/mL) and mTPO (25 ng/mL) with or without 10   M DAPT 
( -secretase inhibitor, Sigma). At day 2, the totality of the cells from each well, representing 
the total progeny generated by the initial 2000 cells seeded at day 0, were collected and 
analyzed by colony assay. Alternatively, cells were numbered and analyzed by flow 
cytometry after labeling with appropriate antibodies at day 5 or 6.  
 
Single cell liquid cultures 
Sorted CD9High or CD9Med MEP subsets were seeded as single cell in wells of 96 wells culture 
plates coated with either IgG or rDll1 and cultured in IMDM medium supplemented as above. 
Colonies were scored after 7 days under bright field microscope as described previously [37].  
qRT-PCR analyses 
Total RNA was extracted using the Rneasy PLUS microkit (Qiagen) and reverse transcribed 
using a Quantitect reverse transcription kit (Qiagen).  qPCR reactions were performed on a 
Mx3000P qPCR instrument (Stratagene) using Light-cycler 480 SybR-Green-Master-Roche 
kit and primers indicated in Table S1. mRNA specific signals were normalized to that of beta-
actin mRNA.  
Statistics 
The data were analyzed by Student t-test. Differences were considered statistically significant 
at P < 0.05. 
 
Results 
 
Sorted MEP generate an increased number of Kit+ progenitors and a decreased number of less 
differentiated megakaryocytic cells upon Notch stimulation 
 FACS-sorted mouse bone marrow MEP progenitors (lin-/Sca1-
/Kit+/CD16/32low/CD34low; Figure S1) were cultured for 5 days in liquid medium 
supplemented with a complete cocktail of myeloid cytokines (IL3, Ftl3l, GM-CSF, SCF, 
IL11, EPO, TPO) in culture wells coated with recombinant Notch ligand rDll1. Cultures 
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performed in the presence of the  -secretase inhibitor DAPT or on coated IgG instead of 
rDll1 were used as negative controls of the Notch activation. Despite variations between 
different MEP preparations, the total number of cells (Figure 1A) as well as the number 
(Figure 1B) and the relative proportions (Figure 1C) of Kit+ progenitors were significantly 
higher in cultures performed on rDll1 than on IgG and were reduced in the presence of Notch 
inhibitor. qRT-PCR analyses performed at day 2 confirmed the expected increase in Hes1 
transcripts attesting Notch pathway activation in the presence of rDll1 and its partial 
repression by DAPT (Figure S2). Further analyses showed that the Kit+ progenitors amplified 
upon Notch activation were characterized by the expression of low levels of CD41 (Figure 
2A) and higher levels of Kit detected at both protein (Figure 1D, E) and transcript levels 
(Figure S2). This amplification of Kit+/CD41Low progenitors upon Notch activation was 
strictly dependent on the presence of SCF. Interestingly the increase in Kit expression was 
readily observed in the absence of SCF (Figure 1D) thus indicating a real contribution of 
Notch to the up-regulation of Kit expression rather than a simple preferential amplification of 
progenitors expressing higher levels of Kit. Taken together, these results indicate that 
activation of the Notch pathway in MEP progenitors increases their Kit expression and 
stimulates the SCF-dependent amplification of their Kit+ progeny.  
 Complementary analyses of the same MEP cultures revealed that Notch stimulation 
was also associated with a reduced number of megakaryocytic Kit-/CD41+/CD42b+ cells 
(Figure 2A and 2B). Moreover, although still CD41+/CD42b+, these megakaryocytic cells 
expressed lower levels of CD41 and CD42b (Figure 2A and 2C), indicative of a less 
differentiated state upon Notch activation. Thus, Notch activation both reduced the number 
and slowed down the differentiation of megakaryocytic cells generated by MEP.   
 
Notch activation stimulates the amplification of bipotent and erythrocytic progenitors from MEP 
population 
 Colony assays performed in methylcellulose supplemented with the same complete 
cocktail of myeloid cytokines revealed that 25% of freshly sorted MEP generated a progeny 
including 50% of pure erythrocytic colonies, 25% of pure megakaryocytic and 25% of mixed 
erythro-megakaryocytic colonies (Figure 3A, Day 0). These results confirmed previous 
studies, that the MEP population (which be referenced as Day 0 in the present study) is 
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actually composed of a mixture of pure erythrocytic and megakaryocytic progenitors in 
addition to truly bipotent progenitors.   
 The same colony assay was used to quantify the variations in the number of each type 
of progenitors induced by a two days culture in liquid medium on either IgG or rDll1 (Figure 
3A). The only change observed after the two days culture on IgG was a symmetrical slight 
increase in megakaryocytic colonies and reproducible but not significant decrease of 
erythrocytic colonies (Figure 3B) that could suggest spontaneous commitment of bipotent 
progenitors towards megakaryocytic differentiation.  In contrast, the two days culture on rDll1 
induced a marked increase in both mixed and erythrocytic colonies and much smaller 
decrease in megakaryocytic colonies (Figure 3C), these effects being blunted in the presence 
of DAPT (Figure 3A). This strongly asymmetrical large increase in erythrocytic versus small 
decrease in megakaryocytic colonies observed on rDll1 cannot be explained only by the 
simple erythrocytic commitment of bipotent progenitors but indicates a concomitant 
preferential amplification of erythrocytic progenitors upon Notch activation. As expected, this 
amplification of bipotent and erythrocytic progenitors induced by Notch activation was also 
strictly SCF-dependent (Figure S3). 
 
Identification of a specific CD9High MEP subset strongly responding to Notch activation 
 Although the number of bipotent and erythrocytic progenitors invariably increased in 
the presence of rDll1, we noticed that the extent of this increase varied (from 1.2 to 3 fold) 
from a MEP preparation to the other. Surprisingly, the fold increase in erythrocytic and 
bipotent progenitors observed upon Notch activation positively correlated with the 
megakaryocytic differentiation bias of the parent MEP populations (Figure 4). The more the 
native MEP population was biased toward the generation of megakaryocytic colonies, i.e. 
contained megakaryocytic progenitors, the more it was responding to Notch activation, 
assessed by increased bipotent (Figure 4A) and erythrocytic (Figure 4C) colonies. This 
intriguing observation prompted us to isolate MEP subsets differing in their megakaryocytic 
differentiation bias in order to compare their response to Notch. An interesting previous study 
reported the existence of a CD150+ /CD9High subset of Lin- /Kit+ /Sca1- mouse bone marrow 
cell population displaying obvious erythro-megakaryocytic bipotency while being strongly 
biased towards megakaryocytic differentiation [38]. Since most of bipotent progenitors 
present in the MEP gate are CD150+[39], CD9 appeared as a very good candidate marker for 
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the sorting of MEP cells according to their megakaryocytic bias. As shown in Figure 5A, 
MEP cells displayed a roughly bimodal distribution of CD9 level allowing us to sort three 
different subsets according to their CD9 expression level (CD9Low, CD9Med and CD9High). 
Colony assays performed on these 3 sorted subsets showed an expected increase in the 
proportion of megakaryocytic colonies correlated with the increase of CD9 expression level 
reaching more than 90% for the CD9High subset associated with a reduced clonogenicity 
(Figure 5B). Since the CD9Low subset appeared to be slightly contaminated by a few 
proportion of granulo-monocytic progenitors (see Figure 5B), we focused the next analyses 
on the comparison of the Notch response between CD9Med and CD9High subsets that contained 
most of the erythrocytic-megakaryocytic potential without detectable granulo-monocytic 
contamination. For that purpose we followed the same protocol described in Figure 2 and the 
results obtained with three independent preparations of CD9Med or CD9High are presented in 
Figure 5C and 5D respectively. As expected, the CD9Med (which represented about 50% of 
MEP), roughly reproduced results obtained with the unfractionated MEP population namely 
an increase of erythrocytic and bipotent colonies and slight decrease of megakaryocytic 
colonies after the two days culture on rDll1 (Figure 5C). In marked contrast, the very low 
numbers of erythrocytic and bipotent colonies generated by CD9High MEP at day 0 were 
spectacularly enhanced (up to 10 and 40 fold respectively) after the two days culture on rDll1 
(Figure 5D) while the numbers of megakaryocytic colonies were again slightly reduced. 
Moreover, as observed with the unfractionated MEP population (Figure 4) the fold increase in 
bipotent(Figure 5E) and erythrocytic (Figure 5G) colonies upon Notch activation still 
correlated with the megakaryocytic bias of the initial CD9High MEP population.   
 Such a spectacular increase in bipotent and erythrocytic colonies led us to hypothesize 
that the CD9High subset might actually include quiescent progenitors that would be reactivated 
by Notch activation. Unexpectedly, FACS analyses performed after double DNA and Ki67 
labeling revealed that up to 80% of CD9Med cells were in G1 phase of cell cycle including 
30% in G0 as compared with CD9High population which contained only 60% of cells in G1 
and 4.7% of cells in G0 (Figure S4A and S4C). In contrast, while both subsets displayed the 
same proportion of cells in S phase, the CD9High subset was characterized by an increased 
proportion of cells in G2/M including cells with reduced Ki67 expression. Moreover, the 
CD9High subset was also characterized by 5% of binucleated cells that may correspond to 
megakaryocytes transiently paused during the process of their polyploidization (Figure S4B 
and S4D). Taken together, these observations prompted us to investigate the possibility that 
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late megakaryocyte progenitors - megakaryocytes present in the CD9High subset might resume 
cell divisions and re-express erythrocytic program upon Notch activation.     
 
CD9High megakaryocytes can resume cell divisions to generate megakaryocytic precursors upon 
Notch activation 
 To explore the role of Notch in the sequential steps of megakaryocytic 
commitment/expansion/differentiation, we sorted the 2N and 4N fractions of the CD9Med and 
CD9High MEP subsets and used colony assay to score only the megakaryocytic progenies 
generated after a two days culture on IgG or rDll1. Colonies containing from 1 (single 
megakaryocyte) to over 8 megakaryocytes were counted (Figure 6). As expected, the total 
megakaryocytic progeny of the 2N or 4N CD9High MEP subsets generated on IgG was around 
4 fold higher than that of the corresponding CD9Med MEP subsets. However, single 
megakaryocytes contributed to most (65%) of the 2N CD9High progeny compared to only 33% 
for the 2N CD9Med (Figure 6B). This difference in the proportion of single megakaryocytes 
obtained from CD9High versus CD9Med MEP subsets was also observed in their 4N fractions 
(89% vs 43% respectively, Figure 6B). Most importantly, the two days culture on rDll1 did 
not significantly change the total megakaryocytic progeny in neither subset. However, Notch 
activation led to a decrease in the proportion of single megakaryocytes and concomitant 
increase of colonies containing higher numbers of megakaryocytes (Figure 6B). These results 
thus indicated that Notch activation was able to reprogram late megakaryocytic progenitors, 
representing most of megakaryocytic progenitors present in CD9High, to resume cell divisions 
instead of going on towards terminal megakaryocytic growth without division. 
 
Single CD9High MEP cells can generate megakaryocytic, erythrocytic, bipotent and tri-potent 
progenitors upon Notch activation 
 Single cell progeny analyses were then performed to directly determine if Notch 
activation was also able to induce lineage reprogramming. For that purpose, single CD9Med or 
CD9High MEP were individually seeded in each well of 96 well culture plates coated with 
either IgG or rDll1 still in the presence of a complete cocktail of myeloid cytokines for 1 
week. Cell progenies were scored by careful inspection of all culture wells using bright-field 
microscope after 7 days of culture as previously described [37] and the qualification of the 
colony (megakaryocytic, erythrocytic, mixed colonies, granulo-monocytic) raised by one 
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single cell is given as a percentage of all single cells that were seeded (Figure 7). The culture 
on either IgG or rDll1 did not significantly change the proportion of CD9Med cells generating 
colonies  including erythrocytic, megakaryocytic, mixed and few granulo-monocytic colonies 
(Figure 7A), indicating no effect of Notch on CD9Med MEP survival. However, the proportion 
of CD9Med MEP cells that led to erythrocytic colonies increased at the expense of those giving 
rise to megakaryocytic colonies (only colonies containing over 4 cells were scored) in the 
presence of rDll1 as compared to IgG (Figure 7B) thus indicating preferential commitment of 
CD9Med MEP towards erythrocytic lineage upon Notch activation. This confirmed the colony 
assay performed with the bulk CD9Med MEP subset (Figure 5C). 
Similarly as observed with the whole CD9High MEP population (Figure 5D), single 
CD9High MEP cells generated upon Notch activation a higher proportion of colonies, 
including megakaryocytic colonies containing more than 4 cells  (Figure 7C, colored bars). 
However, when considering also CD9High MEP generating at least one single megakaryocyte, 
the amount of CD9High MEP cells generating a viable progeny did not change significantly on 
IgG (77%) or rDll1 (71%) (Figure 7C). Remarkably, whereas the progeny of single CD9High 
MEP cells on IgG was exclusively megakaryocytic, up to 15% of this progeny was committed 
into erythrocytic, erythro-megakaryocytic or even granulo-monocytic colonies on rDll1 
(Figure 7C and 7D). This indicates a reprogramming of megakaryocytic-biased CD9High MEP 
towards bipotent and erythrocytic lineages upon Notch activation. 
 In one of these single cell progeny analyses, we further scored the colonies including a 
detailed analysis of megakaryocytic colonies containing from 1 to more than 4 
megakaryocytes. As observed in Figure 6 for the bulk population upon Notch activation, 
single CD9High MEP cells generated a decreased proportion of single megakaryocytes and 
increased proportion of megakaryocytic colonies (Figure 7 E and  7F). These results indicate 
that Notch activation not only stimulates cell divisions of committed megakaryocytic 
progenitors but also induces their reprogramming towards erythrocytic or granulo-monocytic 
lineages. 
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Discussion 
 The aim of this study was to investigate the effect of the Notch pathway on the 
development of the megakaryocytic lineage. To specifically answer this question, we used 
pure bipotent MEP progenitors that were shortly treated with recombinant Dll1.   
 First, we confirmed the heterogeneity of purified MEP populations actually composed 
of a mixture of erythrocytic, megakaryocytic in addition to truly bipotent progenitors. Our 
results showed that activation of the Notch pathway (evidenced by increased levels of the 
Notch target Hes1 mRNA) stimulated the amplification of Kit+/CD41Low progenitorsin short-
term cultures of MEP performed on rDll1. Colony assays further showed that amplified 
progenitors are mainly bipotent and erythrocytic progenitors whereas the number of 
megakaryocytic progenitors slightly decreased. The strong asymmetry between the large 
increase in erythrocytic progenitors versus the small decrease in megakaryocytic progenitors 
indicated that Notch activation stimulates the amplification of committed erythrocytic 
progenitors independently on its contribution to the commitment of bipotent progenitors 
towards the erythrocytic lineage (Figure 7). Importantly, this preferential amplification of 
bipotent and erythrocytic progenitors was strictly SCF-dependent and associated with the 
increased expression of Kit receptor detected at both transcriptional and protein levels. 
Moreover, this increased Kit expression was also observed in the absence of SCF suggesting 
that it is functionally involved rather than being the simple consequence of the SCF-
dependent progenitor amplification induced by Notch. Taken together, these results indicate 
that Notch activation allows the SCF-dependent amplification of bipotent and erythrocytic 
progenitors mediated at least partially through the up regulation of Kit. This conclusion 
corroborates two recent studies showing the contribution of Notch to the SCF-dependent 
amplification of human erythrocytic progenitors in vitro[35] as well as murine erythrocytic 
progenitors during stress erythropoiesis in vivo[36]. Our results also help to resolve some 
controversies about the apparent divergent effects of Notch signaling on megakaryocytic 
differentiation between mouse and human [29]. In particular, our results confirm that Notch 
activation actually favors erythrocytic instead of megakaryocytic commitment as recently 
shown by for PreMegE progenitors [36]. In opposite, another study concluded that Notch 
activation favors megakaryocytic development based on the observation of an increased 
production of CD41+ and MEP progenitors by LSK or CMP multipotent progenitors upon 
Notch activation [27]. However, based on the present data demonstrating that Notch not only 
increases the self-renewal of bipotent MEP, committed erythrocytic progenitors but also that 
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of committed late megakaryocytic progenitors (as evidenced by the size increase of 
megakaryocytic colonies), we suggest that the increased production of MEP and CD41+ 
progenitors observed in this previous study can be best explained by this contribution of 
Notch to self-renewal instead of by a true contribution of Notch to the preferential 
commitment towards megakaryocytic lineage [27]. In addition and in agreement with 
previous results obtained with human CD34+ cells [28], the present study further showed that 
Notch stimulation also partially inhibits murine terminal megakaryocytic differentiation as 
evidenced by the production of a reduced number of double positive CD41/CD42b cells 
expressing lower level of CD42b.   
 The most original finding of our study is the unexpected plasticity of the CD9High 
subset of MEP progenitors revealed by Notch activation. Indeed, in contrast to CD9Med MEP, 
the progeny of CD9High MEP generated in the absence of Notch stimulation was almost 
exclusively megakaryocytic including a large majority of single large mature megakaryocytes 
and few megakaryocytic colonies harboring a reduced number of mature megakaryocytes, 
indicating an advanced stage of megakaryocytic differentiation. Importantly, Notch 
stimulation not only increased the size of megakaryocytic colonies but also reduced the 
proportion of single megakaryocytes. Taken together, these results indicate that the strong 
megakaryocytic bias of CD9High MEP is associated with reduced self-renewal efficiency that 
can be reversed by Notch activation acting until the very last division before terminal 
differentiation, thus allowing progenitors to resume cell divisions instead of endoploidization. 
Interestingly, previous studies reported that binucleated megakaryocytes are able to resume 
cell divisions at very low efficiency [40] thus raising the possibility that the 5% of binucleated 
cells detected in the CD9High MEP populationmight be preferentially involved in the Notch 
response. Although this possibility cannot be excluded, our finding that Notch also increased 
the size of megakaryocytic colonies generated by both CD9Med and CD9High diploid subsets 
already indicates that binucleated megakaryocytes are most probably not the unique Notch 
target cells explaining increased self-renewal of megakaryocytic progenitors.  
 The other intriguing property of CD9High MEP is their capacity to restore the 
generation of mixed, erythrocytic and even few myeloid colonies in response to Notch 
activation contrasting with their almost exclusive megakaryocytic progeny when these cells 
are untreated. The most trivial origin of these non-megakaryocytic colonies could be the 
reactivation and/or the strong preferential amplification of a small number of quiescent 
bipotent and/or multipotent contaminant progenitors. However, we failed to detect quiescent 
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G0 cells in the CD9High subset while such G0 cells were readily detected in the CD9Med subset.  
Moreover, the up to 40 fold increase in bipotent colonies observed after only two days on 
rDll1 (see Figure 5E) would imply a very short cell cycle of around 8-9 hours that seems very 
unlikely for the reactivation of quiescent cells. On the other hand, the three independent 
experiments performed, totalizing the analysis of 252 CD9High single cell progeny, revealed 
exclusively megakaryocytic progeny when cultured on IgG whereas up to 15% of non-
megakaryocytic cells appeared at the expense of the megakaryocytic progeny in cultures on 
rDll1 (Figure 7). Although these results cannot formally exclude the minor contribution of a 
small number (less than 1 out of 252) of quiescent/contaminant pluripotent progenitors 
(possibly CD9High CMP), they already indicate that around 10% of CD9High progenitors can be 
diverted from terminal megakaryocytic towards erythrocytic or mixed differentiation upon 
Notch activation. This strongly supports the emerging view [38] that megakaryocytic 
progenitors actually remain at least bipotent until the very last division before terminal 
endoploidization, an interpretation that is further strengthened by the only slight decrease of 
several erythroid specific genes (KLF1, TFRC, KEL) in single CD9+ MEP as compared with 
CD9- MEP (Figure S5)[41]. Interestingly, transient amplification of CD150+/CD9High bipotent 
progenitors has been shown to accompany platelets recovery in mice injected with anti-
platelet serum [38]. Another study recently reported that stress erythropoiesis depends on 
Notch signaling [36]. The present study raises the intriguing possibility that CD9High MEP 
progenitors might constitute a common dormant reservoir allowing rapid Notch-dependent 
regeneration of red cells or platelets in response to hematopoietic stress.  
 In summary (Figure S6), this study shows that Notch activation favors the erythrocytic 
commitment of bipotent MEP progenitors and stimulates their SCF-dependent self-renewal as 
well as that of all committed erythrocytic and late megakaryocytic progenitors in association 
with increased expression of Kit. Most importantly, this study reveals the unexpected 
plasticity of CD9High late megakaryocytic progenitors that can, upon Notch activation, be 
diverted to resume cell division instead of terminal endo-polyploidization/differentiation to 
regenerate progenitors not only with megakaryocytic but also with erythroid, mixed or even 
myeloid potential. These data demonstrate Notch signaling as a key regulator of the 
homeostasis of erythrocytic/megakaryocytic lineages. 
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Legends to Figures 
 
Figure 1. Notch signaling stimulates the SCF-dependent amplification MEP-derived 
progenitors expressing increased Kit expression. 2000 cells from purified MEP populations 
were cultured in culture plates coated with either recombinant IgG or rDll1 with or without 
 -secretase inhibitor DAPT in liquid medium supplemented by a complete cocktail of 
myeloid cytokines (IL3, EPO, GM-CSF, TPO, Flt3l, IL11) including or not SCF as indicated. 
MEP cell progenies collected after 5-6 days of culture were then numbered and Kit expression 
was analyzed by FACS. Except for the percentages of Kit+  cells (C), all results are expressed 
as relative values standardized to the IgG + SCF condition (means and standard deviations 
from 3 and 8 independent experiments in the absence or presence of SCF respectively). 
Statistically significant variations between the IgG and rDll1 or rDll1+DAPT conditions are 
indicated by asterisks (p  ≤ 0.05 in t-test). A: Histogram showing the relative numbers of total 
cells. B: Histogram showing the relative numbers of Kit+ cells. C: Histogram showing the 
percentage of Kit+ cells of total MEP cells. D: Histogram showing the relative values of Kit 
median fluorescence intensity (MFI) of Kit+ cells. E: Representative FACS profiles showing 
the distribution of Kit levels in the various conditions.    
Figure 2. Under Notch stimulation, MEP generates an increased number of Kit+/CD41Low 
progenitors and a reduced number of Kit-/CD41+/CD42b+ megakaryocytic cells that 
harbored a less differentiated phenotype. Purified MEP were cultured for 6 days in liquid 
medium supplemented with a complete cocktail of myeloid cytokines in culture wells coated 
with either recombinant IgG or rDll1 in the presence or absence of Notch inhibitor DAPT. 
Cells were then analyzed by FACS for their expression of Kit, CD41 and CD42b. A: Typical 
FACS diagram showing the expression levels of CD41 and CD42b in the Kit negative (black 
dots) and the Kit positive (red dots) cells at day 6. Percentages indicate the proportion of the 
CD41+/CD42b+ double positive differentiated megakaryocytic cells. B: Histogram showing 
the relative percentages of CD41+/CD42b+ megakaryocytic cells (relative values standardized 
to the IgG condition). C: Histogram showing the relative fluorescence intensities of CD41 and 
CD42b in the Kit-/CD41+/CD42b cells at the end of the culture (relative values standardized 
to the IgG condition; means and standard deviations from 4 independent experiments). 
Asterisks indicate statistically significant differences between IgG and rDll1 conditions 
(p<0.05 in Student t-test). 
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Figure 3. Notch signaling stimulates bipotent and erythrocytic progenitors amplification. 
2000 bone marrow MEP were cultured for two days in the presence of a complete cocktail of 
myeloid cytokines (IL3, SCF, EPO, GM-CSF, TPO, Flt3l, IL11) in culture wells coated with 
either control IgG or recombinant rDll1 in the presence or absence of DAPT as indicated. 
Total numbers of the different types of progenitors present in the initial untreated population 
(Day 0) and after the two days culture in the different conditions were determined by colony 
assays performed in semi-solid medium in the presence of the same complete cocktail of 
cytokines. A: Piled histograms showing the respective numbers of the various types of 
colonies generated from untreated cells (Day 0) and after a two days culture on IgG, rDll1 or 
rDll1 + DAPT (mean and standard deviations from 5 independent MEP preparations). B: 
Histograms showing the variations of the numbers of the different types of colonies generated 
after two days of culture on IgG as compared with Day 0 cells (same experiments as those 
described in A). C: Histograms showing the variations of the numbers of the different types of 
colonies generated after two days of culture on rDll1 as compared to Day 0 cells (same 
experiments as those described in A). Statistically significant variations are indicated by 
asterisks (p ≤0.05 in t-test). 
Figure 4. The rate of progenitors amplification upon Notch stimulation correlates with the 
megakaryocytic versus erythrocytic bias of the initial MEP population. 
Dot-plot showing the fold variations of the numbers of the different progenitors induced by 
Notch ligand as a function of the ratio of megakaryocytic/erythrocytic progenitors present in 
the native MEP preparation (compiled data from all experiments performed on rDll1 shown in 
Figure 2). Determinant coefficients and significance of the linear regressions (Fisher F test) 
are indicated by R2 and p-values respectively.  
Figure 5.  Notch most responsive bipotent and erythrocytic progenitors are present in the 
CD9High fraction of the MEP population. A: FACS diagram showing the gating windows 
used for the sorting of MEP CD9Low, CD9High and CD9Med fractions. (B-G) Progeny of equal 
numbers of sorted CD9Low, CD9High and CD9MedMEP populations were analyzed by colony 
assays before (Day 0) and after a two days culture either on IgG or rDll1 with or without 
DAPT as described in Figure 2. B: Progeny analysis of the whole MEP population and of the 
CD9Low, CD9Med and CD9High MEP subsets immediately after sorting (Day 0). C, D: Progeny 
analysis of the CD9Med (C) and CD9High (D) populations before (Day 0) and after a two days 
culture on IgG or rDll1 with or without DAPT inhibitor. Piled histograms showing the means 
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and standard deviations of the number of each type of colonies obtained with three 
independent MEP preparations. Means and standard deviations from 3 different experiments; 
statistically significant variations are indicated by asterisks (p ≤0.05 in t-test). E, F, G: Plots 
of the fold variations of the number of mixed (E), megakaryocytic (F) or erythrocytic (G) 
progenitors after two days on rDll1 as a function of the ratio of megakaryocytic/erythrocytic 
progenitors present in the initial CD9High and CD9Med MEP populations.  
Figure 6. Notch signaling increases the size of MEP-derived megakaryocytic colonies. MEP 
were FACS sorted into four subsets according to their CD9 expression levels (CD9High or 
CD9Med) and to their DNA content (2N or 4N) and cultured for two days on IgG or rDll1 
before performing colony assay as described in Figure 2. The number and the size of 
megakaryocytic colonies, according to the numbers of mature megakaryocytes they contain 
(from 1 to more than 8) were recorded (mean results obtained from two independent 
preparations of each subset are presented). A: Numbers of megakaryocytic colonies harboring 
the indicated number of megakaryocytes (MK1 for single megakaryocytes to MK>=8 for 
more than 8 megakaryocytes per colony) obtained per 1000 seeded cells of the indicated 
subsets. B: Relative percentages of megakaryocytic colonies obtained in A as a percentage of 
total colonies.  
Figure 7. Single cell progeny analyses of CD9Med MEP and CD9High MEP with or without 
Notch pathway activation.Single MEP CD9Med or MEP CD9High were individually seeded in 
96 wells culture plate that have been coated with either IgG or rDll1 and containing medium 
supplemented with a complete cocktail of myeloid cytokines. The different types of 
developed colonies were numbered at day 7 by visual inspection of under bright light 
microscope. A, B: Repartition of the indicated type of colony as a percentage of all single 
seeded CD9Med MEP (A) and as a percentage of CD9Med MEPraising colonies (B) (means and 
standard deviations from 3 independent experiments; statistically significant variations are 
indicated by asterisks; p ≤0.05 in t-test). C, D: Repartition of the indicated type of colony as a 
percentage of all single seeded CD9High MEP (C) and as a percentage of CD9High MEPraising 
colonies (D) (means and standard deviations from 3 independent experiments; statistically 
significant variations are indicated by asterisks; p ≤0.05 in t-test). E, F: Detailed results from 
one of the three experiments performed in A and C, in which megakaryocytic colonies were 
further scored according to their content in mature megakaryocytes (form 1 to more than 4), 
expressed as a percentage of all single seeded CD9High or CD9Med MEP (E) and as a 
percentage of CD9High or CD9Med MEPraising colonies (F). 
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Supplementary figures legends 
 
Figure S1 
FACS diagram illustrating the gating strategy used for the sorting of bone marrow MEP and the 2N 
and 4N subsets expressing various levels of CD9.  
 
Figure S2 
Transcript levels changes induced by rDll1 
Transcript levels were determined by qRT-PCR after two days cultures of MEP cells on the indicated 
conditions using ?-actin as a reference. Results are presented as relative levels standardized to the 
culture condition on IgG (means and standard deviations obtained from 3 independent cultures). 
Statistically significant differences are indicated by asterisks, p ≤0.05 in t-test.    
 
Figure S3 
The Amplification of bipotent and erythrocytic progenitors stimulated by Notch signaling is 
dependent on the Kit/SCF signaling.Equal numbers of MEP were cultured for two days in the 
presence or absence of SCF and their progenies were analyzed by colony assay as described in Figure 
2. Results are expressed as fold variations of the number of each type of progenitors between Day 0 
and Day 2 in presence (black boxes) or absence of SCF (white boxes). A: Bipotent colonies. B: 
Megakaryocytic colonies. C: Erythrocytic colonies. Means and standard deviations from three 
different experiments; statistically significant variations are indicated by asterisks; p ≤0.05 in t-test. 
 
Figure S4 
Cell cycle analyses of CD9High MEP and CD9Med MEPbefore and after two days culture in the presence 
of absence of Notch ligand 
A: FACS diagrams of CD9Med MEP (left panel) and CD9High MEP (right panel) after double labeling for 
DNA content (Propidium Iodide) and Ki67 expression immediately following their purification. 
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Percentages indicate the proportion of diploid and Ki67 negative cells corresponding to classical G0 
quiescent cells. Arrow indicates tetraploid cells expressing low levels of Ki67 suggesting quiescent 
G2/M cells that were present specifically in the MEP CD9High subset. B: Cytospins of MEP CD9Med (left 
side) and MEP CD9High cells (right side) after May Gründvald Giemsa staining. Arrow indicates 
binucleated cells specifically present in the MEP CD9High subset. C: Histograms showing the 
repartition of CD9Med and CD9High cells in the G0/G1, S and G2/M  phases of cell cycle before (Day 0) 
and after a two day culture (Day 2) on either IgG or rDll1 (Mean results from two independent 
experiments are shown). D: Histogram showing the selective presence of 5% of binucleated cells in 
the MEP CD9High subset.  
 
Figure S5 
Retrospective transcriptome comparison between CD9+ and CD9- MEP 
A:  Heatmap of genes upregulated (top) or downregulated (bottom) in CD9+ compared to CD9- MEP. 
Analysis of transcriptome row data from the 64 single MEP recently published by Guo et al [41] 
allowed us to identify and to virtually sort 16 and 48 single MEP expressing or not CD9 respectively. 
Heatmap presented here is limited to genes which mean expression levels were found statistically 
different between these virtually sorted CD9+ and CD9- MEP subsets (p-value < 0.05 by Student t-
test). Genes names and p-values are indicated on the left and right of the heatmap respectively. 
Mean expression levels of genes are indicated by numbers in table cells and further illustrated by 
increasing red color intensity. Note the marked difference between the contrasted differential 
expression of genes up-regulated compared to the modest differential expression of down regulated 
genes in CD9+MEP. 
B: Expression profiles of genes differentially expressed between CD9+ and CD9- MEP. Expression 
profiles of genes differentially expressed between CD9+ and CD9- MEP were collected for stem cells 
(LT-HSC or ST-HSC), erythro-megakaryocytic bipotent (MKE), megakaryocytic (MKP) or erythrocytic 
(PreCFUE, CFUe and ProE) committed progenitors from Hemaexplorer database [42]. Heatmap 
presented here corresponds to relative expression levels (mean of all specific probes levels for each 
given gene) normalized to the median expression level of the 7 different populations (number in 
table cells correspond to LOG(2) of normalized expression levels). Genes names are indicated on the 
left of the heatmap and are ordered separately for up-regulated and down regulated genes by 
decreasing expression levels in LT-HSC. Note that all genes up-regulated in CD9+ MEP correspond to 
genes displaying contrasted higher levels in LT-HSC and lower levels in committed erythrocytic 
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progenitors while most slightly down-regulated genes (Downb subset) display contrasted lower 
expression levels in LT-HSC and higher levels in committed erythrocytic progenitors.  
 
Figure S6 
Diagram summarizing the effect of Notch on the different progenitors present in the MEP 
population   
Known filiation between the different progenitors is indicated by thin arrows while their different 
potential are indicated by different colors (Red for pure erythrocytic, yellow for pure megakaryocytic, 
orange for bipotent and light orange for bipotent with high megakaryocytic bias). Thick blacks arrows 
indicate self-renewal efficiency in the absence of Notch ligand. Thick green arrows indicate the 
different effects induced by Notch ligand numbered as follows: 
(1) Increase of Kit expression 
(2) SCF-dependent increase of self-renewal 
(3) Preferential commitment of CD9Med bipotent progenitors towards erythrocytic lineage 
(4) Redirection of CD9High bipotent progenitors from endomitosis and terminal megakaryocytic 
differentiation to the resumption of cell divisions leading to the amplification of megakaryocytic 
progenitors and concomitant emergence of few progenitors with erythrocytic, mixed and possibly 
granulo-monocytic potential. Whether the emergence of these progenitors simply reflects persistent 
bi/multipotency of CD9High progenitors until the last division before endomitosis or results from a 
true reprogramming process (5) remains an open question. 
Table S1Primer sequences used in qRT-PCR 
 
  
Target Forward Primer  Reverse Primer  
?-Actin 5’-TGGGAATGGGTCAGAAGGACTC-3’ 5’-CTGGGTCATCTTTTCACGGTTG-3’ 
Hes1 5’-CTACCCCAGCCAGTGTCAAC-3’ 5’-CGCCTCTTCTCCATGATAGG-3’ 
Gata1 5’-TTCTTCCACTTCCCCAAATG-3’ AGGCCCAGCTAGCATAAGGT-3’ 
Gata2 5’-GAATGGACAGAACCGGCC-3’ 5’-AGGTGGTGGTTGTCGTCTGA-3’ 
Pten 5’-AATTCCCAGTCAGAGGCGCTATGT-3’ 5’-GATTGCAAGTTCCGCCACTGAACA-3’ 
cMyc 5’-TCCTGTACCTCGTCTGATTCC-3’ 5’-CTCTTCTCCACAGACACCACATC-3’ 
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Régulations divergentes du récepteur c-Kit par la TPO et la tétraspanine CD9 : 
Implication dans le contrôle de la balance prolifération/maturation mégacaryocytaire 
 
La thrombopoïétine (TPO) favorise successivement la prolifération et la maturation des 
progéniteurs mégacaryocytaires, soulevant la question du mécanisme expliquant cette dualité 
d’action. La signalisation SCF/ c-Kit est essentielle pour la prolifération de tous les progéniteurs 
hématopoïétiques, alors que l’extinction de l’expression du récepteur c-Kit est requise pour 
l’engagement en différenciation terminale. Réciproquement, l’équipe a montré que la stimulation de 
la voie Notch affecte une sous-population  de progéniteurs bipotents érythro-mégacaryocytaires 
exprimant fortement CD9 (tétraspanine induite durant la maturation mégacaryocytaire) et favorise la 
reprise de leurs divisions au détriment de leur différenciation mégacaryocytaire terminale. Cet effet 
de la voie Notch s’accompagne d’une augmentation de l’expression de c-Kit. Ces observations m’ont 
conduite à m’intéresser aux mécanismes de régulation de c-Kit par la TPO en m’appuyant sur un 
modèle de progéniteurs bipotents immortalisés et dont la prolifération est strictement dépendante 
de la TPO (cellules G1ME). Les travaux réalisés durant ma thèse m’ont permis d’établir que (i) La 
stimulation des cellules G1ME par le ligand de Notch DLL1 favorise l’expression de c-Kit et réprime 
celle de CD9 (ii) L’activation inattendue de c-Kit par la TPO contribue à la prolifération (iii) c-Kit 
contribue activement à restreindre la polyploïdisation des cellules G1ME en présence de TPO (iv) La 
tétraspanine CD9 elle-même réprime l’expression de c-Kit à la membrane. Sur la base de ces 
résultats, nous proposons le modèle selon lequel, la TPO participerait à la fois à la prolifération  des 
progéniteurs du fait de sa capacité à activer c-Kit, mais contribue aussi à l’augmentation de 
l’expression de CD9 qui en atteignant un seuil  suffisant conduit à l’extinction de l’expression de c-Kit 
à la surface, entrainant alors l’arrêt des divisions et la différenciation mégacaryocytaire terminale.  
 
Mots clés : 
 
Divergent regulations of c-Kit receptor by TPO and CD9 in megakaryocytic cells: 
Implication in the dynamic control of the balance proliferation/differentiation 
 
The Thrombopoietin (TPO) favors both the proliferation and the maturation of megakaryocytic 
progenitors, raising the question of the molecular mechanism explaining its dual function. SCF/ c-Kit 
signaling is essential for all hematopoietic progenitors amplification, whereas terminal differentiation 
requires the extinction of c-Kit receptor expression. Reciprocally, we evidenced in our team that 
Notch stimulation enables the induction of c-Kit expression and act on a particular subpopulation of 
bipotent erythro-megakaryocytic progenitors highly expressing the tetraspanin CD9 (induced during 
megakaryocytic maturation) and favors their re-entry in a cycling state by blocking their 
megakaryocytic maturation. These observations lead to the investigation of the molecular 
mechanism of c-Kit regulation by TPO in a cellular model of bipotent progenitors immortalized and 
dependent on TPO, the G1ME cells. During my thesis, I evidenced that: i) Notch stimulation induces 
the expression of c-Kit while repressing CD9 expression; ii) Surprisingly TPO is able to activate c-Kit 
allowing its contribution to cell proliferation; iii) c-Kit also represses megakaryocytic polyploidization 
(endomitosis characterizing megakaryocytic maturation) of G1ME cells; iv) The tetraspanin CD9 
represses the expression of c-Kit. The ensemble of these data allows us to propose the following 
model wherein TPO activates c-Kit allowing the proliferation of megakaryocytic progenitors, while 
concomitantly induces the expression of the tetraspanin CD9 that will reach a sufficient level to 
provoke the extinction of c-Kit expression at the cell surface, thus enabling the arrest of cell cycling 
progress and the engagement into terminal megakaryocytic maturation.  
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